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Abstract 
 
Cytoglobin (CYGB), a novel member of the globin family, has been shown to be upregulated 
in response to hypoxia, oxidative stress and fibrogenesis. Presented here is evidence of CYGB 
expression within cells of fibrotic lesions taken from patients with Idiopathic Pulmonary 
Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD). CYGB staining was 
observed in fibroblasts, endothelial cells, type II pneumocytes, type I pneumocytes, 
haematopoietic stem cells and inflammatory cells, which were identified using cell specific 
markers.  Cell types which express other members of the globin family, including smooth 
muscle and red blood cells were negative for CYGB. Fibroblasts were consistently positive 
for CYGB. CYGB expression was consistently positive within the lesion, and more variable 
at the edge. This study also provides evidence of an increase in CYGB expression in response 
to hypoxic and oxidative stress in vitro; however there was no evidence of cytoprotection 
with over expression of CYGB in response to these insults. There is evidence presented here 
that the increase in CYGB expression with fibrosis previously reported in the literature, is 
likely to relate to the hypoxic environment of the lesion and the influx of fibroblasts which are 
consistently CYGB positive. CYGB is likely to have a role in oxygen and redox homeostasis.  
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CHAPTER 1: GENERAL INTRODUCTION 
 
 
1.1 Cytoglobin 
1.1.1 Identification of Cytoglobin 
Cytoglobin (CYGB) was initially reported in rat tissue in 2001 following a study investigating 
proteomic differences between quiescent and activated rat hepatic stellate cells both in vitro 
and in vivo. Marked upregulation of, a then unknown protein, was observed in activated cells, 
and temporarily termed STAP (stellate cell activation-associated protein) (Kawada et al., 
2001). The protein and cDNA sequence were isolated, identifying a heme protein which was 
found to be a homogenic dimer, with 40% homology to myoglobin and predicted to have 
cytoplasmic localisation (Kawada et al., 2001).   
 
Human CYGB was reported later in 2002 (Burmester et al., 2002). It was initially identified 
on chromosome 17q25 following sequence searching for potential globins (Burmester et al., 
2002). A novel sequence was found, cloned and expressed. The sequence coded for a protein 
190 amino acids in length, and contained the typical helix structure of a globin fold. Northern 
hybridization using mRNA from numerous different human tissues and developmental stages 
showed expression in all tissue samples, and thus the term ‘Cytoglobin’ was coined 
(Burmester et al., 2002). The identification of Human CYGB on chromosome 17q25 was 
further substantiated in 2002 (Trent and Hargrove, 2002) again through searching available 
human genomic sequence data for predictive globin domains. Expression was observed to be 
ubiquitous and the alias ‘histoglobin’ was conceived and used. (Trent and Hargrove, 2002) 
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The term Cytoglobin was later used in preference to histoglobin and STAP. Cytoglobin was 
concluded to be a novel member of the globin protein family, and the 4
th
 identified in humans. 
 
1.1.2 Structure of Cytoglobin 
Akin to the other members of the human globin family (haemoglobin (Hb), myoglobin (Mb) 
and more recently identified neuroglobin (Pesce et al., 2002) (Ngb), CYGB is a heme protein 
(de Sanctis et al., 2003; de Sanctis et al., 2004a; Fago et al., 2004a; Makino et al., 2006; 
Sawai et al., 2003; Sugimoto et al., 2004; Trent and Hargrove, 2002; Vinck et al., 2004). 
Crystallisation of the CYGB protein confirmed a homodimeric structure (de Sanctis et al., 
2003; Fago et al., 2004a; Sugimoto et al., 2004) which dimerises via 2 intramolecular 
disulphide bonds (Sugimoto et al., 2004). Each CYGB chain is composed of a core 150 
residues, in which the heavily conserved three-over-three α-helical sandwich fold of a 
‘classic’ globin resides (de Sanctis et al., 2003; Makino et al., 2006; Sugimoto et al., 2004). 
Additional segments of approximately 20 residues, which are not common to Hb or Mb, were 
observed at the N and C termini (Burmester et al., 2002; de Sanctis et al., 2003; Makino et al., 
2006). A large apolar cavity was evident adjacent to the heme (de Sanctis et al., 2003; de 
Sanctis et al., 2004a), which despite being structurally different to those observed in Hb and 
Ngb (de Sanctis et al., 2004a), could have a role in ligand storage, enzymatic reactions, ligand 
transport (de Sanctis et al., 2003; de Sanctis et al., 2004a) or as a transient ligand docking site 
(de Sanctis et al., 2004a).  
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1.1.2.1 Heme Structure 
CYGB, and Ngb are hexacoordinated hemoglobins (HxHb) (de Sanctis et al., 2003; de 
Sanctis et al., 2004b; Sawai et al., 2003; Trent and Hargrove, 2002; Vinck et al., 2004), whilst 
Mb and Hb are pentacoordinated hemoglobins. Heme is comprised of a porphorin ring with 4 
nitrogen atoms at the centre, bound to an iron (Fe) atom, forming a flat plane. Fe has 6 
binding coordinates, of which 4 are bound via nitrogen atoms to the porphorin ring, and the 
fifth binds a His residue (His113 in CYGB) (Sawai et al., 2003) within the heme vicinity (see 
Figure 1.1). The remaining coordinate remains unbound in pentacoordinate heme, thus can be 
readily bound by ligands. The 6
th
 coordinate of the hexacoordinate heme is bound to another 
His residue, in CYGB His81 ((Sawai et al., 2003).  
 
 
 
 
 
(A) The atomic structure of heme (B) The atomic structure of penta-coordinated Heme. 
Figure 1.1  Heme Structure 
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Hexacoordinated hemoglobins are found in numerous taxa including animals, protests, 
cynaebacteria and all plants (Smagghe et al., 2006; Weber and Fago, 2004), however the 
presence of HxHbs in vertebrates has only recently being discovered (Pesce et al., 2002). The 
roles of HxHbs remain elusive, however they are frequently associated with cellular roles 
such as scavaging of NO and reactive oxygen species (ROS) (see section 1.4 for details about 
ROS), oxygen signaling, enzymatic catalysis, and oxygen transport and storage. Several 
studies have investigated peroxidise activity of CYGB, however the data is conflicting with 2 
reports giving evidence to support this theory (Asahina et al., 2002; Kawada et al., 2001) and 
one refuting it (Trandafir et al., 2007), further research is required to clarify the capacity of 
CYGB for enzymatic reactions. 
 
1.1.2.2 Ligand Binding 
Hexacoordinated heme generally have a lower ligand affinity than pentacoordinated heme, as 
dissociation of the 6
th
 coordinate must occur prior to ligand binding (Hamdane et al., 2003; 
Smagghe et al., 2006; Stryer, 1995; Weber and Fago, 2004). Despite these kinetic 
requirements HxHbs can bind oxygen and other ligands reversibly. CYGB has been shown to 
have an affinity for oxygen comparable to Mb (Sawai et al., 2003; Trent and Hargrove, 2002). 
The oxy-CYGB complex is stable (Sawai et al., 2003), yet oxygen binding is reversible 
(Trent and Hargrove, 2002), enabling a putative role in oxygen transport and storage (Sawai 
et al., 2003; Trent and Hargrove, 2002). Of note although the coordination of the heme is 
distinct between CYGB and Mb, the primary structure of the CYGB heme pocket most 
closely resembles that of Mb than the other human globins (Trent and Hargrove, 2002). The 
influence of other factors on ligand binding has been investigated. It has been reported that 
binding of O2 with CYGB is pH independent, and exothermic (Fago et al., 2004a), which 
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draws further parallels with Mb. The two CYGB heme interact in a positive and negative 
manner, as binding at one heme can encourage or impede binding at the other (Fago et al., 
2004a).    
 
CYGB contains 2 conserved cysteine residues, which are close enough to form a disulphide 
bond (Hamdane et al., 2003). Disruption of this bond by mutating either cysteine, or the use 
of chemical reducing agents such as dithiothreitol (DTT), resulted in a reduced affinity for 
oxygen (Hamdane et al., 2003), due to minor changes in the structure of the heme pocket 
(Vinck et al., 2004). It has subsequently been hypothesised that there is a direct link between 
the redox state of the cell and the affinity of CYGB for oxygen (Hamdane et al., 2003), as the 
presence of an electron donor would initiate release of oxygen by reducing breaking the S-S 
bond (Hamdane et al., 2003). This bond could be fundamental in the role of CYGB, enabling 
CYGB to act as an oxygen reservoir, releasing oxygen under hypoxia. It should be noted that 
although intramolecular disulphide bonds are present in numerous proteins, none have yet 
been found within the globin family. Intermolecular disulphide bonds are fundamental to the 
role of invertebrate extracellular Hbs, but have not been observed in vertebrate Mbs or Hbs 
(Hamdane et al., 2003). 
 
1.1.3 The Globin Family 
Globin proteins are widespread if not ubiquitous throughout the kingdoms of living organisms 
(Fago et al., 2004b). CYGB analogues have been reported in an all the vertebrate classes: fish 
(Fuchs et al., 2005); reptiles (Xi et al., 2007); amphibians (Fuchs et al., 2006; Xi et al., 2007); 
birds (Kugelstadt et al., 2004) and mammals. The most prominent variation between species 
is the presence or absence of the C-terminus extension ((Fuchs et al., 2005; Kugelstadt et al., 
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2004; Patel et al., 2008). The primary and quaternary structural diversity of the globin family 
is vast. However, the characteristic globin fold of the tertiary structure is common throughout 
the globin family, suggesting evolution of all globin proteins from one ancesteral gene 
(Weber and Fago, 2004).  
 
The first globin gene is thought to have originated approximately 1.8 billion years ago, 
corresponding with the accumulation of toxic oxygen in the atmosphere. Consequently the 
original function of globins has been proposed as being a scavenger of toxic gases, including 
oxygen, carbon monoxide and nitric oxide (Fago et al., 2004b; Weber and Fago, 2004). 
 
As yet only 5 globins have been found within vertebrates: Mb, Hb, Ngb, CYGB and the novel 
GlobinX (GbX) (Roesner et al., 2005), which has recently been observed in fish and 
amphibians but appears absent within higher vertebrates. In contrast to the vertebrates, there 
are 3 classes of globins in micro-organisms, and numerous forms in the plant, and invertebrate 
kingdoms. Despite the vast diversity of globins they all occupy one or more of a selection of 
functional niches, including: transport and storage of oxygen, oxygen homeostasis, enzymatic 
activities and scavenging of reactive oxygen and nitrogen species (Weber and Fago, 2004). As 
summarised in section 1.1.2.1, the human globins, Hb, Mb, Ngb and CYGB, fall into two 
classes based on heme structure. It appears the hexa-coordinate globins are of a more ancient 
origin than the penta-coordinate globin, which are thought to have arisen for specific roles 
(Weiland et al., 2004). The ligand affinity of hexa-coordinate hemes typically prevents a role 
in oxygen transport and storage, whilst penta-coordinate hemes are thought to have evolved to 
deal with the demand for oxygen transport as the size of organisms increased through time.     
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1.1.4 Phylogeny of Cytoglobin 
The Human CYGB gene is located on chromosome 17q25, and consists of 4 exons and 3 
introns (Trent and Hargrove, 2002), the most 3’ of which is found in mammals but not 
chicken or fish. The addition of this exon is thought to have arisen during early mammalian 
evolution (Burmester et al., 2004). The translated human protein is 190 amino acids in size, 
(Burmester et al., 2002) considerably larger than known vertebrate Mbs and Hbs, due to N 
and C terminal extensions. The C-terminal extension is thought to be due to the addition of 
the exon, whereas the N-terminal extension is thought to have arisen following a duplication 
event. Similar extensions have previously been observed in several invertebrate and primitive 
A figure to show the fundamental differences between the 4 human globins 
Figure 1.2  The Human Globins 
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vertebrate globins, although the functional properties remain unknown (Burmester et al., 
2002; Pesce et al., 2002) 
 
 
 
 
The structure of CYGB is highly conserved: mouse and human CYGB share over 90% 
identity (Pesce et al., 2002; Trent and Hargrove, 2002), the residue substitution rate is 
estimated to be 0.3x10
-9
 amino acid replacements per year (Burmester et al., 2004; Fago et 
al., 2004b), implying the structure of CYGB to be fundamental to an ancient essential 
biological function. CYGB shares less that 30% primary sequence identity with human 
globins (Trent and Hargrove, 2002), which could be a result of the sequence variation and 
substitution rates of Hb and Mb being considerably higher than that of CYGB. The protein 
A diagrammatic representation of the globin family phylogenetic tree. Adapted from 
Burmester et al 2004. 
Figure 1.3  Globin Family Phylogeny 
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with which it shares the highest sequence identity is Lamphreys Hb (Sugimoto et al., 2004), 
possibly due to a common hexa-coordinate structure. 
 
There is evidence that HxHbs, including CYGB, are more ancient that penta coordinated 
hemoglobins (Sugimoto et al., 2004; Trent and Hargrove, 2002) implying the role of Hxhbs to 
be evolutionarily fundamental.  Hb evolved from Mb and CYGB approx. 600 million years 
ago (See Figure 1.3) (Sugimoto et al., 2004), coordinating with the development of the 
circulatory system. CYGB shares a clade with vertebrate Mb (Burmester et al., 2002; 
Burmester et al., 2004; Sugimoto et al., 2004), and the eye-specific globin in birds (GbE) 
(Burmester et al., 2004; Kugelstadt et al., 2004), indicating CYGB to have a role similar to 
Mb, potentially in oxygen transport (Burmester et al., 2004; Kawada et al., 2001). The 
chromosomal regions in which Mb and CYGB are located are believed to have formed from 
an ancient duplication event (Burmester et al., 2002). CYGB separated from Mb 
approximately 550 million years ago. The close genetic relationship between Mb and CYGB 
implies that of all the globins, the role of CYGB is likely to be most closely related to Mb. 
Potentially Mb and Ngb could be specialised forms of CYGB evolved for oxygen transport in 
muscle and neuronal tissue respectively. 
 
1.1.5 Localisation of Cytoglobin Expression 
1.1.5.1 Tissue and Cell Specific Cytoglobin expression 
CYGB expression was first reported to be ubiquitously expressed following a study by 
Hargrove and Trent. The human tissues investigated in this study were extensive and included 
heart, brain, kidney, lung, breast, skeletal muscle, gastrointestinal tract and pancreas. The 
ubiquitous expression of CYGB has been further substantiated in human studies (Schmidt et 
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al., 2004), as well as in chicken (Kugelstadt et al., 2004), Xenopus laevis (Xi et al., 2007), 
dog (Ostojic et al., 2006), mice (Singh et al., 2009) and rat (Geuens et al., 2003; Nakatani et 
al., 2004) tissues.  
 
There is evidence that CYGB is absent from heart and skeletal muscle in the reptile Iguana, 
and that these organs do not express Mb (Xi et al., 2007). The study compared this to the 
expression of CYGB within the same tissues of X.laevis, in which CYGB and not Mb is 
present, and concluded that expression of CYGB could be compensatory for the absence of 
Mb (Xi et al., 2007) It could also be argued that the opposite is true, with expression of Mb in 
X.laevis tissues compensating for the lack of CYGB. If CYGB is more evolutionarily ancient 
one could argue that the later model is more likely than the former proposed by Xi et al.  
 
CYGB expression has been observed in an array of cell types. There is evidence of CYGB 
expression in fibroblasts of various organs including liver (Nakatani et al., 2004; Schmidt et 
al., 2004) heart, muscle, colon, kidney, tendon, skin (Schmidt et al., 2004), hepatic stellate 
cells (Asahina et al., 2002; Schmidt et al., 2004), myofibroblasts (Kawada et al., 2001), 
chondrocytes, osteoblasts and osteoclasts in rats (Schmidt et al., 2004). Models using mice 
have shown CYGB expression in hepatic stellate cells (Man et al., 2008) and fibroblasts of 
the heart, lung, kidney, thigh muscle and stomach (Man et al., 2008). CYGB expression in 
human fibroblasts (Halligan et al., 2009) and epithelial cells (Shigematsu et al., 2008) has 
also been confirmed in vivo.  
 
Cells which have been shown to be CYGB negative include endothelial cells (Kawada et al., 
2001; Nakatani et al., 2004; Schmidt et al., 2004), kupffer cells (Kawada et al., 2001), 
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hepatocytes (Kawada et al., 2001; Schmidt et al., 2004), epithelial cells (Nakatani et al., 
2004), red blood cells (Nakatani et al., 2004; Schmidt et al., 2004), macrophages (Nakatani et 
al., 2004), dermal fibroblasts (Nakatani et al., 2004), skeletal muscle cells (Nakatani et al., 
2004; Schmidt et al., 2004), mature chondrocytes (Schmidt et al., 2004), goblet cells 
(Schmidt et al., 2004) and  heart muscle cells (Schmidt et al., 2004) in rats. Mice have 
presented with negative staining in endothelial cells, hepatocytes and red blood cells. 
 
Studies into the neuronal expression of CYGB support a model in which CYGB is expressed 
in a sub population of neurons, in both the central and peripheral nervous systems but absent 
from the surrounding glia (Geuens et al., 2003; Ostojic et al., 2006; Ostojic et al., 2008; 
Schmidt et al., 2005), predominantly however, neurons are negative for CYGB.  
 
Although CYGB appears to be expressed is all tissues, there is considerable evidence that 
CYGB is expressed mainly in fibroblasts and cells of the fibroblast lineage, although CYGB 
expression does not appear to be limited to this cell population. It is interesting that CYGB 
has been shown in several studies to be negative in red blood cells, muscle cells and the 
majority of nerve cells, which is notable as each of these cells express a cell specific globin 
which could compensate for the lack of CYGB expression.  
 
1.1.5.2 Subcellular Localisation of Cytoglobin 
There are conflicting reports in the literature regarding the subcellular localisation of CYGB 
in non neuronal cells. An in vitro study presents evidence of exclusive nuclear (Geuens et al., 
2003) localisation of CYGB, whilst several in vivo and in vitro studies show exclusively 
cytoplasmic localisation (Hodges et al., 2008; Huang et al., 2006; Kawada et al., 2001; 
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Nakatani et al., 2004; Schmidt et al., 2004; Xi et al., 2007). There is some evidence to support 
expression of CYGB with the nuclei and cytoplasm of a sub population of mouse liver 
fibroblasts, and hepatic stellate cells (Man et al., 2008). Where CYGB is observed within 
neurons expression has been shown to be both nuclear and cytoplasmic by both in vivo and in 
vitro studies (Hodges et al., 2008; Li et al., 2006; Schmidt et al., 2004). There is however no 
evidence of specific nuclear import of CYGB arguing against nuclear localisation (Schmidt et 
al., 2004). CYGB was not detected in extracellular matrix in vivo (Schmidt et al., 2004), or 
cell culturing media in vitro (Kawada et al., 2001) implying CYGB is unlikely to be excreted. 
CYGB was found to be absent from membrane and mitochondrial cell fractions (Li et al., 
2006). 
 
It is now widely believed that CYGB is an intracellular protein which is likely to localise 
exclusively to the cytoplasm in non neuronal cells, and to both the cytoplasm and nuclei in 
neurons. The regulation and role of CYGB is thus likely to differ between these 2 cells types. 
 
1.1.6 Genetic Regulation of Cytoglobin Expression 
Sequence searching to find putative CYGB gene regulatory elements highlighted binding 
regions for the following transcription factors: AP-1 (Singh et al., 2009; Wystub et al., 2004), 
AP-2, NF-1, NFĸB, STAT (Wystub et al., 2004), C-Ets-1, SP1 (Guo et al., 2006), NFAT 
(Singh et al., 2009), erythropoietin. (EPO) (Guo et al., 2006; Guo et al., 2007; Guo et al., 
2007) and Hypoxia Inducible Factor-1 (HIF-1) (Guo et al., 2007; Singh et al., 2009; Wystub 
et al., 2004). In addition binding of HIF-1 to putative binding sites has also been reported 
(Guo et al., 2007). These transcription factors are known to have role in regulation of 
housekeeping genes and or, protection against oxidative stress, and or the cellular hypoxic 
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response (See section 1.3 for more details about hypoxia). CYGB mRNA contains conserved 
hypoxia inducible stabilisation sites in the 3’ untranslated region (Wystub et al., 2004). 
Collectively this implies a role for hypoxia in regulation of CYGB expression. 
 
Site directed mutagenesis of the c-Ets-1 and SP-1 sites resulted in a significant reduction in 
CYGB promoter activity (Guo et al., 2007). This study concluded that c-Ets-1 and SP-1 had a 
fundamental role in normoxic CYGB expression, and potentially work synergistically. 
Subsequently activity of the CYGB promoter was shown to increase in response to hypoxia, 
potentially via the 3 hypoxia response elements (HRE) in the CYGB promoter, 2 of which 
bind HIF-1, and the other EPO. Mutations to each HRE site individually reduced the hypoxic 
response, whilst mutations to all 3 sites simultaneously blocked the hypoxic response 
completely (Guo et al., 2007). Mutations to HRE’s however did not affect basal transcription 
(Guo et al., 2007), and mutation of the c-Ets-1 and Sp-1 sites did not affect the hypoxic 
response. In addition, HIF-1 has been shown to increase activity of the CYGB promoter 
(Singh et al., 2009). 
 
There is sufficient evidence of an increase in CYGB promoter activity in response to hypoxia, 
via the HIF-1 pathway. The regulatory mechanisms of basal transcription, and hypoxia 
response appear to be distinct.  
 
1.1.7 Hypoxia and Cytoglobin 
Vertebrate CYGB expression at the mRNA and protein level has been shown to increase in 
response to hypoxia in both in vivo ((Fordel et al., 2004; Fordel et al., 2007b; Mammen et al., 
2006; Schmidt et al., 2004) and in vitro models ((Guo et al., 2007; Huang et al., 2006)(Singh 
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et al., 2009) (Fordel et al., 2004; Fordel et al., 2007a).The in vivo models used rodents and 
have shown hypoxic induction of CYGB in a range of organs, including eyes, brain, heart, 
liver and skeletal muscle. Fordel et al (Fordel et al., 2007a) showed reoxygenation following 
hypoxic treatment in vivo and in vitro decreased CYGB expression back to basal levels (Guo 
et al., 2007). The localisation of the CYGB signal in the brain has been shown to remain 
constant with hypoxia (Mammen et al., 2006).  
 
The hypoxic response of CYGB expression was shown to be linked to HIF-1, as hypoxia 
induced CYGB mRNA upregulation was absent in muscle, liver and heart of HIF-1 knockout 
mice (Fordel et al., 2004).  
 
CYGB may have a cytoprotective role against hypoxic stress. Over expression of CYGB in 
islets of langerhanns has been shown to increase cell viability following transplantation, a 
process associated with prolonged ischemic conditions (Stagner et al., 2005). It was proposed 
that CYGB over expression could enable cells to bind and use oxygen under lower oxygen 
tensions than cells without excessive CYGB. An in vitro study however presented conflicting 
data showing that CYGB over expression did not increase cell viability in response to hypoxic 
insult, and neither did inhibition of CYGB expression reduce cell viability (Fordel et al., 
2007a), unless hypoxic insult was accompanied with glucose deprivation.  
 
CYGB has also been associated with regulation of cellular respiration (Halligan et al., 2009). 
Nitric oxide (NO) inhibits mitochondrial respiration. Over expression of CYGB inhibits this 
action of NO, most probably as CYGB can bind NO and convert it into nitrate (Halligan et 
al., 2009). Inhibition of CYGB expression using shRNA reduced nitrate production, increased 
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nitrosylation of proteins and heme, and made cells more sensitive to NO induced inhibition of 
cell respiration (Halligan et al., 2009). CYGB over expression has also been shown to 
increase cell respiration and proliferation (Halligan et al., 2009) 
 
CYGB expression is increased in response to hypoxia, and may have a cytoprotective role 
however current understanding is limited. CYGB may also have a role in regulation of 
respiration.  
 
1.1.8 Oxidative Stress and Cytoglobin 
Oxidative stress is the accumulation of reactive oxygen species (See section 1.4 for more 
details about oxidative stress) CYGB expression in rat brain localised to regions which are 
responsive to oxidative stress (Mammen et al., 2006). CYGB was shown to be upregulated in 
hereditary ferritinopathy neurones, a condition characterised by iron induced oxidative stress 
(Powers, 2006). Additionally an in vitro study showed an increase in CYGB mRNA with 
H2O2 treatment (Li et al., 2007). Oxidative stress could therefore have a role in regulation of 
CYGB.  
 
A cytoprotective role of CYGB against oxidative stress has been speculated in the literature 
and supported by studies which have shown a reduction in oxidative stress induced cell death 
(Fordel et al., 2006) lipid peroxidation (Hodges et al., 2008; Xu et al., 2006) and DNA 
damage (Hodges et al., 2008) with CYGB over expression in vitro. In addition knocking out 
CYGB expression reduced cell viability following H2O2 treatment (Li et al., 2007). CYGB 
offer cytoprotection against oxidative stress by oxyradical scavenging. CYGB overexpressing 
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cells were shown to have an increased rate of oxyradical scavenging, supporting this theory 
(Xu et al., 2006). 
 
CYGB expression is increased in response to oxidative stress, an insult to which CYGB 
appears to offer cytoprotection, potentially through scavenging of ROS. 
 
1.1.9 Cytoglobin and Cancer 
The CYGB gene localises at 17q25, a region associated with cancers (McRonald et al., 2006; 
Xinarianos et al., 2006). The CYGB promoter has been shown to be frequently 
hypermethylated, in a range of tumours, which correlates with a reduction or loss of CYGB 
expression (McRonald et al., 2006; Shaw et al., 2006; Shaw et al., 2009; Shivapurkar et al., 
2008; Xinarianos et al., 2006). Demethlyation of the CYGB promoters with 5’-aza-2’-
deoxycytidine induced CYGB expression (Shaw et al., 2009; Shivapurkar et al., 2008), 
indicating methylation is related to gene silencing.  
 
Tumour development is associated with the onset of hypoxia, as is CYGB expression (See 
section 1.1.7). Using HNSCC (Head and neck squamous cell carcinoma) cells the effects of 
promoter methylation and HIF-1α activity upon CYGB expression were investigated. It was 
shown that at a high level of promoter methylation, indicating methylation of both alleles, the 
CYGB levels were low despite hypoxic treatment and induction of HIF-1α. At lower 
methylation levels, indicating methylation of one allele, CYGB expression increased in 
response to hypoxia. This study supports further a model of CYGB expression in response to 
hypoxia, but indicated that regulation of the CYGB promoter via methylation dominates over 
hypoxia. 
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Although CYGB expression is absent in several cancers, there is evidence of CYGB 
expression in others (Genin et al., 2008; Shivapurkar et al., 2008). RNAi was used to reduce 
CYGB expression in a non small cell lung cancer line, which resulted in an increase in colony 
formation, whilst forced over expression reduced cell growth and colony formation. In 
contradiction another study showed a correlation between a reduction of CYGB expression 
and reduced tumour development, however this study did not specifically target CYGB 
(Sheffer et al., 2007)  
 
The available evidence suggests that CYGB is a putative tumour suppressor.  
 
1.1.10 Cytoglobin and Fibrosis 
The CYGB promoter is regulated in part by c-Ets-1 (Guo et al., 2006), a transcription factor 
associated with airway remodelling, a fibrogenic process. Additionally the original 
identification of CYGB was in a fibrotic study. There has thus been much speculation about 
the relationship between CYGB and fibrosis (See section 1.2 for overview of fibrosis).  
 
Rodent studies have shown an increase in CYGB expression at the mRNA and protein level 
in fibrotic compared to non fibrotic tissues (Kawada et al., 2001; Kida et al., 2007; Man et al., 
2008; Nakatani et al., 2004; Tateaki et al., 2004). CYGB induction was shown to be via PKC 
signalling (Nakatani et al., 2004). The localisation of the CYGB signal appears to remain 
constant (Man et al., 2008). The source of this increase remains elusive and could be due to 
an increase in the number of cells expressing CYGB in the area, or an increase in subcellular 
expression. An increase in CYGB expression in response to fibrotic stimuli has also been 
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reported in vitro (Gnainsky et al., 2007; Kawada et al., 2001; Nakatani et al., 2004; Zion et 
al., 2009). Thioacetamide (TAA), which initiates a fibrogenic response, increases CYGB 
expression in vivo and in vitro (Gnainsky et al., 2007; Zion et al., 2009). The activity of TAA 
can be inhibited by halofuginone, which also inhibited CYGB upregulation in vivo and in 
vitro (Gnainsky et al., 2007; Zion et al., 2009). 
 
The role of CYGB may be pro-fibrogenic, and or anti-fibrogenic.  Reduction in CYGB 
expression in vitro correlated with reduced activation of myofibroblasts, indicating CYGB 
expression to be fibrogenic, however reduction of CYGB expression in this study was not 
targeted independently. CYGB was shown to have a role in regulating fibroblast proliferation 
(Halligan et al., 2009), and over expression of CYGB has also been shown to reduce cell 
migration (Nakatani et al., 2004) and increase collagen production (Nakatani et al., 2004) 
adding further support to a pro-fibrotic role for CYGB.  
 
There is also evidence of an anti-fibrotic role for CYGB. Over expression of CYGB in hepatic 
stellate cells in vivo reduced fibrotic progression and associated necrosis significantly, and 
inhibited the increase in pro-coll 1, TGF-β1 and TIMP-1 transcripts associated with 
fibrogenesis (Xu et al., 2006). Transfection of CYGB after the onset of fibrosis in rats 
induced marked remodelling of the extracellular matrix and reduced fibrosis and necrosis (Xu 
et al., 2006). Additionally in vitro, CYGB over expression prevented oxidative stress induced 
differentiation of hepatic stellate cells into the activated phenotype (Xu et al., 2006). 
 
There is evidently a relationship between CYGB and fibrosis, however the source of CYGB 
expression, regulation, and role CYGB in fibrosis remains elusive 
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1.2 Pulmonary Fibrotic Disease 
1.2.1 The Respiratory tract 
1.2.1.1 Structure 
The respiratory tract is separated into the upper and lower respiratory tracts, which meet at the 
bifurcation of the trachea  The lower respiratory tract refers to the lungs and can be further 
segregated into the conducting and respiratory zones. The conducting zone transports air to 
the respiratory zone where gaseous exchange takes place. The conducting zone comprises of 
bronchi which split repeatedly into the terminal bronchioles. The terminal bronchi are the 
smallest non respiratory bronchioles of the lung, due to the absence of alveoli. The terminal 
bronchi feed into the respiratory zone which is comprised of further divisions of bronchioles 
to alveolar ducts, finally leading to the alveoli.  
 
1.2.1.2 Bronchioles 
Bronchioles are fundamentally comprised of an epithelial layer, smooth muscle and 
mesenchyme (see Figure 1.4). Higher order bronchioles and bronchi may also contain 
cartilage and glands within the structure. The epithelium is predominantly composed of 
ciliated columnar epithelial cells, however an array of other cell types can also be observed. 
The cell type composition of the epithelium varies in accordance with localisation within the 
respiratory tract. Cell types which contribute towards the bronchial epithelial layer include 
Goblet cells, Clara cells, Brush cells and Basal cells to name a few (Breeze and Turk, 1984). 
20 
 
 
 
 
 
 
 
                       
                  
 
Pictures and diagrams to show the structure of bronchioles (left), vasculature (middle) and parenchyma (right). The diagrams were sourced and adapted from the following internet 
sites. Bronchioles (left)  http://media-2.web.britannica.com/eb-mdeia/28/69628-004-BA27EB34.jpg , Artery (middle) http://images.google.co.uk/ imgres? imgurl=http ://www.s-
cool.co.uk/assets/learn_its/alevel/biology/transport/transport-in-mammals/2008-01-22_102617.gif&imgrefurl=http://www.s-cool.co.uk/alevel/biology/transport/ transport-in-
mammals.html, Parenchyma (right) education.vetmed.vt.edu/.../labs/Lab25/lab25.htm.KEY: SM: Smooth Muscle. E: Epithelial cells. L: Lumen. A: Adventisia, M: Media. En: 
Endothelial cells. C: Capillarie. AW: Alveolar Wall. All pictures were taken at x20 and are 30% of original size. 
 
Figure 1.4  Lung Structure 
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1.2.1.3 Vasculature 
Artery walls are comprised of 3 layers (See Figure 1.4), the intima, the media and the 
adventisia. The intima encompasses a layer of endothelial cells, connective tissue and internal 
elastic lamina. The major component of the media is smooth muscle and elastic fibres. The 
adventisia is comprised of connective tissue, predominantly collagen.  
 
The capillary walls of the pulmonary microvasculature are comprised of a layer of squamous 
endothelial cells joined by tight junctions surrounded by extracellular matrix termed the basal 
lamina. (See Figure 1.4) 
 
1.2.1.4 Parenchyma 
Lung parenchyma, or the alveoli bed, is essentially comprised of epithelial cells layered upon 
connective tissue and capillaries (see Figure 1.4). There are two alveolar epithelial cell types, 
termed type I and type II pneumocytes. Type I pneumocytes are thin squamous epithelial 
cells, which overlay the capillaries lining the alveolar bed. Type I pneumocytes cover the 
majority of the alveolar wall and have a primary role in gaseous exchange. Type I 
pneumocytes can be identified using Wheat Germ Agglutinin (WGA). WGA is lectin which 
has been reported to bind N-acetylglucosamine on the surface of type I pneumocytes 
universally (Barkhordari et al., 2004).  
 
Type II pneumocytes are large, round epithelial cells of the alveolar bed (See Figure 1.4). The 
population of type II cells far exceeds that of type I cells, however they occupy only 7% of the 
alveolar surface. Type II cells were first established as ‘defenders’ of the alveolus in 1977 
(Mason and Williams, 1977), since which the roles of the type II pneumocytes have become 
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well known, and include synthesis and secretion of surfactant (which reduces surface tension 
in the lung) (Buckingham et al., 1966), and progenitors of type I pneumocytes in response to 
damage.  The role of type II pneumocytes in surfactant synthesis enables the use of surfactant 
A as a cell specific marker. Cytokeratin immunoreactivity can be used as a marker of 
differentiation of Type II cells into Type I cells (Hinata et al., 2003). Fibroblasts and 
inflammatory cells are also observed within the lung parenchyma.  
 
1.2.2 Fibrosis in the Context of Pulmonary Disease 
Fibrosis can be defined as excessive deposition of extracellular matrix which can impede 
normal organ function. Fibrosis is frequently associated with pulmonary diseases. Pulmonary 
diseases can be categorised as restrictive or obstructive (Green, 2002). Patients diagnosed 
with obstructive lung diseases present with difficulties in exhaling air, due to conditions such 
as Chronic Obstructive Pulmonary Disease (COPD), asthma, and emphysema. COPD is an 
inflammatory disease (Chung and Adcock, 2008; Gadgil and Duncan, 2008), with elements of 
fibrosis in the upper cartilaginous airways and parenchyma (Green, 2002). In contrast 
restrictive lung diseases such as interstitial lung diseases (ILDs) create difficulties in the 
inhalation of air. ILDs are chronic inflammatory diseases with progressive fibrosis of the 
alveolar walls and peribronchiolar and perivascular connective tissue. ILDs can be further 
categorised into three groups, ILDs with known etiology including occupational or 
environmental factors, drugs or infections, ILDs associated with systemic disorders such as 
collagen vascular disorders or sarciodosis, and ILDs with no known cause, the idiopathic 
interstitial pneumonias of which idiopathic pulmonary fibrosis (IPF) is the most common 
(Green, 2002)  
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1.2.2.1 Chronic Obstructive Pulmonary Disease (COPD) 
COPD is a leading cause of morbidity and mortality in both the developed and developing 
world. It was reported in 2003 that COPD affects approximately 1% of the UK population as 
a whole, and the prevalence increases with age to approximately 10% in males over 75 
(Britton, 2003). It is well established that the most significant risk factor is tobacco smoking, 
however only 15-20% of smokers present clinically with COPD (Kim et al., 2008). 
 
COPD is a disorder characterised by irreversible airflow limitation and airway inflammation. 
Airflow limitation is a consequence of a lack of elastic recoil of the lung, and an increase in 
airflow resistance (Szilasi et al., 2006). Emphysema, chronic bronchitis and obstructive 
bronciolitis all contribute to COPD, to varying extents, and as such the range of pathologies 
observed in COPD is vast. COPD is graded according to severity, using a GOLD (Global 
initiative for chronic Obstructive Lung Disease) standard. The GOLD standard takes into 
account the ‘forced expiratory volume in one second’ and ‘forced vital capacity’ to determine 
the classification from stage I, mild to stage IV, very severe (GOLD website 
www.goldcopd.com).  
 
Emphysema is the development of permanent air space enlargement in the terminal 
bronchioles, respiratory bronchioles and alveoli. Emphysema is thought to be the result of a 
protease/antiprotease imbalance caused by repetitive inflammation and episodes of fibrosis 
(Szilasi et al., 2006), which accelerates epithelial and endothelial apoptosis. The 
emphysematous process remains incompletely understood. 
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Chronic bronchitis can be defined pathologically as presenting with increased mucous 
production, goblet cell hyperplasia, epithelial changes, airway inflammation, smooth muscle 
hypertrophy and submucosal bronchial gland enlargement (Szilasi et al., 2006) in the airways. 
The predominant feature is mucous hypersecretion, which doesn’t necessarily result in 
obstruction of the airways. In smaller airways epithelial atrophy and metaplasia is also 
observed. Of note a difference in the pathology of COPD and asthma is the thickness of the 
basement membrane, which in COPD remains within the normal range, and is thickened in 
asthma (Szilasi et al., 2006). 
 
Obstructive bronchiolitis is inflammation of the small and peripheral airways (<2cm in 
diameter). The typical inflammatory insult involves macrophages and CD8+ T lymphocytes 
predominantly (Szilasi et al., 2006). An increase in fibroblast numbers is also observed with 
obstructive bronchiolitis, and an associated increase in extracellular matrix deposition, and 
fibrosis.  
 
The fibrosis observed in COPD is heterogenic both between different patients and sections of 
lung from the same patient. A range of fibrosis is thus observed making COPD a good model 
to investigate the fibrogenic process. 
 
1.2.2.2 Idiopathic Pulmonary Fibrosis (IPF) 
IPF is characterised as fibrosis of the lung in the absence of a known causative agent. The 
overall incident rate of IPF in the UK was reported to be 4.6 in 100 000 in 2003 (Gribbin et 
al., 2006), and the mean survival is approximately 3 years post diagnosis (Meltzer and Noble, 
2008). IPF patients present with Usual Intersitial Pneumonia (UIP), the pathology of which 
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includes dense fibrotic lesions interspersed with normal lung architecture (Meltzer and Noble, 
2008). This increase in scar tissue, and disruption of architecture result in a reduced level of 
gaseous exchange and compliance of the lung. 
 
The pathogenesis of IPF remains elusive, however the literature favours a model of alveolar 
epithelial injury and consequent release of pro-fibroproliferative and pro-inflammatory 
mediators, initiating defective repair pathways. Fibrosis supersedes repair, there is deficient 
resolution of the tissue and subsequently fibrosis progresses (Meltzer and Noble, 2008). 
 
The fibrosis observed in IPF is dynamic and homogenic (Gomperts and Strieter, 2007) and 
non self limiting. IPF is appropriate as a positive control model for fibrosis. 
 
1.2.3 Pulmonary Fibrosis at a Cellular Level 
1.2.3.1 Fibrosis and Repair 
Fibrosis is, in essence, excessive deposition of extracellular matrix (ECM), stimulated through 
injury, infection or inflammation. Fibrosis is therefore readily associated with repair 
pathways.  In normal wound repair there are typically 2 distinct phases, a regenerative phase 
and fiboplasia. Injured cells are replaced by cells of the same cell type during the regenerative 
phase, whilst in fibroplasias, connective tissue supports the region of damage, replacing 
normal cell structure (Wynn, 2008). Fibrosis is thus an essential aspect of wound healing, 
however a lack of balance between fibrogenesis and fibrolysis leads to the formation of 
deleterious fibrotic lesions. The production of fibrotic lesions can be both permanent and 
reversible, such as in idiopathic pulmonary fibrosis (IPF) and acute respiratory distress 
syndrome (ARDS) respectively. The latter can be reversed upon administration of oxygen, 
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however in the absence of oxygen, the point at which the fibrotic lesions transform from a 
reversible to a permanent state is unknown. 
 
The process of fibrogenesis is not uniform throughout pulmonary diseases which present with 
fibrosis, although there are common aspects. Interstitial pulmonary fibrosis typically involves 
injury to alveolar epithelial cells resulting in an inflammatory response which initiates 
migration of fibroblasts to the site of the injury, within the alveolar septum and/or lumen 
where they proliferate and secrete extracellular matrix (Fireman et al., 2001) 
 
1.2.3.1.1 Alveolar Epithelial Cell Injury 
Injury to alveolar epithelial and endothelial cells initiates the release inflammatory mediators 
from endothelial and epithelial cells which, through increased blood vessel permeability and 
basement membrane disruption, enable easy recruitment of inflammatory cells the site of 
injury (Wynn, 2008)  
 
Alveolar epithelial cells could also be directly involved in mediation of pulmonary fibrosis. In 
response to injury or pro-fibrotic factors, alveolar epithelial cells can modify cell morphology 
and gene expression, subsequently producing pro-fibrotic factors which can regulate the 
function and differentiation of fibroblasts (Willis and Borok, 2007). It has also been suggested 
that bidirectional signalling could occur between epithelial cells and fibroblasts, with each cell 
mediating the function, proliferation and survival of the other (Rennard, 2001; Willis and 
Borok, 2007). It has been observed in mice that the presence of an intact epithelium 
suppresses fibroblast proliferation and ECM deposition (Willis and Borok, 2007). This could 
be due to the suggested production of Transforming Growth Factor-β1 (TGF-β1) by healthy 
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alveolar epithelial cells which can inhibit the proliferation of fibroblasts (Hostettler et al., 
2008). Further evidence of the direct involvement of epithelial cells in pulmonary fibrosis is 
Endothelin-1 (ET-1). ET-1 is a vasoconstrictor which is commonly associated with fibrosis. 
ET-1 expression was observed in type I and type II pneumocytes of rats treated with 
bleomycin to induce fibrosis, whilst it was limited to the airways in healthy rats, implying a 
pro fibrotic role of alveolar epithelial cells in fibrosis via the production of ET-1 (Mutsaers et 
al., 1998). Of note ET-1 was also observed in macrophages and peribronchiolar, perivascular 
and alveolar septa connective tissue, and the media and intima of vessels, thus alveolar 
epithelial cells are not the exclusive source of ET-1 during fibrosis (Mutsaers et al., 1998). 
 
Alveolar epithelial cells observed in IPF are morphologically abnormal, frequently 
hyperplasic and hypertrophic, presenting alterations in cytokeratin (CK) expression and 
increased apoptosis especially in regions adjacent to fibrotic foci (Selman and Pardo, 2006; 
Willis and Borok, 2007). The alveolar epithelial cells of IPF patients have been shown to 
express a range of pro-fibrotic chemokines including TGF-β, Tumour Necrosis Factor-α 
(TNF-α), ET-1, Platelet Derived Growth Factor (PDGF) (Willis and Borok, 2007) and 
Connective Tissue Growth Factor (CTGF) (Pan et al., 2001). In contrast, there is evidence of 
the expression of Matrix Metalloproteinases (MMP) by alveolar epithelial cells of IPF 
patients, which degrade ECM, however the expression of MMPs may also contribute to 
remodelling. Chronic inflammation is observed in IPF, and considered to instigate progressive 
fibrosis, there is increasing evidence however that instead IPF results from repeated cycles of 
epithelial injury and activation (Selman and Pardo, 2006). 
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There is a higher abundance of apoptotic alveolar epithelial and endothelial cells, and 
bronchiolar epithelial cells in COPD patients than observed in healthy subjects. This could 
result from an increase in apoptosis or a decrease in clearance of apoptotic cells by 
macrophages (Henson et al., 2006). This persists after ceasation of smoking making it 
unlikely to be an acute response to smoke specific injury. Apoptotic cells produce pro-fibrotic 
chemokines such as TGF-β1, which could contribute to the fibrosis observed in COPD 
(Henson et al., 2006). Smoking is known to kill precursors of epithelial and endothelial cells, 
inhibit airway cell chemotaxis and prolilferation and induce senescence upon epithelial cells, 
preventing efficient repair in response to smoke specific injury, which is likely to augment the 
potentiality of a fibrogenic response (Chung and Adcock, 2008). COPD patients have also 
shown an increase in expression of genes involved in ECM production, degradation and 
apoptosis following microarray analysis of bronchiole epithelial cells and alveolar 
macrophages. An increase in both proliferation and apoptosis of alveolar epithelial cells is 
observed with emphysema, which contributes to COPD (Chung and Adcock, 2008). 
  
1.2.3.1.2 Inflammation 
Inflammation is readily associated with fibrosis however inflammatory cells may have an 
anti-fibrotic, pro-fibrotic and no fibrotic role in pulmonary fibrosis (Luzina et al., 2008). 
Although inflammation typically precedes fibrosis (Fries et al., 1994) there is evidence that 
fibrosis can occur in response to epithelial injury without an inflammatory aspect (Willis and 
Borok, 2007). This has been observed in models of IPF (Selman and Pardo, 2006). Where 
inflammation has a fibrogenic role, the key role is the expression of fibrogenic factors and 
recruitment of fibroblasts. 
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T-lymphocytes, which can be identified immunohistochemically using CD3 as a marker, are 
known to synthesise an array of cytokines which modulate proliferation, recruitment and 
ECM production of fibroblasts, and mediate ECM turnover (Luzina et al., 2008). It has long 
be speculated that inflammation contributes to fibrotic disease progression, however of the 
cytokines released by T-lymphocytes some have anti-fibrotic roles, so potentially T cell 
infiltration could also reduce disease progression (Luzina et al., 2008).  
 
COPD is an inflammatory disease, and subsequently there has been much focus on the 
inflammatory aspects of COPD (Rennard, 2001). The parenchyma has been shown to 
contribute to the activation and recruitment of inflammation (Fries et al., 1994), and 
conversely, inflammatory cells modulate the activity of parenchymal cells (Rennard, 2001). 
There is evidence that inflammation in response to infection is likely to contribute to the 
pathogenesis of COPD (Sethi and Murphy, 2008), and that inflammation in COPD is 
inextricably linked to fibrogenic processes (Hogg, 2008). One direct relationship between 
inflammatory cells and COPD pathogenesis is the enhanced COX-2 expression (See section 
1.2.3.3.3 for more details) observed in alveolar macrophages of COPD patients (Barnes, 
2004). This results in elevated Prostaglandin-2 (PGE) production (see for more details), which 
increases mucous secretion, and coughing (Barnes, 2004). A reduction in mucous secretion 
has been observed with Cox inhibitors. Mediators of inflammation are fundamental to COPD 
and are secreted by inflammatory cells, epithelial cells, endothelial cells and fibroblasts 
(Barnes, 2004). 
 
The influence of inflammation on the fibrotic lesion remains elusive, however an influx of 
inflammatory cells is frequently observed prior and during fibrosis. 
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1.2.3.1.3 Fibroblast migration and activation 
Fibroblasts are known to migrate to the region of injury, where they become activated, 
proliferate, and secrete extracellular matrix components. Fibroblasts are not a homogenous 
population, there are a diverse range of fibroblast phenotypes characterised by cell surface 
markers, receptor expression, cytoskeletal structure and cytokine production (Ramos et al., 
2001). Fibroblast subtypes differ in growth rates, collagen expression levels and responses to 
cytokines (Uhal et al., 1998). It has subsequently been suggested that each fibroblast 
subpopulation could be responsible for specific functions, such as mediating inflammatory 
and epithelial responses, regulating recruitment, activation and proliferation of other 
fibroblasts, and extracellular matrix deposition (Fries et al., 1994). 
 
Myofibroblasts 
Expression of αSMA (alpha smooth muscle actin) by fibroblasts was first identified in 1971 
(Gabbiani et al., 1971), and this subset of fibroblasts was termed myofibroblasts (Fireman et 
al., 2001; Shahar et al., 1999; Uhal et al., 1998). Myofibroblasts are larger (Uhal et al., 1998), 
more proliferative, more contractile and have an increased level of ECM production than 
normal fibroblasts (Darby and Hewitson, 2007), which are typically senescent. Under normal 
repair myofibroblast are lost via apoptotic pathways, enabling resolution of injury. In fibrosis 
myofibroblasts are not lost and instead contribute to fibrotic progression. There is evidence of 
apoptosis resistant myofibroblasts in IPF (Garneau-Tsodikova and Thannickal, 2008; Laurent 
et al., 2008). There was subsequently speculation that differentiation to myofibroblastic 
phenotype could be an initial step in apoptosis in normal repair, however apoptotic fibroblasts 
have been shown to have αSMA+ and αSMA– phenotypes (Uhal et al., 1998), implying no 
correlation between αSMA expression and apoptosis.  
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The bronchoalveolar lavage of IPF patients has more myofibroblast (Fireman et al., 2001; 
Ramos et al., 2001; Shahar et al., 1999), which express higher levels of pro fibrotic 
chemokines (Ramos et al., 2001) than those from healthy subjects. Immunohistochemistry of 
IPF tissue has shown individual αSMA+ cells in the parenchyma dissociated from airways 
and blood vessels considered to be myofibroblasts, and bundles of loosely associated αSMA+ 
cells (Ohta et al., 1995), believed to be smooth muscle.  Proliferation of smooth muscle in IPF 
is a key pathological feature, which results in the formation of ectopic bundles of smooth 
muscle within the parenchyma (Kanematsu et al., 1994). 
 
COX-2 Expression 
COX-2 is an enzyme which produces PGE (prostaglandin E2) from arachidonic acid. COX-2 
expression is controlled primarily at the transcriptional level (Park and Christman, 2006), 
which is induced by TNF-α and IL-1b, in response to TGF-β1. PGE has a short half life (Diaz 
et al., 1998), and so is only locally active and often acts upon the cells from which it was 
produced offing a feedback mechanism. PGE has been shown to decrease fibroblast 
proliferation, inhibit collagen synthesis and promote collagen degradation, indicating PGE to 
be anti-fibrotic (Park and Christman, 2006). TGF-β1 is the most potent pro fibrotic factor yet 
identified, however this pathway offers an anti-fibrotic role for TGF-β1 (Laurent et al., 2008). 
 
The expression of cyclooxygense-2 (COX-2) by fibroblasts is differentially expressed by 
fibroblasts from IPF, COPD and non fibrotic controls subjects. COPD shows an enhanced 
COX-2 mRNA basal level compared to controls and IPF subjects (Xaubet et al., 2004). 
Stimulation of COX-2 expression by interleukin-1b (IL-1b) increased expression in COPD 
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and control fibroblasts but not those from IPF (Xaubet et al., 2004). This loss of induction in 
IPF derived fibroblasts has also been observed following stimulation with PMA, LPS and IL-
1 (Wilborn et al., 1995). Fibroblasts from IPF show a 2 fold decrease in COX-2 expression 
than normal fibroblasts (Wilborn et al., 1995). The fibroblasts from IPF and COPD are thus 
distinct in their COX-2 expression, with excessive expression in COPD and a lack of COX-2 
expression and induction in IPF (Xaubet et al., 2004).  
 
This lack of basal and induced COX-2 in fibroblasts from IPF patients resulting in reduced 
PGE levels (Keerthisingam et al., 2001) could be a fundamental in the onset of fibrotic rather 
than repair pathways. IPF models using bleomycin treated mice have shown that COX-2 
inhibition, or deficiency in expression correlate with a decrease in PGE secretion and 
subsequent increase in fibrotic response and collagen content (Hodges et al., 2004; 
Keerthisingam et al., 2001). Additionally one study showed equal levels of COX-2 
expression, and subsequent PGE in IPF and normal fibroblasts, however these fibroblasts 
produced more thromboxane (Tx), a profibrotic chemokine which increases proliferation of 
fibroblasts and DNA and RNA synthesis (Cruz-Gervis et al., 2002). Despite the equivalent 
levels of PGE between normal and IPF fibroblasts, the IPF fibroblasts were more pro-fibrotic 
due to an increased Tx:PGE ratio (Cruz-Gervis et al., 2002). IPF derived fibroblasts have also 
been shown to express higher levels of CTGF (Pan et al., 2001) and ET-1 (Shahar et al., 
1999) which each stimulate proliferation of fibroblasts. IPF derived fibroblasts also respond 
differently to growth factors than normal fibroblasts including TNF-α, TGF-β1 and PDGF in 
response to which normal fibroblasts increase in prolilferation, whilst IPF derived fibroblasts 
increased synthetic activity (Hetzel et al., 2005). There is sufficient evidence of a pro-fibrotic 
33 
 
fibroblasts phenotype in IPF, which is likely to contribute significantly to the fibrotic 
pathogenesis.  
   
The levels of PGE are increased in COPD (Barnes, 2004), potentially through an increase in 
COX-2 expression in both fibroblasts and alveolar macrophages (Barnes, 2004). This 
induction in expression is thought to be due to chemokines originating from inflammation 
(Barnes, 2004), in addition to an increased rate of basal expression (Xaubet et al., 2004). 
Cigarette smoke has also been shown to increase COX-2 expression and subsequent PGE 
production (Martey et al., 2004), and is known to decrease fibroblast proliferation and induce 
fibroblast senescence (Chung and Adcock, 2008). The onset of a senescent fibroblast 
phenotype in COPD has been speculated to contribute to abnormal wound healing and 
ineffective repair (Chung and Adcock, 2008). The high levels of the anti-inflammatory and 
anti-fibrotic PGE are somewhat contradictory to the fibrotic element observed in COPD, 
however several pro-fibrotic chemokines are upregulated in COPD which could compensate 
for the effects of PGE, these include Tx, ET-1, TNF-α, TGF-β1, IL-1b and MMP. These 
chemokines have roles in regulating the activation, proliferation, migration and section of 
ECM by fibroblasts, and ECM destruction (Barnes, 2004).  
 
Source of fibroblasts 
The source of fibroblasts recruited to fibrosing lesions offers differences in fibroblasts 
phenotypes. There are 3 suggested origins of fibroblasts: proliferation of resident fibroblast; 
circulating fibroblast precursors; and epithelial-mesenchymal transition (EMT).  
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Circulating fibroblast precursors express lymphocyte markers including CD34, CD45, CD13, 
mesenchymal markers such as Pro-collagen I and III, Vimentin and Fibronectin, and 
chemokine receptors CXCR4 and CCR7 which are important in migration from vascular to 
extravascular regions (Gomperts and Strieter, 2007). These are bone marrow derived and have 
the capacity to differentiate into a range of mesenchymal cells, including adipocytes, 
osteoblasts, chondrocytes and fibroblasts, and so have been termed circulating mesenchymal 
progenitor cells (CMPC) (Gomperts and Strieter, 2007). There is evidence that fibroblasts of 
this source could contribute to IPF (Andersson-Sjoland et al., 2008). 
 
EMT can be induced in response to an array of chemokines including TGF-β1, CTGF, IL-1 
and Fibroblast Growth Factor-1 (FGF-1), and can be enhanced by proteolytic degradation of 
the basement membrane (Willis and Borok, 2007). Consequently over expression of MMP 
can disrupt the basement membrane and induce EMT (Willis and Borok, 2007). 
Characteristics of EMT have been observed in IPF (Selman and Pardo, 2006). 
 
1.2.3.2  Microvascular changes 
The extensive remodelling of the alveolar bed in fibrosis, and destruction of lung architecture 
has, unsurprisingly, an effect on the resident microvasculature. There have been conflicting 
reports in the literature as to whether there is an increase in microvasculature loss, or 
neovasculatisation with fibrosis (Tzouvelekis et al., 2006). There is increasing evidence of a 
role in the balance of angiostatic and angiogenic factors in vascular remodelling in fibrotic 
disorders, thus is appears vasculature changes are significant in the pathogenesis of fibrosis. It 
is likely that microvasculature loss, and neovascularisation occur in different regions of the 
same fibrotic lesion, with loss being observed in fibrosed, highly acellular foci, and 
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angiogenesis being focused in the associated fibrosing, cellular tissue. It remains unclear 
whether angiogenesis drives fibrosis through neovasculagenesis supplying fibrogenic factors, 
or acts to compensate the fibrotic insult through supplying anti-fibrotic agents ((Tzouvelekis 
et al., 2006; Voelkel et al., 2007). There is a relationship between hypoxia and fibrogenesis, 
as such one could speculate that excessive ECM deposition causes fibrosis and loss of 
microvasculature, and subsequently the onset of hypoxia. Angiogenesis occurs in response to 
hypoxia, to increase oxygen supply to the region.  
 
The alterations in microvasculature of COPD and IPF remain elusive. IPF is associated 
mainly with angiogenesis, which is thought to contribute to fibrosis (Keane et al., 1997; 
Keane et al., 2001). VEGF is a highly potent angiogenic factor which is differentially 
expressed with different COPD pathologies. There is evidence of increased VEGF in chronic 
bronchitis (Orihara and Matsuda, 2008), however an associated increase in microvessel 
number has yet to be established. Emphysema is associated with a decrease in VEGF, which 
may contribute to the destruction of the alveolar septa via endothelial apoptosis (Orihara and 
Matsuda, 2008; Siafakas et al., 2007). As mentioned earlier within COPD there could be both 
pro and anti-angiogenic events occurring simultaneously in different regions of the lung.    
 
1.2.3.3 Vascular remodelling 
Vascular remodelling of pulmonary arteries is frequently observed in COPD (Vaughan et al.,  
2006). Endothelial cells have impaired function, which subsequently results in an increased 
thrombogenic capacity of the arteries (Voelkel et al., 2007). Pulmonary hypertension is often 
associated with COPD, and believed to initiate intimal thickening, arteriole muscularisation 
and remodelling of the vessel wall. (Jeffery, 2001) In addition endothelial dysfunction and 
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subsequent loss of the moderation of vasculature tone and cell growth may initiate vascular 
wall remodelling (Santos et al., 2002).  
 
Remodelling can be defined as ‘an alteration in size, mass or number of tissue structural 
components that occurs during growth or in response to injury and/or inflammation.’ (Jeffery, 
2001). There are several contributing factors to vascular remodelling in COPD: Intimal and 
medial hyperplasia and/or hypertrophy, intimal and medial fibrosis, elastic lamina changes, 
infiltration of mesenchymal cells and T-lymphocytes (Jeffery, 2004), re-orientation of medial 
smooth muscle fibres (radial alignment from longitudinal), apoptosis, activation and loss of 
endothelial cells, and development of thrombi (Jeffery, 2004; Santos et al., 2002; Vaughan et 
al., 2006).  
 
Unpublished data generated at AstraZeneca by G.Sirico (2006) has shown a correlation in 
desmin and vimentin immunoreactivity with vascular remodelling. There is evidence of an 
increase in disorganised Vimentin staining within the media and intima of severely 
remodelled vessels. High levels of ordered vimentin positive staining was observed in mild 
lesions, the signal of which was lost with moderate remodelling. There was an increase in 
desmin negative zones in the media with increased severity of remodelling, which infiltrated 
into intimal regions in severely remodelled vessels. The loss of a desmin positive population, 
and gain in vimentin indicates a mesenchymal origin of cells involved in vascular 
remodelling. 
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1.2.4 Pulmonary Fibrosis and Associated Hypoxia 
Airflow obstruction and microvasculature loss observed in pulmonary fibrosis may lead to 
decreased oxygen transport and alveolar hypoxia. Sub-cellular hypoxic events are summarised 
in 3.3.1. Hypoxia initiates cellular and structural changes within the lung, and effects the 
pathogenesis of fibrosis. 
 
1.2.4.1 Hypoxia and Fibrotic Pathogenesis 
Hypoxia is involved in regulating numerous cellular processes including collagen synthesis, 
angiogenesis, apoptosis and proliferation, all of which contribute to fibrogenesis (Higgins et 
al., 2008). Hypoxia has been shown to trigger recruitment of inflammatory cells, and increase 
expression of inflammatory mediators, which could initiate and perpetuate fibrosis (Jain and 
Sznajder, 2005).  
 
There is evidence that hypoxia has detrimental effects on alveolar epithelial cells, affecting 
expression of VEGF and surfactant, initiating apoptosis, and disrupting cytoskeletal integrity. 
Epithelial damage could act as an initial insult stimulating the onset of fibrosis, or in a model 
in which a hypoxic environment originates from fibrogenesis, the repeated epithelial damage 
could contribute to the pathogenesis of the disease (Jain and Sznajder, 2005). 
 
Additionally, hypoxia can stimulate epithelial to mesenchymal transition, and inhibition of the 
hypoxic response has been shown to reduce fibrogenesis (Higgins et al., 2007). It is evident 
that hypoxia has a key role in fibrotic pathogenesis, progressing the disease. 
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1.2.4.2 Vascular Remodelling in Response to Hypoxia 
There is evidence of a role for hypoxia in vascular remodelling. Acute hypoxia has been 
shown to increase proliferation of pulmonary fibroblasts, however many in vitro studies have 
found that hypoxia does not have a direct effect upon smooth muscle and endothelial cell 
proliferation (Pak et al., 2007). Proliferation of adventisial fibroblasts is observed within 
hours of hypoxic insult, however medial and intimal remodelling is only observed after days 
of hypoxia. (Pak et al., 2007)(Stenmark et al., 2002) There are many fibroblast subtypes 
within the vessel wall and adventisia (Stenmark et al., 2002). It is plausible that these 
fibroblasts respond to hypoxic insult through proliferation, ECM deposition, secretion of 
mutagenic factors, and differentiation in to a myofibroblast phenotype, and potentially further 
differentiation into smooth muscle cells. These reports in the literature support data generated 
by G.Sirico at AstraZeneca (2006) which showed that a mesenchymal component was key in 
vascular remodelling. 
 
1.2.5 Pulmonary Fibrosis and Oxidative Stress 
Oxidative stress results from an imbalance in the generation of reactive oxygen species 
(ROS), and the antioxidant response. The result is accumulation of harmful oxygen species, 
and subsequent damage to DNA, proteins and lipids (See section 1.4). There is evidence, 
however for an important role of ROS in intracellular signalling. There is mounting evidence 
of oxidative stress in pulmonary fibrosis, potentially originating from an increase ROS 
generated from inflammatory insult, and a decrease in the antioxidant response due to defects 
in endogenous antioxidants (Chung and Adcock, 2008)  
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The primary contributors and perpetuators of pulmonary fibrosis are epithelial and/or 
endothelial cell damage and apoptosis; inflammation; and recruitment, proliferation and 
differentiation of fibroblasts. ROS has been shown to be involved in mediating the 
inflammatory response; inflammatory cells release ROS to recruit further inflammatory cells 
to an area of damage (Chung and Adcock, 2008). ROS initiate activation of growth regulatory 
cytokines, including TGF-β, which is involved in fibroblast recruitment, proliferation, and 
differentiation into the myofibroblast phenotype (Kinnula and Myllarniemi, 2008). 
Additionally redox modulators and antioxidants have been shown to attenuate progression of 
fibrosis (Kinnula and Myllarniemi, 2008). 
 
Although the mechanistic details by which ROS contribute to fibrogenesis remain elusive, 
there is increasing evidence that oxidative stress contributes to fibrotic disease progression.   
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1.3 Hypoxia 
Oxygen deprivation (hypoxia), even transient, can produce irreversible cellular damage to 
cells, which depend on aerobic respiration. Oxygen homeostasis is subsequently fundamental 
to cellular function (Stroka et al., 2001).  
 
1.3.1 Hypoxia Inducible Factor 1 (HIF-1) 
The Hypoxia Inducible Factor 1 (HIF-1) is the principal factor in mediating cellular adaption 
to hypoxia. HIF-1 is a transcription factor, which regulates the expression of numerous genes 
during hypoxia through the binding of conserved HREs (hypoxia response elements) in the 
promoters of target genes, and recruitment of co activators (Stroka et al., 2001). HIF-1 is 
known to regulate the expression of genes involved in angiogenesis, glucose metabolism, 
vasodilation, respiration, erythropoiesis, oxygen sensing, pH homeostasis and autophagy 
(Brahimi-Horn and Pouyssegur, 2009). To achieve these functions, at the subcellular level 
HIF-1 is known to mediate mobility, differentiation, proliferation, cell death and cell survival 
(Berra et al., 2006; Koh and Powis, 2009; Wenger, 2002).  
 
HIF-1 is heterodimeric, comprised of two subunits, HIF-1α and HIF-1β. There are three 
isoforms of the α-subunit (HIF-1α. HIF-2α and HIF-3α) and two isoforms of the β-subunit. 
(Brahimi-Horn and Pouyssegur, 2009). The function and regulation of HIF-1 has been 
studied intently, however HIF-2 and HIF-3 have only recently been identified and so 
knowledge in this field remains limited. Each of the isoforms of the  subunit have been 
associated with oxygen sensing, however the β-subunit is constitutively expressed, and not 
regulated in response to oxygen tension. 
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1.3.2 Hypoxic regulation of HIF-1α Activity 
HIF-1 activity is modulated via post-translational modification of the α-subunit under 
normoxic conditions. Each of the isoforms of the α-subunit are regulated in a similar manner 
(Brahimi-Horn and Pouyssegur, 2009). Under normoxic conditions prolyl hydroxylation, by 
prolyl hydroxylase domain proteins (PHDs), of the ODD (oxygen dependant degradation 
domain) region of the HIF-1α protein occurs. The activity of PHDs is dependent on molecular 
oxygen and   Fe
2+
, and subsequently only occurs under normoxic conditions. Hydroxylation 
encourages interaction with pVHL (von Hippel Lindau tumour suppressor protein), which is 
part of a multi-protein ubiquitin ligase complex (VHL/Elongin B/Elongin C), and covalently 
binds ubiquitin to the HIF-1α protein. Ubiquitin signals HIF-1α for degradation, as it enables 
the docking of the HIF-1α protein into a multi-subunit proteolytic proteasomal complex, 
which specifically degrades ubiquitinated proteins (Brahimi-Horn and Pouyssegur, 2009). In 
addition to signalling HIF-1α for degradation, PHDs also hydroxylase the C-terminal of HIF-
1α, inhibiting binding of transcriptional co-factors (Berra et al., 2006; Brahimi-Horn and 
Pouyssegur, 2009; Wenger, 2002)  
 
Under hypoxic conditions the lack of oxygen inhibits the function of prolyl hydroxylases, thus 
preventing binding of HIF-1α with pVHL. The consequential stabilisation of HIF-1α enables 
translocation to the nucleus, dimerisation with HIF-1β, recruitment of transcription co-factors, 
and subsequent regulation of gene expression.  
 
1.3.3 Non-Hypoxia regulation of HIF-1α 
HIF-1 regulation is not limited to oxygen tension changes. The subunit, HIF-1α is known to 
respond to non hypoxic stimuli including mechanical stress, growth factors, cytokines, and 
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metal ions (Kietzmann and Gorlach, 2005a). There is evidence that ROS which are 
summarised in 2.4, are involved in both hypoxic, and non-hypoxic regulation of HIF-1α 
(Kietzmann and Gorlach, 2005a). Physiologically, an association in the regulation of ROS 
and HIF-1 is logical, as the formation of ROS requires molecular oxygen, and thus the 
pathways involved in ROS generation and oxygen homeostasis are inextricably linked. 
 
ROS signalling is involved in several of the pathways, which stimulate non-hypoxic 
activation of HIF-1α, and as such a role for ROS in non-hypoxic regulation of HIF-1α has 
been studied. Non-hypoxic stimulators of HIF-1α include thrombin, PDGF (Platelet Derived 
Growth Factor) and TGF-β (Transforming Growth Factor-β). Several studies have shown that 
treatment with antioxidants such as ascorbic acid (vitamin C) and vitamin E, inhibit activation 
of HIF-1α by these non hypoxic stimulators, suggesting a role for ROS in signalling HIF-1α 
activation (Kietzmann and Gorlach, 2005a). Hydrogen peroxide has been shown to induce 
HIF-1α activation at low concentrations (0-50µM), but inhibit accumulation of HIF-1α at 
higher concentrations (Kietzmann and Gorlach, 2005a). This supports a model of a sensitive 
redox switch in modulation of HIF-1α  activity, enabling rapid cellular response to stimuli.  
 
The mechanism by which ROS mediates HIF-1α activity remains elusive, however there is 
evidence to suggest a role for NADPH oxidases, which are known to generate ROS, mainly 
superoxides. NADPH oxidases are involved in pathways which link stimulation by thrombin, 
PDGF, angiotensin II, and mechanical stress to HIF-1α activation. Inhibition of NADPH 
oxidases have been shown to inhibit activation of the HIF pathway in response to non hypoxic 
stimuli, and over-expression of a NADPH oxidase subunit resulted in an increase in HIF-1α 
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levels (Kietzmann and Gorlach, 2005a)(Kietzmann and Gorlach, 2005b) ROS derived from 
NADPH oxidases may have a significant role in HIF-1 regulation to non hypoxic stimuli.    
 
1.3.4 Hypoxic regulation of HIF-1α by Reactive Oxygen Species (ROS) 
ROS have been reported to act as signalling molecules in the upregulation of HIF-1α in 
response to hypoxia (Kietzmann and Gorlach, 2005a). The mechanism of ROS mediation 
remains elusive. There is evidence that the heme containing enzymes, such as NADPH 
oxidases, and the mitochondria are involved in hypoxic signalling via ROS generation 
(Kietzmann and Gorlach, 2005a). It could be assumed, based on the relationship between 
ROS and oxygen, that an increase in oxygen levels results in an increase in ROS, and as such, 
increased levels of ROS would inhibit the HIF pathway. In support of this assumption, H2O2 
has been shown to reduce the DNA binding capacity of HIF-1 and destabilise HIF-1α, a 
reduced redox state has been shown to enhance DNA binding and cofactor recruitment, and 
increased levels of the super oxide ion have been shown to decrease HIF-1α levels 
(Kietzmann and Gorlach, 2005a). Studies researching mitochondria ROS generation and 
hypoxia presented evidence to both support and refute this assumption. Numerous studies 
showed that a decrease in mitochondrial ROS initiated a hypoxic response, substantiating the 
above assumption (Kietzmann and Gorlach, 2005a). In contradiction, several studies have 
shown an increase in mitochondrial ROS in hypoxic treated cells, and that inhibition of 
mitochondrial function did not initiate a hypoxic response. (Kietzmann and Gorlach, 
2005a)(Kaluz et al., 2009). It is evident that ROS play a critical role in regulating the HIF 
pathway however the means of this regulation remains unresolved, at present. 
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1.3.5 Carbonic Anhydrase 9 (CAIX) as a Marker of Hypoxia  
Carbonic Anhydrase IX (CAIX), a transmembrane protein with an extracellular CA domain, 
is one of 15 human isoforms of CA (Kaluz et al., 2009). The CAIX gene is readily inducible 
but there is no evidence for a basal level of transcription. Six cis-acting elements have shown 
to function upon the CAIX gene promoter, 5 in a positive, and 1 in a repressive manner. The 
activation elements have been shown to bind SP1, AP1 and HIF-1α to activate the promoter. 
The HIF-1α binding site is key to CAIX expression. Mutations to this region, or an absence of 
HIF-1α, inhibited activation of CAIX expression completely. Binding of factors to the 
additional sites, were shown to enhance or reduce expression in response to HIF-1α.  
 
HIF-1α is rapidly turned over by the cell, reports have stated a half-life in the order of 30 
seconds up to 2 minutes. Detecting HIF-1α protein is therefore problematic, and as the 
regulation emphasis is at a post-translation rather than transcription level, detection of the 
protein activity, in oppose to mRNA levels is key in determining HIF-1α activity. The 
expression of CAIX has been shown to reflect the transcriptional activity of HIF-1α, rather 
than the level of HIF-1α protein, and subsequently has been presented as a marker for HIF-1α 
activity. CAIX can therefore be used as marker for hypoxia, however only in the same manner 
as HIF-1α. It is important to appreciate that CAIX upregulation is also observed following 
non-hypoxic activation of HIF-1 (Kaluz et al., 2009; Valko et al., 2007)  
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1.4 Oxidative Stress 
1.4.1 Oxidative Stress 
Oxidative stress results from an imbalance in the generation and neutralisation of reactive 
oxygen species (ROS). ROS have crucial physiological roles, however as ROS readily oxidise 
DNA, lipids and proteins, accumulation of ROS causes extensive cellular and systemic 
damage. ROS are subsequently associated with numerous human diseases and the process of 
aging (Droge, 2002; Macdonald et al., 2003). 
 
1.4.2 Generation of Reactive Oxygen Species 
ROS are oxygen species, which are more reactive than molecular oxygen, including non-
radicals such as hydrogen peroxide, and radicals such as the super oxide anion (O2
●‾ 
) and the 
hydroxyl radical (HO
●
). The electron transport chain phase of aerobic respiration is the 
primary source of ROS; of all oxygen respired, 1-3% is leaked as O2
●‾ 
 (Valko et al., 2007). 
ROS are also generated by enzymes, such as NADPH oxidases (see section 1.3.3).  
 
Iron has a role in modulating oxidative stress. For example, under oxidative stress O2
●‾ 
can 
release Fe
2+
 from iron containing molecules. Fe
2+ 
is then readily available to react with H2O2 
resulting in the following reaction: 
Fe
2+
 + H2O2     
●
HO + OH
-
 + Fe
3+
. 
The HO
●
 radical is very reactive, as it has a half life of ~10
-9
s it reacts close to its formation. 
This demonstrates the damaging cascade of ROS as although H2O2 has relatively low 
reactivity (see 1.4.5), it has the potential to react further, generating highly reactive oxygen 
radicals (Valko et al., 2007). 
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1.4.3 Antioxidants in the Detoxification of ROS,  
There are numerous factors involved preventing ROS accumulation and maintaining ROS 
homeostasis, these are referred to as antioxidants. Antioxidants are both enzymatic and non-
enzymatic factors, which neutralise ROS to produce non-reactive oxygen species. For 
example, catalase is an antioxidant enzyme, which converts hydrogen peroxide to oxygen and 
water. Other mechanisms of detoxification include vitamins E and C, glutathione (GSH) and 
superoxide dismutase (SOD) (Macdonald et al., 2003; Scandalios, 2005). Antioxidant 
enzymes, such as SOD and catalase, are transcriptionally upregulated under conditions of 
oxidative stress through the binding of the transcription factor NrF-2 (nuclear factor E2-
related factor 2) to enhancer regions, ARE (antioxidant response element) and EpRE 
(Electrophile response element) within their gene promoter sequences (Numazawa and 
Yoshida, 2004) 
 
1.4.4 Roles and Consequences of Reactive Oxygen Species 
At low concentrations ROS have essential physiological roles, of which a few examples are 
summarised here. The arteries of carotid bodies utilise ROS to regulate ventilation. A 
reduction in arterial oxygen reduces cellular respiration, thus decreasing the quantity of ROS 
produced through the electron transport chain. The concentration of ROS acts as a sensor of 
arterial oxygen pressure, and effects signalling to control ventilation (Droge et al 2002). ROS 
also have an immunological role, as the production of free radicals by macrophages acts as a 
broad-spectrum antibiotic, destroying numerous pathogens as the first line of defence. In 
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addition to this ROS activate fibroblasts to synthesise collagen in the process of wound 
healing (Droge, 2002). 
 
In contrast however, at high levels ROS can also be pathogenic. Examples include; the 
excessive production of ROS by macrophages causes chronic inflammation and rheumatoid 
arthritis (Droge, 2002). ROS cause damage to lipids and subsequently membranes. Disruption 
of the mitochondrial membrane ultimately leads to the release of cytochrome c, and the 
initiation of apoptotic pathways (Macdonald et al., 2003). The DNA damage resulting from 
ROS is thought to be involved in the cellular aging process and the formation of cancerous 
cells (Droge, 2002). 
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1.5 Project Aims 
The overall aim of this project was to characterise the CYGB expression profile in fibrotic 
lesions, and use IHC markers of hypoxia, proliferation, angiogenesis and fibrotic severity to 
determine a mechanistic relationship between the fibrotic lesion and CYGB expression. 
Additionally in vitro models were used to investigate 2 insults associated with fibrosis, 
oxidative stress and hypoxia, and determine whether CYGB offered cytoprotection in 
response to these.  
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2.  MATERIALS AND METHODS 
 
2.1 Materials 
All materials were of the highest quality available and the majority were supplied by Sigma-
Aldrich Company Ltd, Poole, UK. The suppliers of other materials are summarised in 
appendix. 
 
2.2  Cell Culture 
2.2.1  Culturing Cells 
Cell culture was carried out under sterile conditions maintained by a class II tissue culture 
hood (Aura 4, Bio Air, Italy). All reagents were autoclaved and exposed solely to sterile 
conditions. Human Embryonic Kidney 293 cells (HEK Cells) and Cytoglobin over expressing 
HEK293 cells (CYGB+ cells) (both cell lines were donated by AstraZeneca) were maintained 
with DMEM media (Dulbecco’s Modified Eagles Medium (1000 mg/L glucose), 10 % (v/v) 
Fetal bovine serum (FBS), 2 mM L-Glutamine, 100 units/ml penicillin, 100 µg/ml 
streptomycin).  
 
The cell lines were cultured in 25 cm
2
 (T25) and 75 cm
2
 (T75) flasks in a humidified chamber 
(AirAura 4, Bio Air, Italy. 5 % CO2, 95 % Air.) at 37˚C. Every other day the cells were either 
reseeded or the media was replaced with fresh media, depending upon the confluency of the  
cells. Cells were re-seeded or frozen once they reached 70-80 % confluency. 
 
 
 
50 
 
2.2.2 Seeding and freezing cells 
The media was aspirated off, and cells washed with phosphate buffered saline (PBS, 2.7 mM 
KCl, 137 mM NaCl, and 10  mM Phosphate Buffer, pH7.4).  Trypsin-EDTA (0.25 % Trypsin, 
0.02 % EDTA) was added to detach the cells from the flask surface. Following a 10 minute 
incubation of the cells in a humidified chamber (37˚C, 5 % CO2, 95 % Air.), DMEM media 
was added, inhibiting the trypsin. The suspension was centrifuged at 1000 rpm for 3 minutes 
using a Sanyo MSE falcon 6/300. The supernatant was removed and the pellet resusupended 
in fresh media, or freezing media (FBS with 10 % (v/v) dimethylsulphoxide (DMSO)). 
 
Cells re-suspended in freezing media were placed into cryovial’s (Nalgene, New York) and 
stored, in a polystyrene box overnight at -80˚C before being moved to liquid nitrogen for 
long-term storage.  Cells re-suspended in fresh media were counted using a haemocytometer 
(a minimum total count of 100 cells, over 4 or more quadrants), and seeded at an appropriate 
density into relevant cellware. 
  
2.3 Protein Analysis 
2.3.1 Protein Extraction 
Cells were cultured in T25 flasks, or 6 well plates. The media was aspirated and cells washed 
with 5 ml of warm PBS. The cells were scraped into RIPA buffer (50 mM Tris pH 7.6, 150 
mM NaCl, 1% (v/v) NP-40, 1 mM EDTA, 1% (w/v) Sodium-deoxycholate, 1 mM NaF) and 
transferred to an eppendorf tube. Cell lysis was achieved by vigorous pipetting with a Gilson 
P1000, followed by 30 minutes incubation on ice, with vortexing at 10 minute intervals. The 
cells were then centrifuged at 13, 000rpm, 4˚C for 10 minutes in a bench top centrifuge 
(Sanyo Hawk MSE 15/05). Following centrifugation the supernatant was aspirated from the 
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pellet and transferred to an eppendorf. This was used immediately or placed in liquid nitrogen 
(snap freezing) and stored at -80˚C. The pellet was discarded.    
 
2.3.2 Protein Quantification 
2.3.2.1 Bradford Assay 
The Bradford assay was used when quantifying proteins at The University of Birmingham. 
Protein quantification was determined using the protocol described by Bradford  
(Bradford, 1976). The reagent was prepared by diluting 1:5 in UHQ water and filtered using a 
syringe and a 0.45µm filter. The absorbance of the samples was measured by a 
spectrophotometer at wavelength 595nm. A standard curve (1-10 µg/ml Bovine serum 
albumin (BSA)) was used to estimate the protein concentration within the samples.  
 
2.3.2.2 BCA Protein Assay  
The BCA Protein Assay Kit was the standard method for quantifying proteins at AstraZeneca, 
Loughborough. This was used to quantify protein samples extracted from HEK 293 and 
CYGB+ following treatment with hypoxia (Chapter 5) and hydrogen peroxide (Chapter 6) 
prior to western blotting. The principle of the kit is similar to that of the Bradford assay, in 
that a colour change occurs upon the addition of protein, and a standard curve is created 
which is used to estimate the concentration of the unknown samples. The kit was used 
following the manufacturer’s instructions.   
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2.3.3 Concentrating Protein Samples 
A centrifugal filter unit (Millipore) was used to concentrate the protein samples, according to 
the manufacturer’s instructions. Protein samples from HEK cells and CYGB+ cells were 
centifuged at 14,000g and 4
o
C for 10 minutes. 
 
2.3.4 Western Blotting 
Unless otherwise stated, 20 µg of protein was loaded onto either a 12% polyacrylamide gel 
obtained from BioRad, or 12.5 % polyacrylamide gel made in house (Stacking gel (4 %): 4 % 
Acrylamide, 125 mM Tris-HCl pH6.8, 0.1 % SDS, 10 μl/10 ml TEMED, 10 % (w/v) APS.  
Resolving gel (12.5 %): 12.5 % Acrylamide, 375 mM Tris-HCl pH8.8, 0.1 % SDS, 15 μl/10 
ml TEMED, 10 % (w/v) APS). At least one molecular weight marker was loaded along-side 
the samples. The gel was electrophorised in running buffer (25 mM Tris base, 192 mM 
glycine, 0.1 % SDS), using BioRad power Pac 200, for 90 minutes at 100 volts.  
 
Following electrophoresis the gel was removed and incubated for 15 minutes at 4˚C in 
transfer buffer (20 mM Tris base, 150 mM glycine, 20 % (v/v) methanol). The stacking gel 
was removed and covered with a nitrocellulose membrane, which had been pre-soaked in 
transfer buffer. This was sandwiched between scotch brite pads and 2 layers of filter paper on 
either side, and placed in the transfer cassette. This was placed, alongside an ice block (for 
cooling), into an electrophoresis tank, filled with transfer buffer, and electrophorised for 120 
minutes at 100 volts. Following transfer the membrane was incubated on a shaker in blocking 
buffer (0.1 M Tris base, 0.15 M NaCl, 0.05 % (v/v) Tween 20, 5 % (w/v) low fat powdered 
milk, pH8) either at 4˚C overnight, or at room temperature for 1 hour.  
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The blocking buffer was removed and the membrane washed with wash buffer (0.1 M Tris 
base, 0.15 M NaCl, 0.05 % (v/v) Tween 20, pH 8). If samples were being probed with 2 
antibodies the molecular weight (MW) marker was used to guide cutting of the membrane in 
half horizontally, so that each half contained the correct area of the membrane. The membrane 
was than incubated with the appropriate dilution of primary antibody (details in legend of 
relevant figure) in blocking buffer, either at 4˚C overnight, or at room temperature for 1 hour, 
on a shaker. 
 
The membrane was then washed 6 x 5 minutes with wash buffer, prior to a 1-hour incubation 
with the secondary antibody (unless stated otherwise a goat anti mouse secondary was used 
(diluted 1:10,000)) diluted in blocking buffer, at room temperature on a shaker. The 
membrane was washed 6 times over 30 minutes with wash buffer. 
 
The membrane was then incubated with chemiluminescence reagents (following 
manufacturer’s instructions) for 1 minute. In the absence of light, hyperfilm was laid onto the 
membrane for a maximum of 5 minutes and then developed using an x-o-graph machine.  
 
2.3.5 Fluorescence Microscopy 
HEK and CYGB+ cells were seeded at 50,000 cells per well on Lab-Tek II chamber slides 
(previously coated with 10 % fibronectin) and incubated overnight in a humidified chamber (5 
% CO2, 95 % Air) at 37˚C. 
 
The cells were fixed in 10 % formalin for 15 minutes at room temperature, followed by 3 
washes with PBS. The permeability of half the wells of each cell line was increased by the 
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addition of 0.1 % triton-x-100/PBS followed by 3 washes with PBS. The cells were then 
blocked with 3 %  BSA/PBS for an hour. The BSA was aspirated and the cells were incubated 
with either an anti-cytoglobin (monoclonal, at 0.125, 0.17, 0.25, 0.5, 1, 2 or 10 µg/ml) or anti-
α-tubulin (5 µg/ml) antibody diluted in 3 % BSA/PBS for 90 minutes. An anti-α-tubulin 
antibody was used as a positive control. Two controls of background staining were used, 
Mouse IgG1 was used as an isotype control (10 µg/ml) to measure non specific antibody 
staining and the primary antibody was replaced with buffer to determine levels of non specific 
binding of the secondary antibody and endogenous fluorescence.  
 
The cells were washed 3 times with PBS and a rabbit anti mouse Alexa-488-labelled 
secondary antibody (diluted 1:300) was added for 40 minutes. Following this the cells were 
washed three times with PBS. The chamber was removed and vectashield mounting medium 
containing propidium iodide and a coverslip added. These could then be kept in the dark at 
4˚C for several weeks and analysed using a confocal microscope (AxioPlan 2 Imaging, 
Zeiss,).  
 
Fluorescence microscopy (AxioPlan 2 Imaging, Zeiss,) was used to visualise the cells, and 
photos were taken digitally (AxioVision 3.1). 
 
2.4 Histology 
Human tissue was fixed for 48 hours in 10 % buffered formalin processed through alcohols 
and embedded in paraffin. Four micron sections were cut by the histology team at 
AstraZeneca, Loughborough, on a microtome and dried overnight at 37
o
C. Sections were 
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dewaxed in xylene, ethanol, and industrial methylated spirit and placed in water prior to 
staining. 
 
2.4.1 Haematoxylin and Eosin Staining 
The histology team at AstraZeneca (Charnwood) stained the sections with Gills II 
Haematoxylin (Pioneer Research Chemicals Ltd, Colchester, Essex, UK), and Eosin Y (Acros 
Organics, Fisher Scientific, Loughborough, Leicestershire, UK) on a Leica ST5020 
Autostainer (Leica Microsystems, Milton Keynes, Buckinghamshire, UK) using standard 
procedures (Bancroft and Stevens 1990).  
 
2.4.2 Immunohistochemistry (IHC) 
The antibodies used to determine cell types immunohistochemically, and the appropriate 
protocols are summarised in Table 3.1 The cell types the antibodies were used to identify are 
summarised in section 3.3.  
 
Standard Procedure  
Antigen retrieval of the sections, where required was achieved by using either trypsin 
digestion or heat treatment through microwaving or pressure cooking. (Table 3.1). Trypsin 
digestion involved the incubation of the slides with 0.1 % trypsin, 0.1 % calcium chloride 
pH7.8 at 37°C for 30 minutes. Microwaving involved submergence of the slides in the 
appropriate retrieval solution (Table 3.1) and microwaving at 98°C, 1 minute using a RHS-2 
rapid microwave histoprocessor (Milestone Srl, Sorisole, Italy). Pressure cooking involved 
incubation of the slides in the appropriate retrieval solution (Table 3.1), and cooking at 15 lb 
pressure for 2 minutes. The subsequent steps were carried out by hand or using a LabVision 
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Autostainer, depending on the slide number, and availability of equipment. The specific 
concentrations and reagents used for each antibody are summarised in Table 3.1.  
 
The slides were washed for 3x2 minutes with wash buffer (PBS, 0.05 % Tween, pH7.4), 
before incubating for 10 minutes with H2O2, (diluted in methanol, see Table 3.1 for 
concentration) to quench endogenous peroxides. The slides were washed in wash buffer for 
3x2 minutes. Slides were then blocked with 20 % (v/v) protein block, to reduce non specific 
binding of the secondary antibody, (see Table 3.1) for 20 minutes prior to incubation with the 
appropriate primary antibody (see Table 3.1, diluted in 0.1 %BSA in PBS with 0.05 % 
Tween, except the anti-cytoglobin antibody (which was diluted in normal horse serum see 
Table 3.2) for 60 minutes at room temperature (or overnight at 4
o
C). Appropriate isotope 
controls (see Table 3.1), applied at the same concentration as the primary antibody of interest 
were used to differentiate between true signal and background. The sections were then 
incubated with the appropriate secondary antibody (see Table 3.1), diluted in 0.1 %BSA in 
PBS with 0.05 % Tween, for 20 minutes at room temperature. Amplification of the signal was 
achieved by incubating with an amplification kit (see Table 3.1 for when each of the kits was 
used) after washing with wash buffer for 3x2 minutes. The amplification kits used were 
StreptABComplex/HRP kit (ABC), Tyramide Signal Amplification
TM
 kit (TSA), and 
EnVision
® 
FLEX (see below for details). All the kits were used following manufacturers 
instructions. When the EnVision
® 
kit was used the wash buffer supplied in the kit was used 
for the IHC protocol instead of the PBS with 0.05 % Tween, the incubation time with the 
primary antibody was reduced to 30 minutes and the block and secondary antibody steps were 
eliminated from the protocol. 
57 
 
 
3,3'-diaminobenzidine (DAB) was used as the chromagen, the incubation time with DAB 
varied depending upon the primary antibody being used. A positive control was used to 
determine the DAB time every time the antibody was used, which was replicated for all other 
sections. The sections were counterstained with haematoxylin and dehydrated by grading 
through the alcohols to xylene, before mounting in mounting medium (Merck, Lutterworth, 
Leicestershire, UK). 
 
Principles of the StreptABComplex/HRP kit (ABC) 
The ABC kit is used after incubation with a biotinylated secondary antibody. A 
Streptavidin/Horseradish Peroxidase (HRP) conjugate from the ABC kit binds to the 
secondary antibody through avidin-biotin binding (See figure 2.1). The HRP then oxidises 
DAB producing a brown colour.  
 
Principles of the Tyramide Signal Amplification
TM
 kit (TSA) 
The TSA kit works on similar principles to the ABC kit, but there is an additional step. The 
TSA kit is used after incubation with a biotinylated secondary antibody. A 
Streptavidin/Horseradish Peroxidase (HRP) conjugate from the TSA kit binds to the 
secondary antibody through avidin-biotin binding (See Figure 2.2). An additional reagent is 
then added, which is oxidised by the HRP and biotin labelled tyramide is produced. The 
biotin labelled tyramide deposits around the site of the antigen. The Steptavidin/HRP 
conjugate is then added again, and binds through avidin-biotin binding, to the deposited 
biotin, thus increasing the number of HRP molecules available in the region The HRP then 
oxidises DAB producing a brown colour. 
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A diagrammatic representation of the principles behind the A) EnVision®FLEX IHC amplification kits (Dako EnVision®FLEX 
kit Brochure) and B) StreptABComplex/HRP (Dako StreptABComplex/HRP kit brochure).  
 
Streptavid
in HRP 
conjugate 
Figure 2.1 Principles of the ABC and EnVision
®
FLEX IHC Amplification Kits 
A B 
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A diagrammatic representation of the Tyramide Signal Amplification kit (TSA) (PerkinElmer® TSA Signal Amplification 
brochure) used for immunohistochemistry. 
 
Streptavidin 
HRP 
conjugate 
Figure 2.2 Principles of the Tyramide Signal Amplification kit (TSA) Kit 
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Principles of the EnVision
®
FLEX kit 
The main element of the EnVision
®
 FLEX kit is EnVision
®
FLEX Peroxidase. This is a 
polymer with a dextran backbone, to which secondary antibody molecules and HRP are 
bound (See Figure 2.1). This is added to the slides for 30 minutes at room temperature after 
incubation with the primary antibody, which must have been raised in either rabbit or mouse. 
The EnVision
®
FLEX Peroxidase binds to the primary antibody through the secondary 
antibody molecules. The HRP on the polymer then reacts with DAB to give a signal. This kit 
doesn’t involve biotin: avidin interactions eliminating any background of a biotin origin.  
 
The signal from the EnVision
®
FLEX kit can be amplified using EnVision
®
FLEX+, where a 
linker is added after incubation with the polymer. The linker increases the amount of HRP 
available for DAB to interact with, increasing the signal. 
 
2.5 The MTT Assay  
The 3-[4,5-dimthylthiazol-2-yl]-2,5-diphenyl Tetrazolium Bromide (MTT) assay is 
commonly used within the literature to measure cell viability, and was originally described by 
Mosmann (Mosmann, 1983). The MTT assay is a colorimetric assay. Water soluble yellow 
MTT readily diffuses across membranes, once within the cell, mitochondrial reductase 
enzymes react with MTT to produce formazan, a purple precipitate. The formazan is 
solubilised by adding DMSO, and the absorbance measured at 570 nm.  The presence of 
formazan is thus representative of mitochondrial function, and cell viability. 
 
CYGB+ and HEK293 cells were seeded onto collagen coated 96 well plates, and grown to 
confluence before incubation with treatments. There were at least 3 sample replicates within 
each experiment. Following treatment MTT was added to a final concentration of 0.5 mg/ml 
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and incubated for 4 hours at 37˚C. DMSO was added directly to the media to a final 
concentration of 50 % (v/v), and incubated for 24 hours at room temperature. The absorbance 
of each sample was measured using a spectrophotometer at 570nm, comparing each sample to 
a blank (equal quantities DMSO and DMEM). The experiment was repeated 3 times, and the 
mean relative absorbance used for analysis. 
 
2.6 RNA Extraction and Quantification 
2.6.1 RNA Extraction 
RNA extraction was carried out using one of 3 kits, the RNAqueaous-4 PCR kit (Ambion), 
RNeasy 96 (Qiagen) or the RNeasy mini kit (Qiagen) following manufacturer’s instructions. 
The kits all work similar principles. Cells were lysed in lysis buffer, and then frozen (in lysis 
buffer) for future RNA extraction or processed immediately. The samples were centrifuged 
onto a filter, which was washed repeatedly before the sample was eluted into RNase free 
water or elution buffer. The RNA samples were stored at -80
o
C. 
 
2.6.2 DNase Treatment of RNA Samples  
Where DNase treatment was necessary RNA was incubated with DNase I in DNase buffer 
(0.2U/µl) in a ratio of 1:1 for 45 minutes at 37
o
C. DNase Inactivation Reagent was added to 
each sample to a final concentration of 5% (v/v), the sample was mixed and incubated at room 
temperature for 1 minute. The sample was then centrifuged at 1000rpm for 10 minutes to 
pellet the DNase Inactivation Reagent.   
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2.6.3 RNA Quantification 
The RNA samples were quantified using one of the 2 following systems, Agilent RNA 6000 
Nano kit or Ribogreen® RNA Quantification kit (molecular probes), following 
manufacturer’s instructions. 
 
2.6.3.1 Agilent 
The Agilent RNA 6000 Nano kit is Lab-on-a-chip technology. RNA samples are loaded onto 
the chip alongside a molecular ladder and read by the 2100 Bioanalyzer. The amount and 
integrity of RNA is determined.  
  
2.6.3.2 RiboGreen 
The RiboGreen® RNA Quantification kit uses fluorescence to measure the RNA 
concentration within a sample.  A RNA standard was used to create both standard curves 
recommended in the kit. The curve covering most closely the range of the sample values was 
used in interpretation of the data. The standard curve and samples were incubated with 
RiboGreen reagent, which reacts with RNA to produce fluorescence, measured at 485nm 
excitation, 585nm emission using a Wallac EnVision™ (Perkin Elmer). 
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CHAPTER 3: THE CYTOGLOBIN EXPRESSION PROFILE 
OBSERVED IN COPD AND IPF TISSUE. 
 
 
3.1 Introduction  
The expression of CYGB has been shown to be induced in response to fibrotic stimuli in vivo 
and in vitro (see general introduction for further details) (Nakatani et al., 2004; Xu et al., 
2006). It has been observed that cytoglobin expression is induced during fibrosis of the lung, 
liver, pancreas and kidney (Nakatani et al., 2004). In vitro over expression of CYGB has been 
shown to offer protection against oxidative stress induced fibrogenesis (Xu et al., 2006), and 
over expression of CYGB in vivo increased recovery prospects of fibrosing tissue (Xu et al., 
2006). Contradictory, over expression of CYGB has also been shown to increase collagen I 
mRNA expression in vitro (Nakatani et al., 2004). 
 
Cytoglobin expression has been observed within fibroblasts in a variety of tissues in man, rats 
and mice. The fibroblast is a key player in fibrogenesis, and a substantial increase in cell 
number is observed. The literature presents evidence of 3 origins of fibroblasts during 
fibrosis: Proliferation of resident fibroblasts; Epithelial mesenchymal transition; and 
migration of circulating mesenchymal precursors. Potentially the cytoglobin expression 
profile of fibroblasts could relate to their origin. 
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The profile of CYGB expression within and around the fibrotic lesion remains elusive, as 
does the characterisation of the cell types which present with cytoglobin expression in fibrotic 
tissue, and the changes with fibrotic disease progression, all of which would aid in 
determining the role of CYGB in the fibrosis. 
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3.2 Aim 
The aim of this study was to characterise the cell types which express CYGB in normal and 
fibrosed human lung, determine the changes in cell type distribution with fibrotic disease 
progression and the subsequent changes in the CYGB expression profile. Lung resections 
taken from COPD and IPF patient were used as models of fibrosis. 
 
The specific objectives were: 
 To identify the cell types within IPF, COPD and non fibrosed control tissue which 
presented with CYGB immunoreactivity. 
 To ascertain the changes in the cell type distribution with fibrosis, and determine any 
correlation with CYGB expression.  
 Determine if the CYGB expression is related to the origin of fibroblasts. 
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3.3 Methods 
3.3.1 Immunohistochemistry 
3.3.1.1  Panel Selection 
The COPD sections used in this study were from Lung Volume Reduction Surgery (LVRS) of 
COPD GOLD Class IV patients and were ethically acquired (see appendix for an example 
ethical form completed by each patient). Tissue sections of 4μm were stained with 
Haematoxylin and Eosin (H&E) in order to determine the morphology of the sections. The 
pathology of the sections was interpreted and the sections were grouped, according to the 
predominant phenotype, into the following classifications: sclerosis, fibrosis, consolidated 
fibroplasia, diffuse fibroplasia and pneumonitis, with the intention of selecting a minimum of 
5 sections to represent each category.  Sections with processing related tissue damage, or 
surgical bleeding were eliminated. A panel of 22 sections from 14 patients was selected, 
representing 1 sclerotic section, 6 fibrosis and 5 of each of the remaining categories. In 
addition to the COPD panel, 9 sections taken from patients with IPF were used as a positive 
control for fibrosis. Sections taken from the periphery of lung tumour tissue were used as 
fibrosis-negative control tissue. From the selection of the control sections available, 5 were 
suitable for use as negative controls, as the others presented with fibrosis. 
 
3.3.1.2  Method Development 
The IHC protocol is summarised in chapter 2. In order to obtain optimal staining, each stage 
of the protocol was adapted specifically for each antibody. All of the antibodies, with the 
exception of those raised against Cytoglobin, had been previously optimised by the histology 
team at AstraZeneca, Charnwood (See below for details of optimisation). The optimised 
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method was tested and developed further, if required.  The final protocols used for each stain 
are summarised in Table 3.1  
 
Optimisation of the IHC Protocol 
The initial approach in optimising the IHC method was to determine the necessity of antigen 
retrieval, and most efficient method. The antigen retrieval methods investigated included 
treatment with either trypsin, or heat. Heat treatments were performed in Antigen Unmasking 
Fluid (Vector Labs: H-3300), using a microwave (98ºC 1 min) or pressure cooker (15lb, 2 
minutes).  
 
The initial protocol optimisation experiment used the following protocol. The sections were 
de-waxed using xylene, ethanol and industrial methylated spirit and placed in water prior to 
antigen retrieval. Endogenous peroxides were quenched with 0.5% hydrogen peroxide, before 
incubating with the appropriate primary antibody, for 1 hour at room temperature. The 
concentration of the primary antibody used was ascertained using manufacturer’s instructions 
and, or previously optimised methods. The sections were then incubated with an appropriate 
secondary antibody, followed by the reagents of the TSA kit. DAB was applied to the sections 
for a maximum of 20 minutes or until a signal was observed. Appropriate isotope controls, 
applied at the same concentration as the primary antibody, were used to differentiate between 
true signal and background (see Table 3.1).  
 
Should staining prove unsuccessful, further antigen retrieval methods were investigated, 
including incubating the slides in Boric Acid (0.2M) at 60
o
C overnight, and using an EDTA 
based buffer, (pH 9) with heat treatment. 
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Antigen 
Recognised 
[Primary 
Antibody] 
(μg/ml) 
Antigen 
Retrieval 
Method 
[H2O2] 
(%) 
Protein 
Block 
(20%) 
Negative Control Secondary 
Antibody 
[Secondary 
Antibody] 
(μg/ml) 
Signal 
Amplification 
System 
αSMA 0.7 None 0.5 NGS Mouse IgG2a kappa BioGaM 4.5 TSA 
CD3 4 PC AUF 0.5 NSS Rabbit Ig BioSaR 1.8 ABC 
CD31 (PECAM-
1) 
3.75 None 3 NGS Mouse IgG1 BioGaM 4.5 TSA 
CD34 Class II 1.6 MW-AUF  6 NGS Mouse IgG1 BioGaM 4.5 ABC 
C-Kit 150 PC-AUF 3 NGS Rabbit Ig BioGaR 0.5 ABC 
Collagen I 5.5 PC-AUF 0.5 NGS Mouse IgG1 BioGaM 4.5 ABC 
Cytoglobin 5 MW-AUF 3 NHS Mouse IgG1 BioHaM 5 TSA 
Cytokeratin 1.7 MW -
EDTA 
0.5 NGS Mouse IgG1 BioGaM 4.5 ABC 
Desmin 2.3 None 0.5 NGS Mouse IgG1 BioGaM 4.5 ABC 
MAC 387 3.3 MW-AUF 0.5 - Mouse IgG1 - - EnVision 
PCNA 0.45 PC-AUF 3 NGS Mouse IgG2a BioGaM 4.5 ABC 
Surfactant 5 MW- 
AUF 
0.5 NHS Mouse IgG2b BioHaM 5 ABC 
Vimentin 3.6 MW- 
AUF 
0.5 NGS Mouse IgG1 BioGaM 4.5 ABC 
Wheat Germ 
Agglutinin 
5 None 0.5 NHS Acetylglucosasmine 
Sugar 
- - ABC 
Table 3.1 Immunohistochemistry Protocol Details for each Antibody 
A table to summarise the details of immunohistochemical protocols used for specific antibodies.  KEY AUF: Antigen Unmasking Fluid (Vector Labs). H:  
High pH Retrieval Solution (Dako). EDTA: 1mM EDTA based buffer pH9 MW: Microwave. PC: Pressure cook. NGS: Normal Goat Serum. NHS: 
Normal Horse Serum. BioGaM: Biotinylated Goat anti Mouse. BioGaR: Biotinylated Goat anti Rabbit. BioSaR: Biotinylated Swine anti Rabbit. BioHaM: 
Biotinylated Horse anti Mouse. TSA: Tryamide Signal Amplification Kit. ABC: Streptavidin AB/HRP kit. αSMA: α smooth muscle actin, PCNA: 
proliferating cell nucleur antigen 
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Once a retrieval method had been established, further optimisation, if required was used to 
enhance the signal and reduce background staining. Different amplification kits were 
investigated, such as ABC, EnVision FLEX® and EnVision FLEX+® (See chapter 2 for 
more details). The concentration of the antibody was increased or decreased, and overnight 
(4ºC) incubation was investigated. The concentration of hydrogen peroxide was increased to 
3% or 6%. Secondary antibodies raised in horse were investigated, as was diluting the 
antibodies in serum rather than diluent.  
 
3.3.1.3  Dual Staining 
Dual staining of S100A4 and CD3 was used to as a marker of fibroblasts. The sections were 
de-waxed using xylene, ethanol and industrial methylated spirit and placed in water prior to 
staining. The sections were pressure cooked in Antigen Unmasking Fluid for 2mins at 15lb 
pressure for antigen retrieval. Endogenous peroxides were quenched with 3% hydrogen 
peroxide for 10minutes at room temperature. Sections were blocked with normal swine serum 
(20%) before incubation with a rabbit anti human anti-CD3 primary antibody (8µg/ml) for 1 
hour at room temperature. The isotype control used was rabbit Ig (Dako). A biotinylated 
swine anti rabbit (5µg/ml) secondary antibody was then added to the sections followed by the 
reagents of the ABC kit. Staining used a nickel DAB chromogen. The sections were stored in 
water during the staining process. A rabbit anti human S100A4 primary antibody (0.9µg/ml) 
was then added for 1 hour at room temperature, followed by the EnVision kit. The isotype 
control was Rabbit Ig (Serotec). The sections were stained using a red chromogen 
(NovaRED), before dehydration by grading through the alcohols to xylene, and mounting in 
DPX mounting medium (Merck, Lutterworth, Leicestershire, UK) 
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3.3.1.4  Sirius Red Staining 
The slides were dewaxed using xylene, ethanol and industrial methylated spirit and placed in 
water prior to staining with Gills Haematoxylin for 10 minutes. The sections were then 
washed in running tap water, before incubating with picro-sirius red (0.1% (w/v) sirius red in 
saturated aqueous solution of picric acid) for 1 hour. The slides were washed twice in 
acidified water (31.25% (v/v) glacial acetic acid) before dehydration in ethanol and xylene, 
and mounting in DPX mounting medium (Merck, Lutterworth, Leicestershire, UK).  
 
3.3.1.5  Microscopy and Photography 
The slides were analysed using an Axioskop 2 plus microscope (Zeiss) with a polarised lens. 
Pictures were taken using a Kodak Imaging programme. 
 
3.3.1.6  Determining Cytoglobin Positive Cell Types 
The panel was stained with an array of cell specific markers which are summarised in the 
table 3.2. Serial sections were stained to enable comparison between one slide and the next. 
Every 5
th
 section was stained for CYGB. Where more than one marker was needed to identify 
a specific cell type, unless stated otherwise, parallel sections were stained with appropriate 
markers and the relative staining of cell populations was compared to identify if a cell 
population was staining with one of the markers or both. The same approach was used to 
identify CYGB positive cell populations: The positive staining cell population observed on 
one slide (representing a specific cell type) was compared to that which stained with CYGB 
on another slide to identify Cygb+ cell populations. Each section selected in the panel was 
examined for the presence of each of the cell types summarised below. The cell types which 
were observed to be Cygb+ on each section were noted. Using serial sections has limitations,  
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Cell Type Markers used 
Positive Negative 
Fibroblast Vimentin  
S100A4 
CD34 
α Smooth Muscle Actin 
CD3 
Haematopoietic 
Fibroblast  
Vimentin  
S100A4  
CD34 
α Smooth Muscle Actin 
CD3 
Myofibroblast Vimentin  
S100A4  
α Smooth Muscle Actin 
CD34 
CD3 
 
Haematopoietic 
Myofibroblast 
Vimentin  
S100A4 
CD34 
α Smooth Muscle Actin 
CD3 
Smooth Muscle α Smooth Muscle Actin 
Desmin 
 
Haematopoietic Stem 
Cell 
c-kit 
CD34 
 
Vimentin 
T cells CD3 
 
 
Endothelium CD31 
 
 
Type II Pneumocytes Surfactant A 
 
Cytokeratin 
Differentiating Type II 
Pneumocytes 
Surfactant A 
Cytokeratin 
 
Type I pneumocytes Lectin 
 
 
Macrophages MAC387  
 
 
Table 3.2  Summary of Cell Specific Markers 
A table to summarise the markers used to identify specific cell types using 
immunohistochemistry. Positive refers to the cell type showing expression of the marker, 
negative refers to the absence of the marker 
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Of particular note one cannot be definite about co-localisation of a stain within a particular 
cell as though present on one slide a cell may be absent from the next. Notably therefore 
populations of cells were compared between serial sections rather than individual cells. 
 
3.3.1.6.1 Identifying Fibroblasts 
Several markers were used to identify fibroblasts, and the sub populations of fibroblasts. 
Vimentin, a mesenchymal marker reacts with fibroblasts cells. S100A4 reacts with fibroblasts 
and CD3+ lymphocytes. Dual staining for S100A4 and CD3 was used to identify fibroblasts, 
however there was some steric hindrance in the dual staining, and as such CD3 did not stain 
all the CD3+ cells in the sections. Parallel staining for vimentin was also used to verify that 
cell populations were of a mesenchymal origin, and therefore fibroblasts. 
 
Myofibroblasts were identified from the fibroblasts population using an antibody against 
αSMA. The fibroblasts were categorised further, by examining cross reactivity with CD34, a 
marker of former haematopoietic origin. 
 
The 4 categories:  
Haematopoietic Fibroblasts    Vimentin+ S100A4+ CD3- CD34+ αSMA-  
Fibroblasts      Vimentin+ S100A4+ CD3- CD34- αSMA-  
Haematopoietic Myofibroblasts   Vimentin+ S100A4+ CD3- CD34+ αSMA+  
Myofibroblasts     Vimentin+ S100A4+ CD3- CD34- αSMA+  
 
Of note, where the S100A4+, Vimentin+, CD3- population was more abundant than the 
staining for both αSMA and CD34, and there was a presence of both αSMA and CD34 
markers, it was assumed CD34+ and CD34-, myofibroblasts and fibroblasts were present (the 
relative amounts of CD34 and αSMA staining were used to determine the assumed ratio of 
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fibroblast phenotypes). Without dual staining it was not possible to ascertain if the CD34+ 
population belonged solely to the αSMA+ or – population, or vice versa. 
 
3.3.1.6.2 Identifying Smooth Muscle Blocks 
It is widely known that actins are proteins which contribute to the microfilament structure of 
the cytoskeleton, and have a role in cellular contraction. There are several different isoforms 
of actin, of which α-smooth muscle actin (α-SMA) is found in smooth muscle cells. This was 
therefore used as a marker of smooth muscle cells, however other cells type are also positive 
for this marker, including myofibroblasts and myoepithelial cells.  
Desmin is another component of the cytoskeleton, and is specific to muscle cells. Staining for 
desmin and α-SMA (on parallel sections) was used to differentiate smooth muscle cells from 
myofibroblast and myoepithelial populations. 
 
3.3.1.6.3 Identifying Stem Cells of a Hematopoietic Origin 
Immunoreactivity with CD34 and c-kit (CD117) was used to identify stem cells of a 
hematopoietic origin.  
 
3.3.1.6.4 Identifying microvasculature 
CD31 was used to identify the microvasculature. The CD34 phenotype of the 
microvasculature was also noted.  
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3.3.1.6.5 Identifying pneumocytes 
Type II pneumocytes were identified using surfactant A. In addition pan cytokeratin was used 
to identify the subpopulation of type II pneumocytes which were differentiating into type I 
pneumocytes. Wheat Germ Agglutinin (WGA) was used to identify type I pneumocytes 
 
3.3.1.6.6 Identifying inflammatory cells 
CD3 was used to identify T-lymphocytes and MAC387 was used as a marker of 
macrophages. Of note CD3 is present on the majority of T-lymphocytes but can be lost with 
maturity.  
 
3.3.1.7  Characterising the Cytoglobin Expression Profile of Fibrotic Lesions 
Each of the COPD, IPF and normal sections were examined and a fibrotic lesion, or a region 
of parenchyma, was selected for analysis on each section. There were 3 criteria which had to 
be met for the region to be selected for analysis, the first was that it was one of the most 
fibrosed regions on the section, the second, that the pathology of the region was constant 
throughout all of the slides being used in analysis, and finally that the region could 
confidently be navigated to on subsequent sections, ensuring comparison of equivalent areas. 
There were 20 lesions interpreted from COPD tissue, 9 from IPF tissue and 5 from controls. 
 
3.3.1.7.1  Applying a Fibrosis Score to each Lesion 
Each selected region was first given an overall grade for fibrosis. A fibrotic score was applied 
using the scoring system described by (Ashcroft et al., 1988). Additionally a Sirius red 
grading system was applied. Sirius red stains small and large collagen fibres green and orange 
respectively, the relative amount of green to orange staining was used for scoring.  Collagen I, 
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which increases with fibrosis, forms classic large collagen fibres, and thus can be typically 
identified by yellow orange staining. Collagen III, which decreases with fibrosis, typically 
forms small reticular fibres which stain green with Sirius red. Of note the size and 
arrangement of the fibre determines the colour observed rather than any other characteristic, 
as the colour generated is due to bifurcation of light via a polarised lens (Montes and 
Junqueira, 1991). Collagen II for example can show weak staining of either colour.  
    
Grade 1: 25% > Orange 
Grade 2: 45% > Orange >26% 
Grade 3: 54% > Orange >46% 
Grade 4: 74% > Orange >55% 
Grade 5: 75% < Orange 
 
The fibrosis scores of the lesion were compared to the scores representing the density of 
specific cell types and the CYGB expression profile observed (see 3.3.1.7.2 for details)  to 
determine if there was a relationship between the extent of fibrosis and the cell type and 
CYGB characteristics of the lesion. 
 
3.3.1.7.2 Characterising the Cell type Distribution and Associated Cytoglobin Profile 
of the Fibrotic Lesion 
Where fibrotic lesions were selected for analysis, the lesion was segregated into zones, the 
‘Acellular Zone’, ‘Fibrotic border’ and ‘Edge’ (See figure 3.1), and each region was 
interpreted independently. For every zone of every lesion the following interpretation was 
done.  
1. To determine the cytoglobin expression across the lesion a cytoglobin expression 
profile was assigned to each region. This took into account the expression of CYGB 
in cells which had previously shown CYGB expression in the panel, as such negative 
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staining observed in smooth muscle cells, red blood cells, tumour cells and nerve 
cells did not contribute to the classification. If all cells (other than smooth muscle, 
red blood cells, nerves and tumour cells) in the region were positive it was assigned a 
Cygb+ profile, if all were negative a Cygb- profile. If there was a mix of Cygb+ and 
Cygb- cells it was classified as showing a mixed profile.  
2. Cell type markers were used to determine the presence or absence of the cell types 
summarised previously (see table 3.2 for details about identifying specific cell types).   
3. Each cell type graded to represent the relative density of the cell type, 0: No staining. 
1: sparse 2: midway and 3: abundant  
4. For each cell type observed within each zone of the fibrotic lesion the CYGB 
expression profile was determined.  
Negative:  There was no evidence of CYGB staining in the cell population 
Mixed:  There was evidence of CYGB staining in the cell population, but not 
the entire cell population 
Positive:  The cell population was all CYGB positive 
 
For example, CD3 was used to identify lymphocytes in a lesion. The AZ and edge were 
negative for CD3 but the fibrosing border demonstrated sparse CD3 immunoreactivity. The 
density of the CD3 cell population was noted to be grade 1 in the fibrosing border and grade 0 
in the AZ and edge. The CD3 population in this region showed both positive and negative 
immunoreactivity for CYGB so was assigned a mixed CYGB profile. 
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Figure 3.1  Zones of the Fibrotic Lesion 
Pictures of H&E staining to show different regions observed in a fibrotic lesion, and a diagrammatic 
representation. Top left picture: an acellular zone observed in COPD (x20). Top right picture: An edge lesion 
observed in COPD (X20). Bottom left picture: An acellular zone and fibrotic border observed in COPD (x10). 
Bottom right picture: an acellular zone and fibrotic border observed in IPF (x10). Black stars highlight 
acellular regions, blue stars highlight the fibrosing border and red stars highlight ectopic smooth muscle 
bundles observed in IPF. The key cell types are presented in the diagrammatic representation of a fibrotic 
lesion Purple region: normal parenchyma. Blue region: Edge. Red region: Acellular zone.     Fibroblasts        
o   Endothelial cells     Inflammatory cells         Type II pneumocytes            collagen and elastins 
Efe   Alveolar wall 
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3.3.1.8  Analysing the cell density data 
The data was collated, and each disease state and lesion zone were analysed independently, 
forming 7 categories: COPD AZ, COPD Fibrosing border, COPD edge, IPF AZ, IPF 
fibrosing border, IPF edge and control tissue. For each category the number of lesions which 
presented with each cell type was calculated. For example, the frequency of lesions in which 
CD3 staining was observed in each category: 
 
           Frequency 
COPD AZ    0 
COPD Fibrosing border  14 
COPD edge     3 
IPF AZ     0 
IPF fibrosing border    9 
IPF edge    1 
Control tissue    4 
 
The number of lesions which presented with each cell type at each density was then calculated 
for each category. For example the frequency with which CD3 was observed at each density 
level: 
 
Density Score:  0 1 2 3 
COPD AZ   18 - - - 
COPD Fibrosing border 6 6 2 6 
COPD edge    16 3 - - 
IPF AZ    9 - - - 
IPF fibrosing border   - 1 2 6 
IPF edge   8 1 - - 
Control tissue   1 4 - - 
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This data was presented graphically, where the total size of the bar of the graph represented 
the number of lesions which present with each cell type, and the formats within the bar 
represented the frequency of each of the density scores for the relevant cell type.  
 
Graphical representation of each category enabled comparative analysis of cell type densities 
between both disease and fibrotic area. 
 
3.3.1.9 Analysing the Cytoglobin Expression Data 
CYGB staining data was collected and analysed in the same manner as the cell density data. 
Each region of the lesion was interpreted individually, and a CYGB profile grade was applied 
to each cell type present. For each cell type, the number of lesions which presented with each 
CYGB grade was calculated. This data was presented graphically, where the total size of the 
bar of the graph represented the number of lesions which present with each cell type, and the 
formats within the bar represented the frequency of each of the CYGB scores for the relevant 
cell type. 
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3.4   Results 
3.4.1 Cytoglobin Expression in a Range of Cell Types Within the Human Lung 
The CYGB expression profile of human lung cells was identified immunohistochemically in 
formalin fixed paraffin embedded tissue sections, ethically acquired from patients with COPD 
(COPD GOLD Class IV) and IPF. Sections from peripheral tumour tissue were used as non 
fibrosed controls. Cell type markers, summarised in the table 3.2, were used to determine the 
specific cell types. In order to determine the CYGB staining profile for each cell type, serial 
sections were stained using anti-CYGB and the relevant cell specific antibody and the positive 
cell populations were compared.   
 
Parenchymal cells which stained positively for cytoglobin in IPF, COPD and control tissue 
included fibroblasts, myofibroblasts (see figure 3.2), lymphocytes, macrophages (see figure 
3.3) endothelial cells (see figure 3.4), type I pneumocytes and type II pneumocytes (see figure 
3.5). Bronchiolar epithelium and peri-bronchiolar chondrocytes stained positively for 
cytoglobin in IPF, COPD and control tissue (see figure 3.6). Peri-bronchiolar smooth muscle 
was consistently negative (see figure 3.6). Within the vasculature, endothelial cells showed 
immunoreactivity for cytoglobin, as did vimentin positive cells within the intima and media, 
and fibroblasts and myofibroblasts within the adventisia (see figure 3.4). Red blood cells were 
consistently negative. Of note, tumour and nerve cells had a cytoglobin negative profile whilst 
glial cells stained positively for cytoglobin (see figure 3.7), however the frequency of these 
observations was too small (n=1) to draw solid conclusions. 
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Figure 3.2 Cytoglobin Staining in Fibroblasts 
Photographs to show cytoglobin staining (top left, highlighted by arrows) in αSMA (top right) 
negative fibroblasts in connective tissue of an IPF section. Vimentin (bottom right) and S100A4 
(bottom left) were used as markers of fibroblasts. All pictures are x20. It is evident that the 
Vimentin and S100A4 positive cell populations are also CYGB positive. Pictures are 40% of 
original size. 
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Figure 3.3 Cytoglobin Staining in Inflammatory cells 
Photographs to show cytoglobin staining (top and bottom left) in inflammatory cells. CD3 staining 
(top right) was used as a marker or lymphocytes and MAC387 (bottom right) was used as a marker 
of macrophages. The top 2 pictures are of an inflammatory foci in COPD tissue, and the bottom, a 
mucous filled bronchiole.  All pictures are x20. It is evident that the CD3 and MAC387 positive cell 
populations are also CYGB positive. Pictures are 40% of original size. Arrows highlight MAC387 
positive cells and circle highlights CD3 positive cells. 
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Figure 3.4  Cytoglobin Staining in the Vasculature 
Photographs to show CYGB staining in the vasculature. Cytoglobin staining (left) was evident in adventisia fibroblasts (small arrow), the endothelium 
(large arrow) and vimentin positive cells in the intima and media (large circle). Negatively staining red blood cells are circled (small circle). The middle 
picture shows CD31 staining which is an endothelial marker to show the endothelium of this vessel is intact and corresponds to the CYGB staining. 
The picture on the right hand side is vimentin staining to show that the vimentin positive cell populations were also CYGB positive in the intima, 
media and adventisia. All pictures were taken at x20, and are at 40% of the original size. The vessel was from a COPD section. 
10µm 
10µm 10µm 
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Figure 3.5 Cytoglobin Staining in Pneumocytes 
Photographs to show CYGB staining in pneumocytes. Cytoglobin staining (left) was evident in type II pneumocytes (arrows pointing downwards) and type I 
pneumocytes (arrows pointing upwards). The middle picture shows surfactant A staining which is a type II pneumocytes marker to show that the surfactant A 
positive cell population corresponds to those cells highlighted by downward arrows in the left hand picture. The right hand picture shows staining of wheat 
germ agglutinin (WGA) which is a type I pneumocyte marker. This picture shows that the WGA positive cell population corresponds to those cells highlighted 
by upward arrows in the left hand picture. All pictures were taken at x20 using a COPD section, and are at 40% of the original size.  
10µm 10µm 10µm 
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Figure 3.6 Cytoglobin Staining in Bronchioles 
Photographs to show cytoglobin positive staining in the epithelium, mesenchyme and chrondrocytes 
of a COPD bronchiole, and negative staining in smooth muscle blocks. The top 2 pictures show 
CYGB staining at x10 and x20 on the left and right respectively. Chondrocytes are highlighted by 
the black arrow, mesenchyme by the green arrow, epithelium by the red arrow and smooth muscle 
by the blue arrow. The middle two pictures show staining of the same region with α smooth muscle 
(muscle marker at x10) and cytokeratin (epithelium marker at x20) on the left and right 
respectively. This validates that the regions labelled in the top pictures are muscle and epithelium. 
The bottom 2 pictures are show vimentin and c-kit staining on the left and right respectively. This 
shows that the region labelled with the green arrows in the top 2 pictures contain mesenchymal 
cells and stem cells with a haematopoietic origin. Pictures are 40% of original size.  
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Figure 3.7  Cytoglobin Staining in Tumour and Nerve cells 
The top pictures shows negative CYGB staining in cells characteristic of tumour cells (x40) 
observed in COPD. The bottom picture shows a nerve bundle with CYGB positive glial cells (small 
arrow) and negative nerve cells (large arrow) observed in COPD (x20). Pictures are 40% of 
original size.  
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3.4.2 Distribution of Cytoglobin Expression Across the Fibrotic Lesion 
The fibrotic lesions observed in COPD and IPF tissue were segregated into 3 distinct regions, 
the ‘acellular zone’ (AZ), the ‘fibrotic border (FB)’, and the ‘edge’ (see figure 3.1). The 
fibrotic borders observed in COPD tissue presented with 2 different phenotypes with respect 
to vascularity, and were grouped accordingly: the vascular fibrosing border (VFB); and the 
fibrotic border with a significant loss of vascularity (FBLoV). Significant loss of vascularity 
was characterised as presenting with either a low density (grade 1, see appendix for 
photographic representation) or complete absence of CD31 staining.   
 
For each lesion analysed an overall CYGB profile was assigned to each area (see section 3.3 
for details). The CYGB profiles assigned were thus: all cells CYGB positive, all cells CYGB 
negative or a mixed profile.  As summarised in table 3.3, the cells in the AZ region 
consistently showed a positive CYGB profile in IPF and COPD lesions. The FBLoV of 
COPD lesions were also consistently positive for CYGB staining. The vascular fibrosing 
border of COPD and IPF lesion frequently displayed a mixed CYGB profile (60 and 40% of 
the lesions respectively). A mixed CYGB profile was ever present in the control tissue and the 
predominant profile at the edge. The overall CYGB expression profile of the IPF and COPD 
lesions was an all positive profile in the AZ, with an increasing bias towards a mixed CYGB 
profile across the fibrosing border towards the edge. In order to determine whether this was a 
characteristic of the lesion itself, or the cell types which localised to the different areas of the 
lesion, the density of each cell type within each area of the lesion, and the relating CYGB 
profile was determined. 
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 Edge VFB FBLoV AZ 
All positive 
CYGB profile 
COPD 35%  
(17) 
40%  
(14) 
100%  
(6) 
100%  
(20) 
IPF 44%  
(9) 
60%  
(9) 
- 100%  
(9) 
Control 0%  
(5) 
- - - 
Mixed Cygb+/- 
profile 
COPD 65% 
 (17) 
60%  
(14) 
0%  
(6) 
0%  
(20) 
IPF 56%  
(9) 
40%  
(9) 
- 0%  
(9) 
Control 100% 
 (5) 
- - - 
Table 3.3  Cytoglobin Expression Observed in Different Areas of the Fibrotic Lesion 
A table to show the overall CYGB expression observed in different regions of the fibrotic lesion, or normal parenchyma. An ‘all positive’ CYGB profile was 
assigned when all cells which have shown reactivity with CYGB were positive in the region. (The CYGB expression in cells such as smooth muscle, nerve, 
tumour and red blood cells was not taken into account as these were consistently negative). A ‘mixed’ CYGB profile was assigned when the cells (not including 
muscle, nerve, red blood or tumour) in the region showed both CYGB negative and positive expression. Represented in the table is the % of lesions interpreted 
which showed each CYGB expression profile. In brackets is the number of lesions interpreted for each category. 
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3.4.3 Distribution of Cell Types, and the Relating CYGB Expression across the 
Fibrotic Lesion 
 
Each region of each lesion was interpreted independently, creating 8 ‘categories’ for analysis: 
COPD AZ, COPD FBLoV, COPD VFB, COPD Edge, IPF AZ, IPF FB, IPF Edge and 
Control. For each category, the cell types present, and relative level of density were noted 
(See section 3.3 for details). The markers used to identify each of the cell types are 
summarised in table 3.2. The density of each cell type within each category was scored as 
follows: 0 non present, 1 low density, 2 midway, 3 high density (See appendix for a 
photographic representation of these classifications for each cell type). In addition a CYGB 
expression profile was assigned. For each cell type it was determined whether the population 
was all positive for CYGB, all negative or showed a mixed profile. The frequency at which 
each cell type presented with each level of density and each CYGB profile was calculated 
(See section 3.3 for more details), and plotted (see figures 3.8-3.11 and 3.13-3.16). 
 
The Ashcroft and Sirius red scores were used to determine if particular cell type profiles in 
the lesion related to either fibrotic score of the lesion. 
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Figure 3.8 COPD Acellular Zone 
Graphs to show the cell types which localised to the acellular zone of COPD fibrotic lesions 
and their density and CYGB expression profile (n=20). Graph A shows the cell density of each 
cell type within the region. The size of the bar represents the frequency of lesions in which 
each cell type was present, and the formats represent the number of lesions in which each cell 
type was at a particular density. White represents sparse, Black abundant and grey neither 
sparse nor abundant (see M&M and appendix for more details). Graph B shows the CYGB 
profile of each cell type within the region. The size of the bar represents the frequency of 
lesions in which each cell type was present, and the formats represent the number of lesions in 
which each CYGB profile was observed. White represents all negative CYGB expression, 
Black represents an all positive profile. F: Fibroblasts, M: Myofibroblasts, SM: Smooth 
Muscle, HSC: Haematopoietic stem cells, T: T lymphocytes, E: Endothelium, II: Type II 
pneumocytes, II-I: Differentiating type II pneumocytes, I: Type I pneumocytes 
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Figure 3.9 COPD Fibrosing Border with a Significant Loss in Vascularity 
Graphs to show the cell types which localised to the fibrosing border with a significant loss of 
vascularity in COPD fibrotic lesions (n=6) and their density and CYGB expression profile. 
Graph A shows the cell density of each cell type within the region. The size of the bar 
represents the frequency of lesions in which each cell type was present, and the formats 
represent the number of lesions in which each cell type was at a particular density. White 
represents sparse, Black abundant and grey neither sparse nor abundant (see M&M and 
appendix for more details). Graph B shows the CYGB profile of each cell type within the 
region. The size of the bar represents the frequency of lesions in which each cell type was 
present, and the formats represent the number of lesions in which each CYGB profile was 
observed. White represents all negative CYGB expression, Black represents an all positive 
profile. F: Fibroblasts, M: Myofibroblasts, SM: Smooth Muscle, HSC: Haematopoietic stem 
cells, T: T lymphocytes, E: Endothelium, II: Type II pneumocytes, II-I: Differentiating type II 
pneumocytes, I: Type I pneumocytes 
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Figure 3.10 COPD Vascular Fibrosing Border  
Graphs to show the cell types which localised to the vascular fibrosing border in COPD 
fibrotic lesions (n=14) and their density and CYGB expression profile. Graph A shows the cell 
density of each cell type within the region. The size of the bar represents the frequency of 
lesions in which each cell type was present, and the formats represent the number of lesions in 
which each cell type was at a particular density. White represents sparse, Black abundant and 
grey neither sparse nor abundant (see M&M and appendix for more details). Graph B shows 
the CYGB profile of each cell type within the region. The size of the bar represents the 
frequency of lesions in which each cell type was present, and the formats represent the 
number of lesions in which each CYGB profile was observed. White represents all negative 
CYGB expression, Black represents an all positive profile, Grey represents a mixed profile. F: 
Fibroblasts, M: Myofibroblasts, SM: Smooth Muscle, HSC: Haematopoietic stem cells, T: T 
lymphocytes, E: Endothelium, II: Type II pneumocytes, II-I: Differentiating type II 
pneumocytes, I: Type I pneumocytes 
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Figure 3.11  COPD Edge Lesion  
Graphs to show the cell types which localised to the edge of COPD fibrotic lesions (n=17) and 
their density and CYGB expression profile. Graph A shows the cell density of each cell type 
within the region. The size of the bar represents the frequency of lesions in which each cell 
type was present, and the formats represent the number of lesions in which each cell type was 
at a particular density. White represents sparse, Black abundant and grey neither sparse nor 
abundant (see M&M and appendix for more details). Graph B shows the CYGB profile of 
each cell type within the region. The size of the bar represents the frequency of lesions in 
which each cell type was present, and the formats represent the number of lesions in which 
each CYGB profile was observed. White represents all negative CYGB expression, Black 
represents an all positive profile, Grey represents a mixed profile. F: Fibroblasts, M: 
Myofibroblasts, SM: Smooth Muscle, HSC: Haematopoietic stem cells, T: T lymphocytes, E: 
Endothelium, II: Type II pneumocytes, II-I: Differentiating type II pneumocytes, I: Type I 
pneumocytes 
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  CYGB               αSMA          Vimentin 
         
CYGB              CD31              C-kit 
         
CYGB              Surfactant             WGA 
         
Figure 3.12  Cytoglobin Staining in Cells of the COPD Lesion  
Pictures to show CYGB staining within different areas of COPD fibrotic lesions. Top row is 
the AZ (x20), the middle row VFB (x10), and the bottom shows the edge (x20). Cell type 
markers are shown to demonstrate which cell type typically reside in the region. In the top 
row, the arrow highlights CYGB staining in cells which are also immunoreactive for αSMA 
and vimentin. In the middle row the thick arrow highlights CYGB staining in a cell which is 
morphalogically similar to one which stained for c-kit on a serial section. The thin arrow 
highlights CYGB staining in an endothelial cell. In the bottom row, the arrow highlights 
CYGB staining in type I and II pneumocytes at the lesion edge. Pictures are 30% of original. 
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3.4.3.1  COPD 
3.4.3.1.1 Acellular Zone 
The AZ was comprised primarily of collagen and matrix, with little or no immunoreactivity 
(IR) for any cell type marker, indicating a predominantly acellular phenotype (see figure 3.8). 
The predominant cell type was CD34- myofibroblasts, which were present in all lesions with 
some cellularity (see figures 3.8 and 3.12). Small blocks of smooth muscle were observed in a 
subset of lesions.  
 
In the AZ all cells present were positive for CYGB, with the exception of smooth muscle, 
which was consistently negative (See figure 3.8). 
 
3.4.3.1.2 Fibrosing Border with a Significant Loss of Vascularity 
The fibroblasts observed in FBLoV were exclusively either a fibroblast or myofibroblast 
population, and were present in all FBLoV, at a moderate to high density. These were 
subsequently the predominant cell type (see figure 3.9 and 3.12).  All myofibroblasts were 
CD34-.  The fibroblast population was mixed in terms of CD34 staining.  
 
Hematopoietic stem cells (HSC) were observed in all FBLoV (see figure 3.9), mostly 
however at a low density. Lymphocytes were mainly either absent or at low levels in FBLoV. 
Smooth muscle was rarely seen in the FBLoV.  By definition endothelial cells were absent or 
sparse in the FBLoV regions. Staining of the endothelial marker, CD31 was observed in 5 of 
the FBLoV lesions, of which 1 showed co-localisation with CD34 in all CD31 positive cells, 
3 showed co-localisation with CD34 in subsets of the CD31+ cells and 1 was CD34-.  
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In the FBLoV cells were predominantly CYGB positive, with the exception of smooth muscle 
which was negative. Cells of a fibroblast lineage, HSCs and T lymphocytes were exclusively 
positive for CYGB staining (see figure 3.9 and 3.12). 
 
3.4.3.1.3 Vascular Fibrosing Border 
T lymphocytes, HSCs and endothelial cells were observed consistently in VFB at a moderate 
to high cell density (see figure 3.10 and Figure 3.12). Co-localisation of the endothelial 
marker CD31 with CD34 in the VFB was observed in all lesions with the exception of 1 (see 
figure 3.10). Pneumocytes and smooth muscle were rarely present in the VFB. Cells of a 
fibroblast lineage were present in all VFB. Myofibroblasts and fibroblasts co-localised in 29% 
of VFB lesions, an exclusively myofibroblast phenotype was observed in 42% of lesions, and 
an exclusively αSMA negative fibroblast phenotype in 29% of VFB lesions.  The density of 
myofibroblasts and fibroblast varied across the lesions. A CD34+ fibroblast phenotype was 
observed in 80% of the VFB lesions, in both myofibroblasts and fibroblasts.   
 
Myofibroblasts and fibroblasts were consistently CYGB positive within the VFB. Smooth 
muscle was consistently CYGB negative, and pneumocytes consistently presented a mixed 
CYGB profile. T lymophocytes, HSCs and endothelial cells predominantly stained positive 
for CYGB, however some mixed CYGB profiles were observed (see figure 3.10). The lesions 
with a mixed CYGB profile for HSCs also presented with a mixed profile for endothelial 
cells. The lesions with a mixed CYGB profile in T-lymphocytes were not the same as those in 
which a mixed CYGB profile was observed in HSCs and endothelial cells. Individual T-
lymphocytes in the parenchyma were consistently positive, however foci of T-lymphocytes 
regularly presented with both Cygb+ and Cygb- staining within different cells of the foci.  
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There was a shift towards a mixed CYGB profile in the VFB, although most cell types 
presented with an all positive CYGB profile. (See figure 3.10 and 3.12). 
 
3.4.3.1.4 Edge Lesions 
The predominant cell types at the edge lesion were type I, type II and differentiating type II 
pneumocytes (see figure 3.11 and 3.12). The density of the different pneumocytes varied 
throughout the lesions. Cells of a fibroblast lineage were observed underneath pneumocytes at 
the fibrotic edge in 16 of the 17 edge lesions investigated, frequently at high densities (see 
figure 3.11 and 3.12). The predominant phenotype was a CD34- myofibroblast, however of 
the 16 lesions in which cells of a fibroblast lineage were observed, 9 lesions showed some co-
localisation with CD34 (56% of lesions).  Positive CD31 staining was observed in only 58% 
of the edge lesions, notably of those lesions without endothelial staining, the majority (63%) 
presented with a significant loss of vascularity in the fibrosing border (FBLoV).  CD34 
staining co-localised with CD31 staining in all but one lesion.  A minority of lesions (3) 
showed a mixed CD34+ and CD34- endothelium population. T-Lymphocytes and HSCs were 
rarely observed at the edge. 
 
Cells of a fibroblast linage were consistently positive for CYGB at the edge (See figure 3.11 
and 3.12) HSC, T-lymphocytes, and endothelial cells were predominantly CYGB positive at 
the edge. Type II pneumocytes had either an all Cygb+ or mixed a CYGB profile. Type I 
pneumocytes presented with a Cygb-, Cygb+ and mixed profile. A Cygb- profile was rare, 
observed in only 1 of 17 edge lesions.  
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At the edge, the predominant CYGB expression profile was a mixed or Cygb+ profile for all 
cell types, with the exceptions of fibroblasts and myofibroblasts, which were exclusively 
Cygb+ (see figure 3.11 and 3.12).  
 
3.4.3.2 IPF  
3.4.3.2.1 Acellular Zone 
The AZ of IPF lesions was mostly acellular, comprised of matrix and collagen. 
Immunoreactivity with any of the cell specific markers was observed in only 40% of lesions. 
Where the AZ presented with some cellularity, it consistently contained cells of a fibroblast 
lineage (See figure 3.13 and 3.16). Of the cellular lesions, 80% presented with 
myofibroblasts. CD34 staining co-localised with myofibroblasts in only 40% of lesions (n=5). 
All of the cells in the AZ were exclusively positive for CYGB expression. 
 
3.4.3.2.2 Fibrosing Border 
CD34- fibroblasts, HSCs, lymphocytes and smooth muscle cells were the predominant cell 
types in the fibrosing border of IPF lesions, and observed in all lesions, predominantly at a 
moderate or high cell density (See figure 3.14 and 3.16). Other fibroblastic phenotypes of 
cells such as CD34+ fibroblasts and myofibroblasts (CD34+ and CD34-) were observed in a 
subset of lesions (See figure 3.14). The endothelium was CD34+ in 7 of the 9 lesions. All 
lesions had a moderate to high density of endothelial cells, however the amount of CD34 
positive staining in the endothelial cells was variable throughout the IPF lesions. 
Pneumocytes were absent from the FB in IPF (See figure 3.14). 
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All fibroblast phenotypes, HSCs and endothelial cells consistently presented with Cygb+ 
staining, and smooth muscle was consistently negative for CYGB (See figure 3.14). T-
lymphocytes presented with both an all positive and mixed CYGB population (See figure 
3.14). Where a mixed population was observed it was localised to inflammatory foci where 
not all cells were Cygb+, individual T-lymphocytes in the parenchyma were consistently 
positive.   
 
3.4.3.2.3 Edge Lesions 
Differentiating type II pneumocytes (CK+) were the predominant cell type at the edge of IPF 
lesions (See figure 3.15 and 3.16). Type I pneumocytes were mostly sparse or absent See 
figure 3.15. Fibroblasts were observed under the pneumocytes in all lesions, although the 
phenotypes varied See figure 3.15. Endothelial cells were also observed in all lesions (See 
figure 3.15). A mix of CD34+ and CD34- endothelial cells was observed in 6 of the 9 lesions, 
CD34 staining was absent from one lesion, and in 2 lesions endothelial cells were exclusively 
CD34+. HSC and T-lymphocytes were rarely observed at the edge of IPF lesions, and smooth 
muscle was absent. 
 
All of the fibroblast phenotypes, HSCs, T-lymphocytes and endothelial cells were 
consistently positive for CYGB. Type II pneumocytes were exclusively Cygb+ in 
approximately half of the lesions, and had a mixed CYGB profile in the other half of the 
lesions. Type I pneumocytes predominantly had a mixed CYGB profile (See figure 3.15).  
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Figure 3.13  IPF Acellular Zone 
Graphs to show the cell types which localised to the acellular zone of  IPF fibrotic lesions and 
their density and CYGB expression profile (n=9). Graph A shows the cell density of each cell 
type within the region. The size of the bar represents the frequency of lesions in which each 
cell type was present, and the formats represent the number of lesions in which each cell type 
was at a particular density. White represents sparse, Black abundant and grey neither sparse 
nor abundant (see M&M and appendix for more details). Graph B shows the CYGB profile of 
each cell type within the region. The size of the bar represents the frequency of lesions in 
which each cell type was present, and the formats represent the number of lesions in which 
each CYGB profile was observed. White represents all negative CYGB expression, Black 
represents an all positive profile. F: Fibroblasts, M: Myofibroblasts, SM: Smooth Muscle, 
HSC: Haematopoietic stem cells, T: T lymphocytes, E: Endothelium, II: Type II pneumocytes, 
II-I: Differentiating type II pneumocytes, I: Type I pneumocytes 
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Figure 3.14  IPF Fibrosing Border 
Graphs to show the cell types which localised to the fibrosing border of IPF fibrotic lesions 
and their density and CYGB expression profile (n=9). Graph A shows the cell density of each 
cell type within the region. The size of the bar represents the frequency of lesions in which 
each cell type was present, and the formats represent the number of lesions in which each cell 
type was at a particular density. White represents sparse, Black abundant and grey neither 
sparse nor abundant (see M&M and appendix for more details). Graph B shows the CYGB 
profile of each cell type within the region. The size of the bar represents the frequency of 
lesions in which each cell type was present, and the formats represent the number of lesions in 
which each CYGB profile was observed. White represents all negative CYGB expression, 
Black represents an all positive profile. F: Fibroblasts, M: Myofibroblasts, SM: Smooth 
Muscle, HSC: Haematopoietic stem cells, T: T lymphocytes, E: Endothelium, II: Type II 
pneumocytes, II-I: Differentiating type II pneumocytes, I: Type I pneumocytes 
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Figure 3.15  IPF Edge Lesion 
Graphs to show the cell types which localised to the edge of IPF fibrotic lesions and their 
density and CYGB expression profile (n=9). Graph A shows the cell density of each cell type 
within the region. The size of the bar represents the frequency of lesions in which each cell 
type was present, and the formats represent the number of lesions in which each cell type was 
at a particular density. White represents sparse, Black abundant and grey neither sparse nor 
abundant (see M&M and appendix for more details). Graph B shows the CYGB profile of 
each cell type within the region. The size of the bar represents the frequency of lesions in 
which each cell type was present, and the formats represent the number of lesions in which 
each CYGB profile was observed. White represents all negative CYGB expression, Black 
represents an all positive profile. F: Fibroblasts, M: Myofibroblasts, SM: Smooth Muscle, 
HSC: Haematopoietic stem cells, T: T lymphocytes, E: Endothelium, II: Type II pneumocytes, 
II-I: Differentiating type II pneumocytes, I: Type I pneumocytes 
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Figure 3.16  Cytoglobin Staining in Cells of the IPF Lesion  
Pictures to show CYGB staining within different areas of an IPF fibrotic lesions. Top row is 
the AZ (x20), the middle 2 rows show the fibrotic border (x10), and the bottom shows the edge 
(x20). Cell type markers are shown to demonstrate which cell types typically reside in the 
region. In the top row, the arrow highlights CYGB staining in cells which are also 
immunoreactive for αSMA and vimentin. In the middle rows the arrow highlights CYGB 
staining in all cells in a region which shows immunoreactivity for CD31, c-kit and vimentin. 
The circle highlights negative staining in αSMA positive muscle. In the bottom row, the arrow 
highlights CYGB staining in CK+ type II pneumocytes at the lesion edge. Pictures are 30% of 
original. 
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Figure 3.17  Control Tissue 
Graphs to show the cell types which localised in non fibrosed lung parenchyma and their 
density and CYGB expression profile (n=5). Graph A shows the cell density of each cell type 
within the region. The size of the bar represents the frequency of lesions in which each cell 
type was present, and the formats represent the number of lesions in which each cell type was 
at a particular density. White represents sparse, Black abundant and grey neither sparse nor 
abundant (see M&M and appendix for more details). Graph B shows the CYGB profile of 
each cell type within the region. The size of the bar represents the frequency of lesions in 
which each cell type was present, and the formats represent the number of lesions in which 
each CYGB profile was observed. White represents all negative CYGB expression, Black 
represents an all positive profile. F: Fibroblasts, M: Myofibroblasts, SM: Smooth Muscle, 
HSC: Haematopoietic stem cells, T: T lymphocytes, E: Endothelium, II: Type II pneumocytes, 
II-I: Differentiating type II pneumocytes, I: Type I pneumocytes 
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3.4.4 Cytoglobin Expression Within Specific Cell Types In Non Fibrosed 
Control Tissue 
An array of cell types were observed in the control tissue at a high or moderate density (see 
figure 3.17), including endothelial cells, type I pneumocytes, type II pneumocytes, and 
fibroblasts (αSMA-). Myofibroblasts and T cells were sparse or absent (see figure 3.17). 
HSC’s were present in 80% of the sections, half of the lesions in which they were present, 
HSCs were at a high density and the other half they were sparse. CD34 staining co-localised 
with fibroblasts in all control tissue, there was a mix of CD34+ and CD34- fibroblasts on all 
sections, with an approximately equal ratio in 3 of the 5 sections, and in 2 of the 5 sections 
there was substantially more CD34- than CD34+ fibroblasts. CD34 was observed in all 
endothelial cells of control sections, however in 80% of sections, populations of CD34- 
endothelial cells were also observed. In 50% of the sections which presented with both 
CD34+ and CD34- staining in endothelial cells, the CD34+ and CD34- populations were at 
approximately equal densities, whilst in the other 50% the predominance was a CD34+ 
phenotype. 
 
Pneumocytes constantly had a mixed CYGB expression profile. Fibroblasts of all phenotypes 
were constantly all CYGB positive. Of the 5 control lesions, 2 presented a mixed CYGB 
profile in HSC’s, T-Lymphocytes and endothelial cells, whilst of the other 3 lesions, where 
these cell types were present they were all Cygb+. 
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3.4.5 Correlating Cell Type Distribution to Fibrotic Severity 
The density of several cell types showed heterogeneity between lesions in IPF and COPD. 
The data was ordered according to the Ashcroft and Sirius red scores for each lesion and the 
scores for each heterogenic cell type were analysed to determine whether there was a 
correlation between the fibrosis of the lesion and the cell type distribution.  
 
The AZ of COPD lesions differed in the presence or absence of smooth muscle. The presence 
of smooth muscle in the AZ correlated to lesions with high Ashcroft scores. The FBLoV, 
VFB and edge of COPD lesions showed heterogeneity in fibroblast phenotypes. There was no 
correlation in the cross reactivity of CD34 with fibroblasts at the edge, or in the fibrosing 
border of COPD lesions, with the Ashcroft or Sirius red scores. However when ordered 
according to Ashcroft score there was a trend for an increase in myofibroblasts cell density 
with increasing Ashcroft score, and a decrease in the density of αSMA- fibroblasts (See figure 
3.18). Similar observations were made at the edge. Fibroblast were observed at the edge of 
COPD lesions with low Ashcroft and Sirius red grades but absent from those with higher 
scores. An extended study would be required to draw any solid conclusions. 
 
Variations in the density of different pneumocytes at the edge, and CD34 staining of 
endothelial cells in the fibrotic border of COPD lesions were not associated with the Ashcroft 
or Sirius red scores of the lesion.  
 
There was more homogeneity in the cell types which localised to the IPF lesions. There were 
variations in the CD34 staining of endothelium in the fibrosing border, and fibroblast 
phenotypes at the edge but these did not show any correlation with the Ashcroft or Sirius red  
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scores of the lesion. The presence of type I pneumocytes at the lesion edge varied between 
lesions. Lesion with type I pneumocytes tended to have lower Sirius red scores than those 
without type I pneumocytes. Again an extended study would be required to form solid 
conclusions.   
 
3.4.6 Comparing the Cell Types which Localise to IPF and COPD Lesions 
The distribution of cell types varied between the IPF and COPD lesions. Overall there was a 
higher density of HSCs and CK+, differentiating type II pneumocytes in IPF lesions than 
COPD lesions, and a lower density of endothelial cell (See chapter 4 for more details). The 
predominance of COPD lesions showed co-localisation of CD34 with endothelial cells, where 
as a CD34- endothelial phenotype was also observed in the majority of IPF lesions. The 
density of T lymphocytes showed little variation between the diseases. The most varied cell 
type between the diseases was fibroblasts. 
 
Fibroblasts were observed in the AZ of IPF and COPD lesions, with the myofibroblast 
phenotype being the most prevalent for both diseases. The co-localisation of CD34 with 
fibroblasts varied slightly between COPD and IPF, with CD34 staining being more frequently 
observed in IPF lesions. 25% (n=16) and 40% (n=5) of cellular AZ lesions presented CD34+ 
reactivity with fibroblast and or myofibroblasts in COPD and IPF respectively. 
 
In the fibrotic borders of COPD and IPF (both vascular and avascular), fibroblasts were again 
one of the predominant cell types for both diseases, however the phenotypes differed. The 
fibroblasts phenotypes in COPD lesions were heterogenic (see 3.4.5), whilst those observed in 
IPF fibroblast were predominantly CD34- fibroblasts (αSMA-). Also of note a key difference 
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between the IPF and COPD fibrotic border was the presence of ectopic muscle blocks in IPF 
lesions. 
 
At the edge of IPF lesions the fibroblast phenotypes were heterogenic with all lesions 
showing some CD34 reactivity in myofibroblasts or fibroblasts. Whilst approximately half (8 
of 17 lesions) of the COPD lesions showed no CD34 co-localisation with fibroblast cells. The 
predominant fibroblasts phenotype was CD34- myofibroblasts in the COPD edge lesion. 
 
3.4.7 Comparison of the Cytoglobin Expression Profile in COPD and IPF 
Lesions 
With the exception of smooth muscle, all cells expressed CYGB within the AZ of IPF and 
COPD lesions. All fibroblast phenotypes showed CYGB expression in all regions of the 
COPD and IPF lesions and in non fibrosed control tissue. Endothelial cells, HSCs and T cells 
showed variability in CYGB expression. The fibrotic borders and edge of the IPF and COPD 
lesions were similar in that they showed some variability in CYGB expression in these cell 
types but predominantly an all Cygb+ profile was observed. Pneumocytes had a variable 
expression profile. A similar CYGB profile was observed in type II pneumocytes at the edges 
of both IPF and COPD lesions with an approximately 50:50 split in lesions which had an all 
Cygb+ profile and those which had a mixed CYGB profile for both COPD and IPF lesions. 
The CYGB profile of type I pneumocytes differed between COPD and IPF, with no IPF 
lesions having an all Cygb+ profile.  
 
The CYGB expression profile of the COPD and IPF lesions differed to that observed in the 
same cell types in non fibrosed tissue. In non fibrosed tissue, HSCs, T cells, and endothelium 
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presented as frequently with a mixed CYGB profile as a Cygb+ profile, however within the 
lesions these cell types predominantly presented with a Cygb+ profile. The pneumocytes of 
non-fibrosed tissue consistently had a mixed CYGB profile, whereas at the lesion edge a 
Cygb+ profile was also observed.    
 
The characteristics of the lesion may have an effect upon the CYGB expression profile in the 
cells which showed variation in expression. This is investigated in chapter 4.  
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3.5 Discussion 
3.5.1 Cytoglobin Positive Cell types 
Presented in this study is evidence of CYGB expression within a variety of cell types 
including bronchiole epithelium, type I pneumocytes, type II pneumocytes, endothelial cells, 
lymphocytes, macrophages, chondrocytes, fibroblasts and myofibroblasts. 
 
Studies in the literature support these findings. Cytoglobin has been previously reported in 
human fibroblasts (Halligan et al., 2009) and epithelial cells (Shigematsu et al., 2008). 
Studies using rodent models have shown CYGB expression in fibroblasts of the lung (Man et 
al., 2008) as well as in numerous other organs including liver (Nakatani et al., 2004; Schmidt 
et al., 2004), heart (Man et al., 2008; Schmidt et al., 2004),  muscle (Man et al., 2008; 
Schmidt et al., 2004), colon (Schmidt et al., 2004), kidney (Man et al., 2008; Nakatani et al., 
2004; Schmidt et al., 2004), tendon (Schmidt et al., 2004), stomach (Man et al., 2008) and 
skin (Schmidt et al., 2004). CYGB immunoreactivity has also been observed in bronchiolar, 
alveolar and vascular interstitial tissue in rats (Nakatani et al., 2004). 
 
In contrast to that reported here, endothelial cells ((Kawada et al., 2001; Man et al., 2008; 
Nakatani et al., 2004; Schmidt et al., 2004), epithelial cells (Nakatani et al., 2004) and 
macrophages (Nakatani et al., 2004), have been reported to be negative for CYGB expression 
in rodent studies. These observations were made in pancreas, liver or kidney of fibrotic or 
healthy subjects. The contrasting CYGB profile could be due differences between the organs. 
CYGB may have a role in oxygen homeostasis, and the key role of the lung is in inhalation of 
oxygen, thus the expression of CYGB in the lung is likely to differ to that elsewhere in the 
body. 
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The focus and conclusion of several studies in the literature was the exclusive expression of 
CYGB in activated stellate cells and fibroblasts (Kawada et al., 2001; Kida et al., 2007; Man 
et al., 2008; Nakatani et al., 2004). Subsequently, cytoglobin has been presented in the 
literature as a marker of fibroblasts and, or activated stellate cells. Presented in this study is 
evidence of CYGB expression in cells other than fibroblasts thus these data would oppose the 
use of CYGB as a fibroblast marker.  
 
3.5.2 Cell Types which showed Variation in Cytoglobin Expression 
The expression profile of CYGB observed in this study was constant is several cell types. 
Fibroblasts were consistently positive, whilst smooth muscle, neurons, and erythrocytes were 
constantly negative. Cell types which showed variation in CYGB expression included 
endothelial cells, HSC, T-Lymphocytes, type I pneumocytes and type II pneumocytes. This 
variation in expression supports a model in which CYGB expression is not specific to a 
particular cell type, but all cells have the capacity to express CYGB, in response to stimuli.  
 
3.5.3 Cytoglobin Negative Cell types 
3.5.3.1 Cytoglobin Expression is not Observed in Cells which Express Other 
Globin Proteins 
This study, and previous rodent studies have observed negative CYGB expression in smooth 
muscle cells (Nakatani et al., 2004; Shigematsu et al., 2008), neurons (Burmester et al., 2007; 
Schmidt et al., 2004) and erythrocytes (Man et al., 2008). Cytoglobin expression has however 
been documented in a small population of neuronal cells in the rodent brain (Burmester et al., 
2007; Schmidt et al., 2004), a predominantly CYGB positive profile was observed in neurons 
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of the eye (Burmester et al., 2007; Ostojic et al., 2006; Ostojic et al., 2008a; Ostojic et al., 
2008b; Schmidt et al., 2005) and CYGB expression has been observed in neuronal cells in 
culture (Hodges et al., 2008; Li et al., 2007; Schmidt et al., 2004), all of which indicates that 
neurons are not an exclusively CYGB negative cell population.  
 
The cell types which present with a negative CYGB profile: smooth muscle; erythrocytes; and 
neurons have each been reported to express the cell specific globins: myoglobin; 
haemoglobin; and neuroglobin respectively. The presence of cells which are negative for 
CYGB argues against the model proposed in 3.5.4, that all cells have the capacity to express 
CYGB. However, suppose these globins compensate for the lack of CYGB expression, 
induction of CYGB may occur under an environment where CYGB induction stimuli are 
excessive.  This could offer an explanation for the observation of CYGB expression in 
neurons. CYGB is evolutionarily more ancient than Mb and Hgb (See introduction), so one 
could speculate that the more specialised Mb and Hgb have evolved from CYGB. The 
expression of Mb and Hgb in specific cell types would subsequently make the requirement for 
CYGB expression redundant. 
 
The function of CYGB is likely to relate to those of other members of the globin family and 
could be expected to fall into one of the common functional niches for the globin family, such 
as transport and storage of oxygen, oxygen homeostasis, oxidase or peroxidise activity. 
 
3.5.3.2 Cytoglobin Expression is not Observed in Tumour Cells 
In the literature CYGB+ promoter methylation, and associated gene silencing has been 
observed in a variety of human cancers (McRonald et al., 2006; Shaw et al., 2007; Shaw et 
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al., 2009; Shivapurkar et al., 2008; Xinarianos et al., 2006). The absence of CYGB 
immunoreactivity observed in lung tumour cells in this study supports the observations in the 
literature, and proposals of CYGB as a tumour suppressor protein.  
 
3.5.4 Localisation of Cell types to Regions of the Fibrotic Lesion 
The same cell types localised to the same areas of the lesion in IPF and COPD, with only one 
exception. Ectopic smooth muscle bundles, which have previously reported in IPF tissue 
(Ohta et al., 1995) were observed in the fibrosing border of all IPF lesions, but were only 
occasionally observed in COPD.  
 
The density of other cell types, and the specific phenotypes varied between COPD and IPF. 
Fibroblasts were the predominant cell type in acellular regions of dense matrix and collagen 
in both IPF and COPD lesions, although the density of fibroblasts observed in IPF was greater 
than that in COPD, and phenotypes differed (see 3.5.5 for more details). Fibroblasts, HSC, T-
lymphocytes and endothelial cells localised to the fibrosing border in IPF and COPD. T-
lymphocytes and Macrophages were more abundant in the fibrosing border of IPF than 
COPD. Inflammation precedes and drives the fibrosis observed in COPD, whilst abnormal 
fibroblasts drive fibrosis in IPF. Consequently one may expect to observe a higher level of 
inflammation in COPD than IPF. IHC captures a snapshot of events within the lesion, and the 
fibrosis observed in COPD is in response to waves of inflammation. As COPD is self limiting 
one could assume that inflammation results in a distinct fibrotic event, the fibroblasts of 
which are not pro-inflammatory, preventing recurrent cycles of inflammation and fibrosis. 
Subsequently, the sequential events of inflammation followed by fibrosis would result in the 
co-localisation of inflammation with the fibrotic lesion in an IHC section to be unlikely. The 
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pathogenesis of IPF however is different, in response to an unknown trigger fibroblasts 
proliferate uncontrollably, have abnormally low or absent levels of anti-fibrotic PGE 
production, and release cytokines which initiate an inflammatory response, this is not self 
limiting but each perpetuates one another and thus events are observed in parallel and foci of 
fibrosis are associated with inflammation.  
 
The edge and fibrotic borer of IPF tissue regularly showed more staining for CD31, 
representing the microvasculature, than observed in COPD. Notably, the CD31 staining in 
IPF was frequently associated with PCNA (See chapter 4 for more details about PCNA 
staining), a marker of proliferation and could relate to neovascularisation or aberrant 
angiogenesis, both of which have been reported in IPF. Alterations in the microvascularity in 
COPD remains inconclusive, with both evidence of both angiogenic and angiostatic events 
being presented with chronic bronchitis and emphysema respectively. Presented here is 
evidence of microvasculature heterogeneity between COPD lesions, where some lesions 
presented with angiogenesis (See chapter 4) and others avascularity. 
 
CD34 expression in endothelial cells of the alveolar wall has been previously reported in 
healthy lung tissue (Pusztaszeri et al., 2006). The endothelial cells in COPD lesions were 
predominantly CD34 immunoreactive, however in IPF a CD34+ and CD34- endothelial 
population was observed in most lesions. The loss of this haematopoietic marker could 
indicate maturation of endothelium which is not commonly observed in normal tissue. 
Potentially in healthy tissue endothelial cells may turnover before loss of the CD34 marker. In 
IPF there are abnormalities in several cell types, such as apoptosis resistant myofibroblasts, 
and apoptosis sensitive epithelial cells. Potentially, subpopulations of endothelial cells which 
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are resistant to apoptosis may also be present. These may contribute to fibrosis through 
synthesis of pro-angiogenesis or pro-fibrotic factors.   
 
Type I pneumocytes were present at the edge of all COPD lesions, but were absent from many 
IPF lesions. Type II pneumocytes in IPF were large and consistently positive for CK in IPF, 
which complemented the morphology of IPF type II pneumocytes reported in the literature 
(Laurent et al., 2008; Selman and Pardo, 2006; Willis and Borok, 2007). Type II pneumocytes 
observed in COPD were immunoreactive for CK in only a subset of lesions, considerably 
smaller than IPF type II pneumocytes, and more morphologically similar to those observed in 
non fibrosed control tissue.     
 
3.5.5 Fibroblast Phenotypes in IPF and COPD 
The phenotypes of fibroblasts varied across the lesions. The predominant phenotypes in each 
area were (MF: Myofibroblast, F: Fibroblast): 
COPD      IPF 
AZ   CD34-  MF   CD34-  MF 
 
 
FBLoV  CD34-  MF     
CD34+/-  F     
 
 
VFB   CD34+  MF  
   CD34+ F   CD34-  F 
 
 
Edge   CD34+/-  MF   CD34+/- MF   
        CD34+/- F 
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The CD34 expression of fibroblasts in the COPD lesion was both positive and negative at the 
edge, all positive in the VFB, mixed in the FBLoV and all negative in the AZ. Taking CD34 
as a marker of haematopoietic origin, it could be speculated from these data that the 
fibroblasts in the VFB of COPD lesions have originated from circulating mesenchymal 
progenitor cells. In addition is could be speculated that (CMPC) migrate to the lesions 
through the capillaries in the vascular fibrosing border of the COPD lesion, from where they 
migrate either further into the lesion, or towards the edge where maturation and loss of the 
CD34 expression takes place. Considering the proposed origins of fibroblasts in fibrosis and 
the structure of the lesion, it would be logical that the localisation of fibroblasts within the 
lesion correlated to their source, with EMT derived fibroblasts, and resident fibroblasts to 
migrate to the edge of the lesion whilst CMPC migrate into the fibrosing border. The 
contribution of fibroblasts from various origins could thus have a significant effect upon the 
pathogenesis of the lesion.  
 
The CD34 profile of fibroblasts in IPF is distinct to that of COPD lesions, and would argue 
against this model, as the FB and AZ of the IPF lesion were predominantly CD34-, whilst the 
edge showed a mixed CD34 profile. One could speculate that CMPC could also migrate to the 
lesion from the circulation in the parenchyma contributing to the mixed CD34 profile at the 
edge of the lesion. There is evidence of a CMPC contribution to IPF (Andersson-Sjoland et 
al., 2008). The fibroblast within the lesion could originate from continued proliferation of 
fibroblasts localised within the lesion.   
  
All areas of the COPD lesion contained myofibroblasts, but the fibroblast phenotype was 
predominantly only observed in the fibrosing border. Assuming differentiation of fibroblasts 
118 
 
into a myofibroblast phenotype does not occur until migration into the fibrotic lesion, this 
would be in-keeping with the above model of fibroblasts migrating into the lesion via the 
circulation of the VFB. 
 
The AZ of IPF lesions was predominantly myofibroblasts, whilst fibroblasts were 
predominant in the FB, and a mixed population was observed at the edge. The predominance 
of αSMA negative fibroblasts within the IPF fibrotic lesion has previously been reported 
(Kapanci et al., 1995; Yoshinouchi et al., 1999). Several studies using the fibroblasts derived 
from the BAL of IPF patients have concluded the fibroblasts in IPF are less proliferative, 
contractile and express αSMA ((Fireman et al., 2001; Kanematsu et al., 1994; Ohta et al., 
1995; Ramos et al., 2001; Shahar et al., 1999), which contradicts that observed here, as 
observed here, the predominant fibroblast phenotype of the lesion were αSMA- fibroblasts. It 
should be noted that these fibroblasts were derived from the BAL and not the lesion of IPF 
patients. This study shows that the phenotype of fibroblasts varies across the lesion and thus 
BAL derived fibroblasts may not be truly representative of those within the lesion.  
 
The origin and phenotype of fibroblasts are evidently different between IPF and COPD 
lesions. These differences are likely to contribute to the differences observed in the pathology 
of the fibrotic lesions in IPF and COPD, with particular reference to the self limiting nature of 
fibrosis in COPD, and self perpetuating nature of fibrosis in IPF. 
 
3.5.6 Cell Type Changes As Markers Of Lesion Severity 
This study provides preliminary evidence that with increasing fibrotic severity, smooth 
muscle and myofibroblasts are more frequently observed in COPD lesions. The increase in 
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frequency in myofibroblasts agrees with that proposed in the literature, that the myofibroblast 
is a fundamental cell type in fibrosis. 
 
It was intriguing that the Ashcroft and Sirius red scores did not correlate to changes in the CK 
phenotype of type II pneumocytes in COPD lesions, as the expression of CK is indicative of 
differentiation and damage. One could speculate that the damage to pneumocytes at the edge 
of the COPD lesion may not contribute to the fibrotic progression, and that the events which 
occur at the edge and within the lesion are independent. The structure of the fibrotic edge is 
the same as that of the parenchyma, a layer of pneumocytes, associated on occasion in COPD, 
and always in IPF with endothelial cells via connective tissue. The fibrotic edge is equivalent 
to the local lung parenchyma and responds to localised damage. In contrast to IPF, the type II 
pneumocytes are not known to be abnormal. The fibrotic lesion is distinct to the edge, 
essentially it is a region of wound healing and comprised primarily of fibroblasts, and 
connective tissue with an absence of pneumocytes. The pathology of the regions are therefore 
distinct. This supports a model in which the fibrosis of the COPD lesion is driven primarily 
by the migration of CMPC and other fibrogenic cell types into the fibrosing border (see 
3.5.5), and thus the fibrogenesis develops from within the lesion rather from repeated damage 
to the edge. This is highly speculative based on these data.  
 
The IPF lesions with the highest Sirius red scores, indicative of deposition of larger collagen 
fibres, had an absence of Type I pneumocytes at the lesion edge. One could speculate that the 
loss of type I pneumocytes from the lesion may relate to the level of damage of the lesion. 
The perpetuating fibrosis observed in IPF could support a model in which the edge and the 
lesion are not independent. Bidirectional signalling between inflammatory cells and 
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fibroblasts, and epithelial cells and fibroblasts has been observed in pulmonary fibrosis. 
Potentially damage to type I pneumocytes could initiate pro-fibrotic pathways which 
perpetuate the fibrosis within the lesion. Additionally the pathogenesis of IPF has been 
proposed to be related to epithelial cell damage (Willis and Borok, 2007).  
 
Recently it has been speculated that fibrosis can occur independently to inflammation (Willis 
and Borok, 2007), it was therefore unsurprising that the severity of the lesion was not related 
to the density of T-lymphocytes in COPD or IPF. 
 
3.5.7 Cytoglobin Expression of the Lesion in IPF and COPD 
CYGB was expressed in the AZ of IPF and COPD lesions, and the FBLoV of COPD lesions. 
The vascular fibrotic borders of IPF and COPD lesions showed some mixed CYGB 
expression (positive and negative) within HSCs, T-lymphocytes and endothelial cells 
although predominantly these regions were Cygb+. The edge of IPF and COPD lesions had a 
more mixed CYGB profile than the fibrotic border, but again a CYGB positive profile was 
predominant.  
 
The expression of CYGB has been shown to increase at the mRNA and protein level in 
fibrosed compared to non fibrosed tissue (Kawada et al., 2001; Kida et al., 2007; Man et al., 
2008; Nakatani et al., 2004; Tateaki et al., 2004), and in response to fibrotic stimuli both in 
vitro (Gnainsky et al., 2007; Kawada et al., 2001; Nakatani et al., 2004; Zion et al., 2009) and 
in vivo (Gnainsky et al., 2007; Zion et al., 2009). These data presented in this study show that 
fibroblasts are the predominant cell type within the AZ and fibrosing borders of IPF and 
COPD lesions, and that fibroblasts are exclusively Cygb+ in both fibrotic and non fibrotic 
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tissue. This supports a model in which an increase in CYGB expression with fibrosis is a 
consequence of the migration of fibroblasts, and proliferation of fibroblasts in the region, 
which express CYGB.  
 
Additionally this study has shown variable CYGB expression within T-lymphocytes, HSCs 
and endothelial cells, all of which were more frequently Cygb+ within the fibrotic lesion than 
in normal tissue or at the edge.  Variable expression was also observed in pneumocytes, with 
a Cygb+ profile being observed more frequently at the lesion edge of IPF and COPD tissue 
than in non fibrosed controls. This would support a model in which CYGB is upregulated in 
response to local fibrogenic stimuli or as a consequence of fibrosis, as the CYGB profile of 
these cell types alters in accordance with their localisation in the fibrotic lesion.  
 
There is a relationship between hypoxia and oxidative stress with the fibrosis, as a 
consequence of the loss of microvascularity, angiogenesis induced reperfusion injury and 
inflammation. CYGB expression has been reported to increase in response to both hypoxia 
(Fordel et al., 2004; Fordel et al., 2007a; Fordel et al., 2007b; Guo et al., 2007; Huang et al., 
2006; Mammen et al., 2006; Schmidt et al., 2004; Singh et al., 2009) and oxidative stress (Li 
et al., 2007; Mammen et al., 2006; Powers, 2006), and thus induction of CYGB within the 
fibrotic lesion could be via hypoxic or redox pathways. The relationship between the CYGB 
expression of the lesion with hypoxia, and other markers of fibrogenesis were subsequently 
investigated, and this work is discussed in Chapter 4.   
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CHAPTER 4: DETERMINING THE SUBCELLULAR ROLE 
OF CYTOGLOBIN WITHIN THE FIBROTIC LESION. 
 
 
4.1      Introduction 
Several studies have used IHC to determine the tissue, cell and subcellular localisation of 
CYGB expression. As yet there are no studies which have looked at mechanistic markers to 
determine the relationship between CYGB distribution and the profile of the fibrotic lesion. 
Understanding this relationship could shed light on roles of CYGB in fibrosis.  
 
The cells within the fibrotic lesion are assumed to be under hypoxic stress due to a loss of 
local vascularity, and CYGB has been associated in the literature with hypoxic cytoprotection. 
CYGB has also been associated with cytoprotection against oxidative stress, which is related 
to inflammation and repair, processes which are involved in fibrosis. Here we present IHC 
data from lungs of a severe COPD patient group correlating CYGB expression and markers of 
the profile of the fibrotic lesion. 
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4.2 Aim 
The overall aim of this chapter was to add to the current understanding of the role of CYGB 
during fibrosis  
 
The specific objectives were: 
 Determine the relationship between CYGB and hypoxia within the fibrotic lesion 
 Determine whether CYGB could be a marker of proliferation 
 Determine if CYGB is a marker of inflammation 
 Determine whether CYGB could be a marker of repair 
 Determine if CYGB expression is a marker of fibrotic severity 
 Determine the relationship between CYGB expression and vascular remodelling 
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4.3 Methods 
4.3.1 pVHL and CAIX Immunohistochemistry 
pVHL and CAIX immunohistochemistry was performed using standard procedures (see 
M&Ms). For CAIX staining, antigen retrieval was achieved by microwaving to boil in antigen 
unmasking fluid prior to staining. Staining used 0.5% hydrogen peroxide to quench 
endogenous peroxides, normal goat serum to block, a rabbit anti human CAIX antibody at 
1µg/ml, a biotinylated goat anti rabbit secondary (0.5µg/ml), and the Streptavidin AB/HRP kit 
for signal amplification. The pVHL protocol was similar, with the following differences, 
antigen retrieval was achieved using 15lb pressure in antigen unmasking fluid and a 
biotinylated goat anti mouse secondary was used. The isotype controls used were Rabbit Ig 
and Mouse IgG1 for CAIX and pVHL respectively. 
 
The lesions interpreted in Chapter 3 were further interrogated to determine the pVHL and 
CAIX profile of the cells types. The methods used to interpret the sections and analyse these 
data were the same as those described in chapter 3.  
  
4.3.2 Characterising the Fibrotic Lesions 
Markers of collagen deposition, proliferation and inflammation were also used to characterise 
the fibrotic lesions interpreted in Chapter 3. A score for each was assigned to each region of 
each lesion 
 
4.3.2.1  The Collagen Deposition Score 
The structure and density of collagen I was used as a measure of fibrosis because during 
fibrogenesis there is an increase in collagen I (Desmouliere et al., 1999; Schwarz and King 
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1993). The collagen present is characteristically different to that in non-fibrosed tissue, in 
terms of shape, positioning and thickness. It is also often frayed due to the action of proteases 
such as collagenase (Schwarz and King 1993). The amount and intensity of the Collagen I 
staining was graded according to the scoring system as follows: 0: No Staining, 1: weak and 
sparse, 2: midway, 3: strong and abundant. (See appendix for photographic representation of 
these grades) 
 
4.3.2.2 The Proliferation Score 
PCNA (proliferating cell nuclear antigen), is a co-factor of DNA polymerases which encircle 
DNA during replication, and can therefore be used to identify the nuclei of proliferating cells. 
The use of PCNA as a marker for proliferation is limited to detection of cells within the 
replication, or S phase of the cell cycle (Lodish, 2004; Miura, 1999). Proliferating cell nuclear 
antigen was used as a marker of proliferation. Proliferation was graded using the scoring 
system as follows: 0: No staining, 1: sparse, 2: midway, 3: abundant. (See appendix for 
photographic representation of these grades) 
 
4.3.2.3  Inflammation Score 
MAC387 and CD3 were used as markers of inflammation as they identify macrophages and  
T lymphocytes respectively. Each were graded using the scoring system as follows: 0: No 
staining, 1: sparse, 2: midway, 3: abundant. (See appendix for photographic representation of 
these grades) 
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4.3.3  Data Analysis 
Each region of each lesion interpreted in chapter 3 was assigned a score for the each of the 
following: 
      Marker used 
Loss of vascularity    Density of CD31 
Fibrotic Severity    Ashcroft score, Sirius Red Score, Collagen Score 
Proliferation     Density of PCNA 
Inflammation     Density of CD3 and MAC387 
Pneumocyte mediated repair   Density of CK+ type II pneumocytes 
Angiogenesis     Co-localisation of CD31 and PCNA 
Stem cell mediated repair   Density of c-kit     
 
The data regarding the CYGB profile of different cell types was grouped according to each of 
these markers. For example, to determine the relationship between the level of proliferation 
with CYGB expression in the COPD vascular fibrosing border, the data was segregated into 3 
groups: those which were negative for PCNA; those which were positive in less than 50% of 
the cell population; and those which were positive in more than 50% of the population. The 
CYGB expression profile of each cell type was compared between the groups, in order to 
highlight, for example, if a mixed CYGB expression profile in HSCs was exclusively 
observed in lesions which were negative for PCNA  
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4.3.4 Grading the Vasculature 
The vasculature was graded using an algorithm designed by P Vaughan (Vaughan et al., 
2006) For each vessel the sum of the following was calculated: 
For each feature of the vasculature in the list below 2 points were assigned if >50% of the 
vessel was affected, 1 point if <50% of the vessel was affected, and 0 points if absent. 
 
Intima       Media 
Hypertrophy and or hyperplasia   Hypertrophy and or hyperplasia  
Roughened endothelium    Radial smooth muscle cells/re-orientation 
Luminal thrombus     Apoptosis 
Sclerosis/collagen deposition    Sclerosis/collagen deposition 
New internal elastic lamina    Leucocytes in vessel wall 
       Indistinct internal elastic lamina 
       Indistinct external elastic lamina 
 
The severity of damage to the vessel was also scored using desmin and vimentin as markers 
of remodelling. The scores assigned were originally identified by G Sirico (Sirico et al., 
2006.). G Sirico observed that in mildly damaged vessels, desmin and vimentin staining was 
dense and structured. In moderately damaged vessels there was a re-organisation of vimentin 
and subsequent loss of signal, and larger regions of negative desmin staining. In severely 
damaged vessels, there were large regions of negative desmin staining, and immunoreactivity 
for vimentin was strong, but the structure was disorganised.  
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4.3.5 Grading Cytoglobin Expression in the Vasculature 
Alongside grading the vessels for desmin and vimentin, the CYGB expression profile was 
also investigated. The CYGB expression profile was vimentin and desmin positive cells was 
determined using methods described in chapter 3. The intensity of the CYGB signal was 
noted as follows: 0: negative, 1: weak, 2: midway, 3: strong (See appendix for photographic 
representation of these grades) 
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4.4   Results 
4.4.1 Cytoglobin as a Marker of Hypoxia 
4.4.1.1 Localisation of pVHL staining within the fibrotic lesion 
pVHL staining was used as a marker of non hypoxia, where non hypoxia refers to an cellular 
oxygen tension which is not hypoxic but could be normoxic or hyperoxic. The AZ and FB of 
IPF lesions were negative for pVHL staining in all cell types, as was the AZ and FBLoV of 
COPD lesions (see figure 4.1, 4.2, 4.5 and 4.6). The edge of the IPF lesion showed 
immunoreactivity for pVHL in type II pneumocytes only (see figure 4.7 and 4.9), which was 
observed in all lesions. In contrast the VFB of the COPD lesion showed some pVHL 
immunoreactivity in HSCs, and or T-lymphocytes, and or endothelium, and or pneumocytes 
in a subset of lesions (20% of lesion) (see figure 4.3). pVHL staining was observed in type I 
and type II pneumocytes at the edge of all COPD lesions (see figure 4.4), 8 lesions had an all 
pVHL positive population in all pneumocytes whilst in the other lesions pneumocyte 
populations had a mixed pVHL profile (total number of lesions in which each cell type was 
observed: 13 for type II, 11 for type II-1, 14 type I). Non-fibrotic controls predominantly 
presented with a mixed pVHL+/- profile in type II and type I cells (See figure 4.8).  
 
4.4.1.2 Localisation of CAIX Staining within the fibrotic lesion 
Carbonic Anhydrase IX is regulated via HIF-1α, and so was used as a marker of HIF-1α 
activity. CAIX immunoreactivity was observed in all cell types identified (see figures 4.1-
4.9), including smooth muscle.  The CAIX expression profile was variable across the lesion in 
all cell types, overall however there was a predominance of positive staining within the cells 
of the AZ and FBLoV of COPD lesions, and the AZ and FB of IPF lesions (See figures 4.1-
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4.9). The VFB and edge of the COPD lesions and edge of IPF lesions predominantly had a 
mixed CAIX profile (see figures 4.3, 4.4 and 4.7).  
 
The IPF lesions presented with a greater level of CAIX staining than observed in COPD. 
Control tissue presented primarily with a mixed CAIX+/- profile in pneumocytes, the most 
abundant cell type present (See figure 4.8). All fibroblast were positive for CAIX in control 
tissue. 
 
4.4.1.3 Correlating the pVHL, CAIX and Cytoglobin Staining 
All cells in the IPF and COPD AZ were positive for CYGB, and the expression of CYGB 
became more variable through the lesion to the edge (See chapter 3). The pVHL staining had 
an opposite profile. pVHL staining was absent from the AZ regions, and localised primarily to 
the edge in type II pneumocytes in IPF and type I and type II pneumocytes in COPD lesions. 
Pneumocytes, which offered the most variability in CYGB expression were thus the 
predominant pVHL positive cell type. However, there was no relationship between an all 
positive pVHL population at the edge and a mixed CYGB profile, or vice versa. 
 
The CAIX staining mirrored that of CYGB, although smooth muscle also presented with 
CAIX immunoreactivity. CYGB staining was frequently observed in more cells than CAIX in 
COPD. There was a difference in the pVHL profile of the pneumocytes at the COPD lesion 
edge between lesion where the CAIX=CYGB and those in which CAIX<CYGB. The 
pneumocytes at the edge of COPD lesions were all pVHL positive in lesions where 
CYGB>CAIX signal, but showed a mixed pVHL profile in lesions where CAIX=CYGB.     
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Figure 4.1 pVHL and CAIX staining in the COPD Acellular Zone 
Graphs to show the cell types which stained for pVHL and CAIX in the acellular zone of 
COPD fibrotic lesions (n=20). Graph A shows the pVHL staining of each cell type within the 
region. Graph B shows the CAIX profile of each cell type within the region. The size of the bar 
represents the frequency of lesions in which each cell type was present, and the formats 
represent the staining profile. White represents all negative, Black all positive and grey mixed 
(see M&M and appendix for more details). F: Fibroblasts, M: Myofibroblasts, SM: Smooth 
Muscle, HSC: Haematopoietic stem cells, T: T lymphocytes, E: Endothelium, II: Type II 
pneumocytes, II-I: Differentiating type II pneumocytes, I: Type I pneumocytes 
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Figure 4.2 CAIX and pVHL Staining in the FBLoV of COPD Lesions 
Graphs to show the cell types which stained for pVHL and CAIX in the FBLoV of COPD 
fibrotic lesions (n=6). Graph A shows the pVHL staining of each cell type within the region. 
Graph B shows the CAIX profile of each cell type within the region. The size of the bar 
represents the frequency of lesions in which each cell type was present, and the formats 
represent the staining profile. White represents all negative, Black all positive and grey mixed 
(see M&M and appendix for more details). F: Fibroblasts, M: Myofibroblasts, SM: Smooth 
Muscle, HSC: Haematopoietic stem cells, T: T lymphocytes, E: Endothelium, II: Type II 
pneumocytes, II-I: Differentiating Type II pneumocytes, I: Type I pneumocytes 
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Figure 4.3 CAIX and pVHL Staining in the VFB of COPD Lesions 
Graphs to show the cell types which stained for pVHL and CAIX in the VFB of COPD fibrotic 
lesions. Graph A shows the pVHL staining of each cell type within the region (n=13). Graph B 
shows the CAIX profile of each cell type within the region (n=14). The size of the bar 
represents the frequency of lesions in which each cell type was present, and the formats 
represent the staining profile. White represents all negative, Black all positive and grey mixed 
(see M&M and appendix for more details). F: Fibroblasts, M: Myofibroblasts, SM: Smooth 
Muscle, HSC: Haematopoietic stem cells, T: T lymphocytes, E: Endothelium, II: Type II 
pneumocytes, II-I: Differentiating Type II pneumocytes, I: Type I pneumocytes 
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Figure 4.4 CAIX and pVHL Staining in the Edge of COPD Lesions 
Graphs to show the cell types which stained for pVHL and CAIX in the edge of COPD fibrotic 
lesions (n=17). Graph A shows the pVHL staining of each cell type within the region. Graph B 
shows the CAIX profile of each cell type within the region. The size of the bar represents the 
frequency of lesions in which each cell type was present, and the formats represent the 
staining profile. White represents all negative, Black all positive and grey mixed (see M&M 
and appendix for more details). F: Fibroblasts, M: Myofibroblasts, SM: Smooth Muscle, HSC: 
Haematopoietic stem cells, T: T lymphocytes, E: Endothelium, II: Type II pneumocytes, II-I: 
Differentiating Type II pneumocytes, I: Type I pneumocytes 
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Figure 4.5 pVHL Staining in the AZ of IPF Lesions 
Graphs to show the cell types which stained for pVHL in the AZ of IPF fibrotic lesions (n=9). 
The graph shows the pVHL staining of each cell type within the region. The size of the bar 
represents the frequency of lesions in which each cell type was present, and the formats 
represent the staining profile. White represents all negative, Black all positive and grey mixed 
(see M&M and appendix for more details). F: Fibroblasts, M: Myofibroblasts, SM: Smooth 
Muscle, HSC: Haematopoietic stem cells, T: T lymphocytes, E: Endothelium, II: Type II 
pneumocytes, II-I: Differentiating Type II pneumocytes, I: Type I pneumocytes 
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Figure 4.6 CAIX and pVHL Staining in the FB of IPF Lesions 
Graphs to show the cell types which stained for pVHL and CAIX in the FB of IPF fibrotic 
lesions. Graph A shows the pVHL staining of each cell type within the region (n=9). Graph B 
shows the CAIX profile of each cell type within the region (n=3). The size of the bar represents 
the frequency of lesions in which each cell type was present, and the formats represent the 
staining profile. White represents all negative, Black all positive and grey mixed (see M&M 
and appendix for more details). F: Fibroblasts, M: Myofibroblasts, SM: Smooth Muscle, HSC: 
Haematopoietic stem cells, T: T lymphocytes, E: Endothelium, II: Type II pneumocytes, II-I: 
Differentiating Type II pneumocytes, I: Type I pneumocytes 
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Figure 4.7 CAIX and pVHL Staining in the Edge of IPF Lesions 
Graphs to show the cell types which stained for pVHL and CAIX in the edge of IPF fibrotic 
lesions. Graph A shows the pVHL staining of each cell type within the region (n=9). Graph B 
shows the CAIX profile of each cell type within the region (n=3). The size of the bar represents 
the frequency of lesions in which each cell type was present, and the formats represent the 
staining profile. White represents all negative, Black all positive and grey mixed (see M&M 
and appendix for more details). F: Fibroblasts, M: Myofibroblasts, SM: Smooth Muscle, HSC: 
Haematopoietic stem cells, T: T lymphocytes, E: Endothelium, II: Type II pneumocytes, II-I: 
Differentiating Type II pneumocytes, I: Type I pneumocytes 
 
138 
 
 
 
 
 
 
 
 
 
Figure 4.8 CAIX and pVHL Staining in Control Tissue 
Graphs to show the cell types which stained for pVHL and CAIX in the non fibrosed control 
tissue. Graph A shows the pVHL staining of each cell type within the region (n=5). Graph B 
shows the CAIX profile of each cell type within the region (n=5). The size of the bar represents 
the frequency of lesions in which each cell type was present, and the formats represent the 
staining profile. White represents all negative, Black all positive and grey mixed (see M&M 
and appendix for more details). F: Fibroblasts, M: Myofibroblasts, SM: Smooth Muscle, HSC: 
Haematopoietic stem cells, T: T lymphocytes, E: Endothelium, II: Type II pneumocytes, II-I: 
Differentiating Type II pneumocytes, I: Type I pneumocytes 
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Figure 4.9  Cytoglobin, CAIX and pVHL Staining in an IPF 
Fibrotic Lesion 
Photographs to show cytoglobin (top and bottom left), CAIX (top right) and pVHL (bottom right) 
staining in an IPF lesion. The arrows in the top pictures highlight muscle blocks in the fibrosing 
border, and the circles highlight the AZ region. The arrows in the bottom pictures highlight type II 
pneumocytes. Pictures are 40% of original size, and were taken at x20 magnification. 
 
10µm 10µm 
10µm 10µm 
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4.4.1.4 Correlating Cytoglobin Staining with the Loss of Vascularity 
All cells were CYGB positive in regions of avascularity such as the AZ of IPF and COPD 
lesions. The fibrosing border of COPD lesions were grouped according to vascularity and it 
was evident that in avascular fibrotic borders (FBLoV) all cells were CYGB+ whilst in 
fibrotic borders with vascularity a mixed CYGB profile was seen in some cell types (see 
chapter 3 for more details).  At the fibrotic edge of IPF and COPD lesions and in non fibrosed 
control tissue where the microvascular was intact a mixed CYGB profile was more frequently 
observed. A mixed CYGB profile correlated to lesions with higher levels of vascularity. 
 
4.4.2 Cytoglobin as a Marker of Fibrosis 
During fibrosis there is an increase in proliferation, inflammation, repair, deposition of 
extracellular matrix and angiogenesis. Makers for each of these were used to characterise each 
of the fibrotic lesions and or lesion areas analysed in chapter 3. The CYGB expression profile 
of cells which showed variability in chapter 3 were compared to the profile of these markers 
to determine whether there was a relationship between the characteristic of the lesion and the 
CYGB profile.  
 
4.4.3 Correlating Variations in Cytoglobin Expression with Fibrotic Severity of 
the Lesion in COPD and IPF 
The Ashcroft scoring system was used to determine the extent of fibrosis within each lesion 
and Sirius red and collagen I staining were used as markers of collagen deposition. The 
CYGB expression data was ordered according to the Ashcroft score for the lesion or grouped 
according to the lesion score for collagen (grouped according to grade) or Sirius red (3 groups 
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according to grades: 1-2, 3 or 4-5), to determine whether specific CYGB profiles correlated 
with fibrotic scores.   
 
In the VFB and edge of COPD lesions the variations observed in the CYGB profile in HSCs, 
endothelial cells and T-lymphocytes or type II pneumocytes and type I pneumocytes 
respectively showed no correlation with the Ashcroft, Sirius red or collagen scores.  At the 
edge of IPF lesions there was no definitive correlation between the Ashcroft, Sirius red or 
collagen scores and CYGB profile in type II pneumocytes. However, all lesions with a score 
of 4 or higher for Sirius red, corresponding to deposition of large collagen fibres, and 
acellularity had an all positive CYGB expression profile. 
  
4.4.4 Cytoglobin as a Marker of Pneumocyte-Mediated Alveolar Repair 
In response to fibrogenic insult, the lung presents with repair mechanisms including increased 
density of type II pneumocytes and increased differentiation of type II to type I pneumocytes.  
Cytokeratin was used as a marker of differentiation of type II pneumocytes. 
 
The type II pneumocytes observed in IPF tissue were larger than those in COPD tissue, and 
frequently showed co-localisation with CK in all type II pneumocytes at the edge, indicating 
differentiation into the type I phenotype. Co-localisation of CK was observed in COPD tissue 
but was never observed in all cells at the lesion edge. COPD lesions which did not present 
with CK staining in pneumocytes at the edge, had a mixed CYGB profile at the fibrotic edge, 
in Type I, Type II and differentiating type II pneumocytes (n=8). Where CK+ type II 
pneumocytes were most abundant at the edge lesion, indicating a high level of repair, type I, 
type II and differentiating type II pneumocytes were predominantly CYGB+ (n= 5).  
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Figure 4.10 Cytoglobin Expression in Pneumocytes   
Graph A. The expression profile of CYGB in type I and type II cells at the edge of COPD 
lesions. Data is grouped according to the CK profile of type II cells at the edge of the lesion. 
The size of the bar corresponds to the number of lesions in which each cell type was present. 
The formats represent the CYGB profile. Grey: mixed profile, Black: all cell CYGB+. Graph 
B shows relationship between the CYGB expression profile of type II pneumocytes and 
presence of type I pneumocytes at the IPF lesion edge. The bar represents the % of IPF lesions 
with the relevant CYGB profile which presented with type I pneumocytes at the lesion edge 
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CK+ type pneumocytes were the predominant cell type at the edge of all IPF lesions. The 
CYGB profile of these cells varied, either a mixed CYGB profile or CYGB+ profile was 
observed. It was noted that 80% of the IPF lesions with a CYGB+ profile in type II 
pneumocytes were lacking in type I pneumocytes (n=5), whilst type I pneumocytes were 
observed at the edge of lesions with a mixed CYGB+ profile (n=4). Additionally lesions 
without type I pneumocytes and with a CYGB+ profile in type II pneumocytes had high sirius 
red scores. 
 
4.4.5 Cytoglobin as a Marker of Proliferation, Inflammation, Angiogenesis and 
Stem Cell Mediated Repair 
PCNA was used a marker of proliferation, CD3 and MAC387 were used as markers of 
inflammation, cross reactivity of CD31 and PCNA was used as a marker of angiogenesis and 
co-localisation of c-kit and CD34 were used as markers of stem cells. Each region of every 
lesion was given a score corresponding to the density of each of these markers (see appendix 
for scores), as described in chapter 3. As described earlier this was correlated to CYGB 
expression. 
 
The cell populations which stained for each of these markers were both CYGB positive and 
negative. There was no correlation between the expression profile of CYGB and distribution 
of these markers. 
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4.4.6 Cytoglobin as a Marker of Vascular Remodelling 
CYGB expression was observed in the endothelium, media and adventisia of the vasculature. 
The staining in the media was variable, from weak and sparse to dense and strong. The level 
of damage to the vessel was assessed and a score assigned. The staining of desmin and 
vimentin was compared to that of CYGB to determine the source of the CYGB signal, and the 
relationship with remodelling. 
 
The vimentin positive cells were CYGB positive in all COPD, IPF and control blood vessels. 
Variations in intensity of the CYGB signal mimicked that of vimentin, in that vessels 
presented with strong staining for both or neither. The vessels with a high score indicating 
severe remodelling, presented with stronger CYGB staining than those with lower scores 
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Figure 4.11  Cytoglobin and Vimentin Staining in Remodelled Vessels 
10µm 10µm 
10µm 10µm 
Pictures to show CYGB (Top) and Vimentin (Bottom) staining in severely (left) and moderately 
(right) damaged COPD vessels. Arrows highlight areas which are negative for these 2 stains but 
stained positively for desmin. Pictures were taken at x20, and are 40% of the original size.  
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4.5 Discussion 
4.5.1 Hypoxia and the Fibrotic Lesion 
Fibrogenesis involves many processes which are activated via hypoxic pathways, such as 
collagen synthesis, apoptosis, angiogenesis, proliferation and inflammation (Higgins 2008, 
Jain 2005). Hypoxia is subsequently thought to be related to fibrotic pathogenesis.  
 
pVHL and CAIX were used a markers of non hypoxia, and HIF-1α activity respectively. HIF-
1α is the key modulator of the cellular hypoxia response, and its activity is known to increase 
in response to hypoxia, resulting in an increase in CAIX expression. HIF-1α also responds to 
non hypoxic stimuli however so detection of HIF-1α activity via CAIX does not exclusively 
represent hypoxic activation of HIF-1α. Cells with CAIX- and, or pVHL+ phenotypes are 
subsequently likely to be non-hypoxic. This phenotype was frequently observed at the lesion 
edge, and thus it is likely that cells in this area are non hypoxic.  Within the lesion pVHL 
immunoreactivity was lost from the fibrotic border and AZ regions. The CAIX- phenotype 
was observed within the VFB of COPD lesions, but was less frequent in the FBLoV and AZ 
of COPD lesions, and the FB and AZ of IPF lesions. This non hypoxic phenotype is 
subsequently lost further into the lesion where the fibrosis becomes more severe. The CAIX 
and pVHL expression profiles support a model of a non-hypoxic fibrotic border with 
increasing hypoxia into the centre of the lesion. A loss of vascularity within the lesion was 
also observed in this study.  Avascularity is likely to contribute to the onset of hypoxia, 
adding further support to this model. 
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4.5.2 Cytoglobin as a Marker of Hypoxia 
Cells at the edge of IPF and COPD lesions presented predominantly with a mixed CYGB 
profile, and this was the area which was the least immunoreactive with CYGB. The centre of 
the lesion was CYGB positive in all cells. Assuming, as indicated by the vascularity and 
pVHL and CAIX expression profile of the lesion, that the edge is non hypoxic, whilst the 
centre of the lesion is hypoxic, these data support a model in which CYGB is expressed in the 
lesion in response to hypoxic stimuli, as in regions where non hypoxia is evident, there is less 
expression than regions where there is no evidence of non hypoxia.  In support of this a mixed 
CYGB expression profile was observed in lesions, and lesion regions, with relatively high 
vascularity, whilst a CYGB+ phenotype was more readily observed in lesions, or lesion 
regions which presented with avascularity.  
 
Should CYGB expression be exclusively induced by hypoxia, an increase in the pVHL+ 
phenotype, representing non hypoxia, would be expected to correlate with a mixed CYGB 
expression profile, representing a decrease in CYGB expression. In contrast to this model 
there was no evidence to show a correlation between the pVHL+ profile and a mixed CYGB 
expression profile. This could indicate that an increase in non hypoxia, or conversely a 
decrease in hypoxia is not related to CYGB expression. However, CYGB expression is in part 
controlled by HIF-1α activity (see general introduction), which responds to both hypoxic and 
non hypoxic stimuli. In regions of pVHL+ phenotypes and thus non-hypoxia, CYGB 
expression could be as a consequence of non hypoxic stimuli. In support of this, cells which 
showed CAIX immunoreactivity, which is induced in response to non hypoxic stimuli, were 
also CYGB positive. CYGB frequently showed a higher level of staining than CAIX, the 
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lesions in which this was observed all had a pVHL+ edge. One could speculate that an all 
pVHL+ edge is indicative of a lower level of hypoxia within the lesion, as the edge is 
assumed to all be non-hypoxic, whereas lesions with a mixed pVHL+ profile where the edge 
is unlikely to be exclusively non-hypoxia, could be assumed to have a higher level of hypoxia 
within the lesion. Should this be the case, CYGB expression was shown to exceed than of 
CAIX in lesions with less hypoxia, thus it could be speculated that CYGB upregulation 
precedes that of CAIX in response to hypoxia. In vitro studies would be required to support 
this.    
 
Also of note, CAIX expression was observed in smooth muscle cells which were consistently 
negative for CYGB. The hypoxic response in smooth muscle is likely to differ due to 
myoglobin expression.  
 
Several papers in the literature present evidence that CYGB protein and mRNA is induced in 
vivo in response to hypoxia (Hankeln et al., 2004; Li et al., 2007; Mammen et al., 2006; 
Schmidt et al., 2004), a model which is substantiated by this study. Studies into CYGB 
expression and hypoxia in vivo have predominantly subjected rodents to varying degrees of 
hypoxia and determined the changes in CYGB expression compared to normoxic controls. As 
yet there are not any reports relating expression of CYGB in response to non hypoxic 
activation of HIF-1α. 
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4.5.3 Cytoglobin as a Marker of Fibrosis 
These data presented here argue against a role of CYGB as a marker of proliferation, 
inflammation, angiogenesis or stem cell mediated repair. A slight correlation was observed 
between the level of ECM deposition and CYGB expression. Whether this is causative or 
consequential remains to be determined. In the literature, over-expression of CYGB reduced 
differentiation of fibroblasts into an active myofibroblast phenotype, as characterised by 
expression of TIMP-1 and TGF-1 mRNA and a reduction in the levels of collagen 
production was observed (Xu et al., 2006).  It could be interpreted from the study by Xu et al 
that CYGB expression inhibits expression of collagen, which could contradict the 
observations made in this study. Potentially in the study by Xu et al, CYGB offers 
cytoprotection which prevents the induction of collagen expression, however in vivo, the 
threshold of this cytoprotection could be surpassed, and thus collagen and CYGB expression 
are observed simultaneously.  
 
A correlation between an increase in type II pneumocyte to type I pneumocyte differentiation 
in COPD and CYGB expression was observed in this study. The predominant contributor to 
COPD is smoking which induces oxidative damage via reactive oxygen species (ROS). 
Potentially differentiation of type II pneumocytes could be indicative of this oxidative 
damage. HIF-1α activity and CYGB expression have previously been shown to increase in 
response to ROS. It could be speculated therefore that type II pneumocytes express CYGB as 
a cytoprotective response to smoke mediated oxidative damage.  
 
A similar model could be proposed in the IPF lesion where the absence of type I pneumocytes 
correlated with a CYGB+ expression profile. One could speculate a loss of type I 
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pneumocytes is representative of excessive injury, in response to which type II pneumocytes 
express CYGB.  
 
 
4.5.4 Cytoglobin as a Marker of Vascular Remodelling 
 Evidence of the absence of CYGB staining in smooth muscle cells was presented in chapter 
3, further substantiation of this is presented here as CYGB expression was consistently 
negative in desmin positive cells of the vessel wall.  
 
CYGB expression paralleled that of vimentin in the vessel wall. Morphologically, these cells 
are likely to be fibroblasts, which are thought to play a critical role in vascular remodelling. 
Hypoxia may increase proliferation, ECM deposition, production of mitogenic factors and 
differentiation of fibroblasts of the vessel wall and adventisia (Pak et al., 2007) subsequently 
contributing to vascular remodelling. Expression of CYGB within the mesenchymal element 
of vascular remodelling could be in response to such hypoxic stimuli.  
Potentially CYGB expression could increase the capacity of the cell to extract oxygen from 
the local hypoxic environment to enable efficient cell function and vessel remodelling.  
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CHAPTER 5: CYTOPROTECTION OF CYTOGLOBIN 
AGAINST HYDROGEN PEROXIDE INDUCED OXIDATIVE 
STRESS 
 
 
5.1 Introduction 
There is contradictory evidence surrounding the role of cytoglobin (CYGB) in cytoprotection 
against oxidative stress (see general introduction), and the function of CYGB during cellular 
adaptation to this toxic insult remains unclear. Studies have shown CYGB to possess 
antioxidant enzymatic activity, including peroxidase (Kawada et al., 2001)(Trandafir et al., 
2007) whilst others found no evidence to support this (Trandafir et al 2007). CYGB 
expression has been shown to reduce oxidative stress in vitro ((Fordel et al., 2006; Hodges et 
al., 2008; Powers, 2006) and CYGB expression was observed in regions of high oxidative 
damage in vitro (Fordel et al., 2006)  
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5.2 Aim 
The overall aim of this chapter was to add to the current understanding of the possible role of 
CYGB in cytoprotection against oxidative stress. In particularly we tested the hypothesis that 
the putative peroxidase activity of CYGB would be protective against H2O2 induced oxidative 
stress  
The specific objectives were: 
 To determine a concentration range of H2O2 which would induce oxidative stress, but 
not affect cell viability 
 To use a CYGB over expressing HEK293 cell line, and a control HEK293 cell line as 
an in vitro model to investigate possible cytoprotection of CYGB over-expression 
against H2O2 induced oxidative stress, using DNA damage and cell death as end 
points.  
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5.3 Methods 
5.3.1 Preparation of Nuclear and Cytoplasmic Proteins 
Cells were cultured in T75 flasks, media was aspirated and the cells washed in warm PBS. The cells 
were scraped into 1ml PBS, and centrifuged at room temperature, 8000 rpm for 3 minutes to collect 
the cells. The supernatant was aspirated, the pellet re-suspended in 500 μl ice cold buffer A (0.6 % 
(v/v) NP-40, 150 mM NaCl, 10 mM Tris pH 8, 1 mM Na2EDTA, 10 μl/ml protease inhibitor), and 
incubated on ice for 20 minutes, vortexing at 5-minute intervals. The suspension was then centrifuged 
at 4˚C, 4000 rpm for 10 minutes. The supernatant (100 μl) was aspirated from the pellet and kept on 
ice, the rest of the supernatant was discarded. The pellet was then washed 3 times by re-suspension in 
200 μl ice cold buffer A, centrifugation (4˚C, 4000 rpm, 10 minutes) and removal of the supernatant 
by aspiration. Following the final wash the pellet was re-suspended in 50 μl buffer B (25 % (v/v) 
glycerol, 450 mM NaCl, 20 mM Tris pH 8, 0.2 mM Na2EDTA, 1.5 mM MgCl2, 0.5 mM DTT 
(Dithiothreitol), 10 μl/ml protease inhibitor) and incubated on ice for 30 minutes, vortexing at 5 
minute intervals. Both samples were then centrifuged at 15,000 rpm and 4˚C for 20 minutes. The 
supernatant of both these samples was then removed and used immediately or stored at -80˚C.  
 
5.3.2 Analysis of Hemoprotein by Spectroscopy 
CYGB is a heme protein, and correct incorporation of heme is required for function. 
Spectroscopy was used to determine the presence of hemoprotein within the CYGB+ cell line 
compared to the control, HEK293 cell line. Cells were cultured in 75 cm
2
 flasks as described 
previously, media was aspirated and the cells washed with PBS, prior to scraping into 4 ml 
PBS. Protease inhibitors (10 μl/ml) were then added to the cell suspension, prior to 
homogenisation on ice. 1ml samples of each cell type were placed into 2 cuvettes with 
approximately 10 mg of sodium dithionite. Sodium dithionite reduces the iron in the heme 
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enabling it to bind irreversibly with CO. CO was generated by reacting concentrated HCl and 
sodium formate and the generated CO was bubbled through one of the 2 cell samples, before 
a difference wavelength scan was taken using a U-3010 Spectrophotometer. 
 
5.3.3 Measuring Oxidative Stress using Fluorescent Dyes 
Intracellular dyes cis-PnA (cis-parinaric acid: 9,11,13,15-cis-trans-trans-cis-octodecaeonic 
acid: Molecular Probes) and DCFH-DA (2',7'-dichlorofluorescin diacetate) were used to 
assess the level of lipid peroxidation and oxidative stress respectively within HEK293 and 
CYGB+ cells. Cis-PnA is a fluorescent, 18-carbon poly-unsaturated fatty acid, which once 
incorporated into cellular membranes irreversibly loses fluorescence upon oxidation. This 
characteristic enables its use as a probe to evaluate oxidative stress within the cell as the 
reduction of fluorescence can be used to represent an increase in lipid peroxidation (Gomes et 
al., 2006). DCFH-DA readily diffuses across the cell membrane into the cell where it is 
hydrolysed by cellular esterases, to DCFH (2',7'-dichlorofluorescin), which cannot diffuse out 
of the cell. Oxidation of DCFH by reactive oxygen species, principally H2O2, forms the 
fluorescent product DCF (1,2-dichlorofluororescein), thus an increase in fluorescence 
represents an increase in oxidative stress (Gomes et al., 2006). 
 
5.3.3.1 cis-Parinaric acid (cis-PnA) 
Cells were cultured in 6 well plates, and grown to confluence over 2 days. The media was 
aspirated and the cells washed with PBS. The cells were incubated with phenol-free DMEM 
supplemented with the appropriate concentration of H2O2 at 37˚C, 5 % CO2, 95 % air for the 
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appropriate time period. Following treatment, the media was aspirated off and the cells 
washed 3 times with PBS, before phenol free DMEM containing 10μM cis-PnA was added to 
the cells, and cells incubated for 30 minutes at 37˚C, 5 % CO2, 95 % air. A blank containing 
no dye was included in all experiments. The cells were then washed, and each sample of cells 
was resuspended in PBS. The level of fluorescence was measured using a fluorimeter, or 
fluorimeter plate reader. The excitation and emission were 312nm and 455nm respectively. 
PBS only blank readings were subtracted from all readings. 
 
5.3.3.2  DCFH-DA 
Cells were cultured in 6 well plates, and grown to confluence over 2 days. The media was 
aspirated and the cells washed with PBS. The cells were incubated with phenol-free DMEM 
supplemented with 10 μM DCFH-DA for 30 minutes at 37˚C, 5 % CO2, 95 % air. Following 
the incubation the media was aspirated off and the cells were washed 3 times with PBS, 
before phenol free DMEM containing treatments was added to the cells, and they were 
incubated for the appropriate time period at 37˚C, 5 % CO2, 95 % air. A blank containing no 
dye was included in all experiments to control for any endogenous cellular fluorescence. The 
cells were then washed, and each sample of cells was resuspended in PBS. The level of 
fluorescence was measured using a fluorimeter, or fluorimeter plate reader. The excitation and 
emission were 502nm and 520nm respectively. PBS only blank readings were subtracted from 
all readings. 
 
The Kolmogorov-Smirnov test was used to determine whether the data fitted a normal 
distribution. As the data didn’t fit a normal distribution the Wilcoxon ranking test, and Mann 
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Whitney test were used to determine if any effects were significant, for paired and 
independent data respectively. 
 
5.3.4 The Comet Assay 
Cells were cultured and grown to confluence in 6 well plates over 2 days. The media was 
aspirated and the cells washed with PBS, prior to being replaced with phenol-free media, 
containing 0-800 µM H2O2 and incubated for the 2, 8 or 24 hours.   
Following treatment the media was aspirated, the cells washed with PBS, and scraped into 0.5 
ml PBS. The cell suspension was centrifuged at 8000 rpm for 5 minutes at room temperature. 
The supernatant was removed and the pellet re-suspended in 100 μl ice cold phenol free 
media, 3 μl of the suspension was added to 300 μl LMPA (0.5 % (w/v) low-melting point 
agarose, dissolved in PBS). Two 150 μl aliquots were taken from each treatment and spread 
onto two NMPA (0.5% (w/v)) normal-melting point agarose dissolved in PBS) coated 
microscope slide (BDH, U. K.), and a cover slip was added to each. The microscope slides 
were prepared 48 hours prior to the assay by cleaning with 70% ethanol before coating with 
NMPA. Once the LMPA had set, the coverslips were removed and the slides placed into a 
Coplin jar for 1 hour at 4˚C filled with ice cold complete lysis buffer (2.5 M NaCl, 0.1 M 
EDTA, 3.33% (v/v) sodium-lauryl-sarcosinate, 10 mM Tris, 0.5 % (v/v) triton-x-100, 5 % 
(v/v) DMSO pH 10. DMSO and Triton-x100 were added immediately prior to use).  
 
After lysis, the slides were washed, 3 x 5 minutes with FPG enzyme buffer (40 mM HEPES, 
0.1 mM KCl, 0.5 mM EDTA, 0.2 mg/μl BSA, pH 8.) 2 slides for each treatment were 
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prepared and to one of these 1 unit of FPG enzyme in 50 μl FPG enzyme buffer was added, 
whereas to the other 50 μl FPG enzyme buffer alone was added prior to a coverslip.  The 
slides were incubated in the dark for 1 hour, at 37˚C.  
 
The slides were then incubated in electrophoresis buffer (0.3 M NaOH, 1 mM EDTA) with 
coverslips removed, for 10 minutes at room temperature, prior electrophoresis for 20 minutes 
at 25 volts. Following electrophoresis the slides were neutralised by 3 x 5 minute washes with 
neutralisation buffer (0.4 M Tris pH 7.5). The excess was removed, 50 μl Sybr Gold solution 
and a coverslip was added to each slide, prior to analysis by inverted fluorescence microscopy 
(250x magnification, excitation wavelength 515-560 nm, emmision wavelength 590 nm; 
Zeiss, Germany) using komet image analysis software, version 3 (Kinetic Imaging Ltd. 
Liverpool, U. K.).  100 cells were counted on each slide. The % tail intensity was used as a 
relative measurement of DNA breaks. The median from each experiment was taken as the 
result and the mean of the medians from 5 replicates was used for analysis. The Kolmogorov-
Smirnov test was used to determine whether the data fitted a normal distribution. As the data 
didn’t fit a normal distribution the Wilcoxon ranking test, and Mann Whitney test were used 
to determine if any effects were significant, for paired and independent data respectively.  
 
5.3.5 Assessment of mRNA expression by RT-PCR 
The overall principle of RT-PCR is that the RNA within a sample is reverse transcribed to 
cDNA. Gene specific primers are used to amplify the cDNA through PCR, each cycle of PCR 
doubles the amount of DNA copies of the gene of interest. This DNA is fluorescently 
labelled, and so the increase in fluorescence emitted from the sample is proportional to the 
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amount of cDNA in the reaction, and thus the amount of RNA in the original sample. RNA 
extraction and quantification methods are summarised in chapter 2. 
Data Analysis 
An exponential pattern of fluorescence increase is seen due to the principles of PCR. An 
appropriate threshold level of fluorescence was selected following each PCR run. For each 
sample the number of cycles (CT) to reach the threshold, was used for data analysis. The more 
cycles it takes to reach the threshold, the lower the amount of cDNA within the sample, and 
vice versa. The CT Values were used to calculate absolute values. A standard curve with 10 
fold increments was made from a cDNA sample known to contain the target cDNA and used 
to calculate an arbitrary value for the amount of cDNA within each sample. Units 100, 10, 1, 
0.1 and so on were used for each concentration on the standard curve.  The curve is then used 
to calculate the ‘absolute value’ of cDNA within each sample. The amount of target cDNA 
was divided by the amount of housekeeping cDNA to normalise the data. The normalised 
values of the treated samples, was then divided by the normalised value of the control sample 
to determine fold change.    
 
5.3.5.1  One Step RT-PCR  
TaqMan® One Step RT-PCR Mix (2.5 µl), CYGB TaqMan (applied biosystems) primers and probes 
(0.625µl) and DEPC treated water (7.375µl) were pipetted into a TaqMan plate. 5 µl of sample RNA 
or standard curve RNA was added to each well. A standard curve was made using RNA from a 
CYGB+ cell line sample and loaded at 100% 10%, 1%, 0.01%, 0.001%, 0.0001%, 0.00001% and 
0.000001%. Immediately before use 5 µl TaqMan® RT Enzyme Mix was added. The plate was span 
at 1000 rpm for 1 minute, and then placed into an Applied Biosystems Real-Time PCR 7500 System. 
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The programme used was 50
o
C for 30 minutes; 95
o
C for 15 minutes; followed by 45 cycles of 94
o
C 
for 15 seconds; 57
o
C for 30 seconds; 76
o
C for 30 seconds.   
The data from the one step RT-PCR was calculated as absolute values. The RNA 
concentration within each sample was determined using RiboGreen, and used to normalise the 
data. The data was then presented as % fold change relative to each of the negative control 
siRNA. In comparing the data to the negative controls this will highlight knockdown which is 
specific to the presence of TAK-1 positive siRNA. The data did not fit a normal distribution, 
as determined using the Kolmogorov-Smirnov test  and therefore the Wilcoxon’s ranking test 
was used to determine and statistically significant effects 
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5.4 Results 
5.4.1  Characterisation of Cytoglobin Over Expressing HEK293 cells 
5.4.1.1  Expression of Functional Cytoglobin in HEK293 cells 
AstraZeneca (Charnwood) supplied 4 HEK293 cells lines, one of which was a control cell line, whilst 
the other 3 had been engineered to over express CYGB. AstraZeneca used retroviral vectors 
containing cloned human normal brain cDNA to transfect HEK293 cells with the CYGB gene. The 
CYGB gene was controlled by a CMV promoter and as such was constitutively expressed at high 
levels. The CYGB over expressing cell lines differed in that they synthesised either an untagged 
CYGB protein or the CYGB protein with a C or N terminal His Tag.  
 
Whole cell protein was extracted from each of the cell lines, and analysed using western blotting. A 
polyclonal mouse anti-human CYGB primary antibody (Abnova Taiwan Corporation, Taipei, Taiwan 
(H00114757-A01)), was used to detect the CYGB protein. An anti- β-actin antibody was used to 
detect actin, as a positive control.  
 
The western blot (see Figure 5.1(A)), showed a band at the expected size of approximately 20kDa in 
the untagged cell line, indicating presence of CYGB (Figure 5.1 (A)). The bands on the blot, which 
correspond to the samples obtained from the cell lines expressing a tagged CYGB protein were at a 
higher position on the blot than the sample from the cell line expressing the untagged protein, due to 
the increased the molecular weight caused by the presence of the tag. The western blot showed that in 
the control cell line CYGB protein expression was not detectable. The actin band was evident within 
all samples, confirming that protein extraction had been successful. This western blot demonstrates 
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that the cell lines are expressing the appropriate CYGB protein and that they had not become 
contaminated.  
 
The purpose of generating His-tagged CYGB protein was that the tag could be used to detect the 
presence of the CYGB protein, as at the time of engineering a commercial antibody was not available. 
This western blot however demonstrated that an effective antibody was now available and therefore 
using the tags would be unnecessary for the purposes of this study. His tagged cell lines were excluded 
from all further experiments. 
 
CYGB is a heme containing protein, it was therefore essential to confirm that the CYGB present 
within the CYGB+ cell line was heme bound and not just apoprotein. Heme is known to bind carbon 
monoxide when reduced by sodium dithionite, producing a diagnostic peak between 400 and 550nm. 
Analysis by difference spectroscopy revealed a significant peak around 425nm in the CYGB over-
expressing cell line (see Figure 5.1 (B)), confirming the presence of heme bound CYGB. This peak 
was absent in the control cell line, showing that it was specifically derived from the over expressed 
CYGB protein. 
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1. Western blot to show which cell lines are expressing CYGB. Gel A shows CYGB 
antibody binding, at approx 21kDa (0.2mg/ml polyclonal mouse anti-human CYGB 
primary antibody. Gel B shows An anti- β-actin (Diluted 1:10,000) antibody binding, as 
a positive control. The lanes on both gels (12% polyacrylamide) contain 20µg of the 
same samples. A goat anti mouse secondary antibody was used (diluted 1:10, 000) MW: 
Molecular weight marker Control: Control cell line, CYGB+: CYGB overexpressing 
cell line, N-Tag: N-terminal tagged CYGB expressing cell line, C-Tag: C-terminal 
tagged CYGB expressing cell line 
2. A graph to show a carbon monoxide difference spectra of HEK293 and CYGB+ cell 
lines. There is a significant peak in the CYGB+ cell line scan indicating extensive 
binding of carbon monoxide, and the presence of  excessive heme. 
Figure 5.1 Characterisation of the CYGB+ cell line 
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5.4.1.2  Subcellular Localisation of Cytoglobin in HEK293 Cells 
Cytoplasmic and nuclear extracts from HEK293 and CYGB+ cell lines were analysed in duplicate by 
western blotting for the presence of CYGB (see Figure 5.2). Lamin was used as a positive control for 
nuclear material, whilst Actin was used as a positive control for cytoplasmic material.  
 
Western blotting showed bands in the lanes which contained CYGB+ cell cytoplasmic extracts. There 
was an absence of staining from all other samples. This implies that in this cell line CYGB presence is 
limited to the cytoplasm. In addition to the western blot, CYGB+ and control HEK293 cells were 
cultured in 96 well plates. The cells were fixed and stained with an anti CYGB antibody and a 
fluorescent secondary antibody (see Figure 5.2). The observations made from the fluorescent 
microscopy supported the western blot data, that CYGB localised exclusively within the cytoplasm 
and there was no evidence to support nuclear localisation. 
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1. A western blot blocked with 20μg/ml polyclonal mouse anti-human CYGB primary 
antibody. Anti-Lamin A/C (0.4μg/ml) and anti-β-Actin (0.15μg/ml) were used as 
controls for successful separation of nuclear and cytoplasmic extracts (blot not shown).  
The labels correspond to the following samples: 
Nuclear +  CYGB+ cell line nuclear extract 
Cytoplasm +  CYGB+ cell line cytoplasmic extract  
Nuclear -  HEK293 cell line nuclear extract  
Cytoplasm - HEK293 cell line cytoplasmic extract.  
2. A digital photograph of CYGB+ cells. They were lysed before incubating with a 
mouse anti- human CYGB primary antibody (10μg/ml), followed by an Alexa-488 
secondary rabbit and mouse antibody (green). Nuclear staining was achieved using 
propidium iodide (red).This shows the subcellular localisation of cytoglobin to be 
cytoplasmic. 
Figure 5.2 Subcellular Localisation of Cytoglobin in CYGB+ Cells 
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5.4.2   Experimental Model Development 
The MTT assay was used to determine a hydrogen peroxide concentration range which did 
not significantly affect cell viability. Fluorescent dyes which detect the levels of reactive 
oxygen species, and oxidative stress in the form of lipid peroxidation were used to determine 
the time points for further investigation. From this preliminary data, a range of time points 
resulting in oxidative stress in the absence cytotoxicity were selected for more detailed 
analysis  
  
5.4.2.1  Selection of an Appropriate Concentration Range through Assessment of 
Cell Viability 
CYGB+ and HEK293 cells were cultured in 48 well plates and treated with a range of 
hydrogen peroxide concentrations (0, 200, 400, 600, 800, 1000 µM) for 24 hours and cell 
viability was assessed using the MTT assay. The MTT assay used followed the optimised 
protocol described in chapter 5. The data was presented as the relative absorbance (mean % of 
control).  
 
It can be seen in the Figure 5.3  that there was a concentration dependant decrease in cell 
viability, however this was not statistically significant. There was a 21.2% (±14.9) and 18.1% 
(±14.8) decrease between the cell viability of the control and 1000 µM treatment in the 
HEK293 and CYGB+ cell lines respectively. Although this was not a statistically significant 
decrease it was indicative of cytotoxicity, so 800 µM was used as the maximum concentration 
in all further studies. 
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5.4.2.2  Time Dependant Generation of ROS by Hydrogen Peroxide  
CYGB+ and HEK293 cells were cultured in 6 well plates and treated with 0, 200, 400, 600 
and 800 µM H2O2 for 1, 2, 4, 8, 16 and 24 hours. Prior to treatment DCFH-DA was added as a 
marker of accumulated intracellular oxidative stress (see 5.3.3 for details). Preliminary data 
showed that adding cis-PnA resulted in low readings for long time points as the fluorescence 
was lost over time with oxidative stress.  cis-PnA was thus added after treatment to represent 
the level of lipid peroxidation (see 5.3.3  for details), at that time point.  The data of the 
selected time points is presented in Figure 5.3 as the mean % of control from 3 experimental 
replicates.  
 
An distinct increase in oxidative stress (not statistically significant) was observed at all time 
points, as measured by both dyes. 2, 8 and 24 hour treatment times were selected to 
investigate the potential cytoprotective role of CYGB over expression against H202 induced 
DNA strand breaks and cell death, using the Comet and MTT assay’s respectively.  
 
These data were analysed to determine if CYGB over expression offered any cytoprotection 
against H202. There was no statistically significant difference between the cell lines in terms of 
the fluorescence emitted from either dye at any of the time points investigated, representing 
no difference between the cell lines in the levels lipid peroxidation or accumulation of ROS. 
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A: A graphical representation of the relative absorbance of HEK293 (white bars) and CYGB+  (black 
bars) cells treated with hydrogen peroxide for 24 hours and assessed for cell viability using the MTT 
assay. A mean of 3 repeats is presented. Error bars represent standard deviations. B: Graphical 
representation of the relative fluorescence from HEK293 (white bars) and CYGB+ (black bars) cell 
samples which had been treated with H2O2 for the time periods stated in the graph titles, and incubated 
with DCFH. The mean from 3 repeats is presented. Error bars represent standard deviations.  C: A 
graphical representation of relative fluorescence from HEK293 (white bars) and CYGB+ (black bars) 
cell samples which had been treated with H2O2 for the time periods stated in the graph titles, and 
incubated with cis-PnA. The mean from 3 repeats is presented. Error bars represent standard 
deviations.  
Figure 5.3  Experimental Model Development 
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5.4.4 The Effect of Cytoglobin Over Expression in Cytoprotection Against H2O2 
CYGB+ and HEK293 cell lines were treated with 200, 400, 600 and 800 µM H202 for 2, 8 and 
24 hours and assayed using the MTT and comet assay as end points of cytotoxicity and DNA 
damage respectively. 
 
  
 
 
        
 
 
 
 
 
5.4.4.1  Assessment of Cytoprotection using Cell Viability as an Endpoint. 
It is evident from Figure 5.4 that there is a concentration and time dependant response, as 
there is a decrease in cell viability with increased time and H2O2 concentration. However 
statistically these trends were not significant, and neither was any difference between the cell 
lines. 
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Figure 5.4  Effect of CYGB Over expression on Cell Viability 
 
Graphical representation of cell viability, as measured by the MTT assay, of HEK293 
(white bars) and CYGB+ (black bars) cells following treatment with H2O2, for 2, 8 or 
24 hours. Data presented is the mean relative absorbance from 3 repeats. Error bars 
represent standard deviation.  
H2O2 Concentration (µM) 
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5.4.4.2 Assessment of Cytoprotection using DNA Strand Breaks as an Endpoint. 
Unmodified Comet Assay 
Figure 5.5 shows the results of the comet assay presented as the mean median % tail intensity. 
Figure 5.5 shows an increase in % tail intensity with dose at 2 and 8 hours in the samples not 
incubated with FPG in both cells lines, but not at 24 hours. This trend was not statistically 
significant. 
 
Modified Comet Assay 
A concentration response can be seen in Figure 5.5 after 2 and 8 hours treatment, there was an 
increase in % tail intensity with increasing H2O2 concentration. This trend however was not 
statistically significant and there was no significant difference between the cell lines. 
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A. Comet Assay 
     
   
 
B. Modified Comet Assay 
     
 
 
 
 
 
 
 
A graphical representation of the mean median % tail intensity calculated following 5 repeats of 
the comet assay.  The % tail intensity represents the relative amount of damaged DNA within the 
sample.  HEK293 (white bars) and CYGB+ (black bars) cells were treated with H2O2  for 2, 8 or 24 
hours, before analysis with the comet assay. The modified comet data shows the mean median of 
samples which had been incubated with the FPG enzyme. The error bars represent standard 
deviation.   
Figure 5.5   Effect of Cytoglobin Over Expression on DNA Damage 
2 hours 
24 hours 8 hours 2 hours 
24 hours 8 hours 
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5.4.5 Expression of Cytoglobin in Response to H202 Treatment 
Subsequent to the previous experiments regarding H202 treatments, a paper was published 
which stated that CYGB was upregulated through treatment with H202 (Li et al., 2007). In 
order to ascertain if induction of CYGB was happening in this experimental model, HEK293 
cells were cultured in 6 well plates and treated with 200, 400, 600, 800 and 1000 µM H202 for 
2, 8 and 24 hours. Following treatment, protein and RNA were extracted from the same 
samples independently.  
 
5.4.5.1  Expression of Cytoglobin mRNA 
Single step RT-PCR was used to assess the CYGB mRNA levels within the RNA samples. 
The data is presented in Figure 5.6 as the relative expression of CYGB mRNA to the control. 
The data was normalised to RNA concentration. It can be seen from Figure 5.6 that at 2 and 8 
hours there is a concentration dependant induction of CYGB, which peaks at 600 µM. At 24 
hours there is no evidence of CYGB mRNA induction. This trend was not statistically 
significant. 
  
5.4.5.2 Expression of Cytoglobin Protein 
Western blotting was used to determine the presence of the CYGB protein within the protein 
samples. 20 µg of protein was loaded on the gel, the blot was incubated with 0.2 µg/ml of 
CYGB antibody overnight at 4
o
C. Figure 5.6 shows the blot, no bands are evident in any of 
the test samples, indicating that the CYGB protein was undetectable within any of the 
samples using this method. 
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A) A graphical representation of CYGB mRNA levels in HEK293 cells following treatment with 
H2O2 for 2, 8 or 24 hours. Presented is the mean fold induction of CYGB mRNA from 3 repeats. 
Error bars represent standard deviation. B) A western blot of protein samples taken from 
HEK293 cells treated with  various concentrations (labelled on figure (µM))  of H2O2 for 8 hours 
(Blots for 2 and 24 hours are not shown, but gave the same result). Lane 1 contains a protein 
sample extracted from CYGB+ cells, used as a positive control. 20µg of protein was loaded into 
each well, 2µg/ml monoclonal mouse anti-human CYGB primary antibody was used. Anti-β-
Actin (0.15μg/ml) primary antibody was used as a positive control for protein. The blot was 
incubated with primary antibody overnight. 
 
  
Figure 5.6 Induction of Cytoglobin Expression Following 
Treatment with Hydrogen Peroxide  
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5.5 Discussion 
5.5.1 Cytoglobin in Cytoprotection against Oxidative Stress 
At the start of this study there was much speculation in the literature regarding a role for 
CYGB in cytoprotection against oxidative stress, although there was no evidence to support 
this theory. During the course of this work, evidence has begun to emerge in the literature to 
support this hypothesis, however in general it has been limited to studies on neuronal cell 
lines (Fordel et al., 2006; Hodges et al., 2008; Li et al., 2007; Xu et al., 2006). Here we 
investigated a potential role for CYGB in cytoprotection against oxidative stress in a non 
neuronal cell line, HEK293. In contrast to data presented in the literature this study found no 
evidence to support cytoprotective role of CYGB against hydrogen peroxide induced 
oxidative stress. There was no difference in DNA damage, cell viability, lipid peroxidation or 
intracellular ROS of cells over expressing CYGB compared to a control cell line, which 
expressed only endogenous CYGB. Of note this is the first study to look at HEK293 cells. 
 
Xu et al (Xu et al., 2006) investigated cytoprotection of CYGB against 50 M Ferric 
nitrolotriacetate and 20 M arachidonic acid induced oxidative stress, using a rat hepatic 
stellate cell line which had been transfected with a CYGB, or GFP (control) over expressing 
plasmid (Bondarenko et al., 2006). Over expression of CYGB reduced the level of oxidative 
stress within the cells, as measured using markers of lipid peroxidation. Evidence was also 
provided to support the hypothesis that this was through increased levels of oxyradical 
scavenging (Bondarenko et al., 2006).   
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All other studies have used neuronal cell lines, in which (see chapter 5) CYGB has been 
shown to localise to the nuclei and cytoplasm, in contrast to non-neuronal cells in which most 
evidence suggests a strictly cytoplasmic localisation (see chapter 5). The differences in the 
subcellular localisation patterns of the cell types indicates that the role of CYGB within the 
different cell lines may vary, so although these studies are of interest, the difference between 
the cell lines used could explain the contradictions in the data generated.  
 
Hodges et al (Hodges et al., 2008) presented evidence of cytoprotection of over expressed 
CYGB against oxidative stress in a neuronal cell line TE671 (Ostojic et al., 2008). Following 
exposure to Ro19-8022, which causes oxidative DNA damage, the cells showed an increase in 
intracellular ROS and oxidative DNA damage (8-oxo-dG), which was reduced by 
overexpression of CYGB. 8-oxo-dG is formed from oxidation of the DNA sugar Guanine, 
which occurs readily under oxidative stress. Of note, over expression of CYGB did not confer 
protection against DNA damage which was not specifically 8-oxo-dG (Ostojic et al., 2008). 
The levels of damage observed in this study with and without FPG incubation were 
comparable for the CYGB overexpressing cell line, whereas the control cell line exhibited 
distinctly more damage following FPG incubation. This implies that the protection offered by 
CYGB was specific to oxidative stress induced DNA damage. 
 
There are 2 studies in the literature which present evidence of CYGB mediated cytoprotection 
against H2O2 induced oxidative stress, however both studies used neuronal cells lines. The 
first used N2a (mouse) neuroblastoma cells (Hodges et al., 2008), and the second in SH-
SY5Y (human) neuroblastoma cells ((Kida et al., 2007). The study in N2a cells used a siRNA 
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vector to reduce CYGB expression (Li et al., 2007), and observed that following treatment 
with 500 M H2O2 for 4 hours, the cells with reduced CYGB protein expression suffered a 
significantly greater loss in cell viability than the cells with endogenous CYGB 
expression(Hodges et al., 2008). The study in SH-SY5Y cells took a different approach and 
looked at over expression of CYGB (Kida et al., 2007). Exposure of CYGB over expressing 
cells, GFP (control) over expressing cells, and non-transfected controls to 300 μM for 24 
hours, showed 70% (significant) less cell death, in those cells with CYGB over expression 
compared to the non-transfected controls. Of note, transfection with a GFP plasmid offered 
28% less cell death, thus one can assume that 40% of the reduction in cell death was due to 
the presence of excessive CYGB (Kida et al., 2007).  
 
Further studies by Fordel et al in SH-SY5Y cells investigated the effect of anoxia on the 
generation of H2O2 (Shigematsu et al., 2008). Cells containing antisense CYGB, which 
effectively reduced the production of CYGB mRNA by 47%, showed a significant increase in 
H2O2 generation following 16 and 24 hours anoxia, whilst over expression of CYGB (verified 
at the mRNA and protein level) led to a decrease in H2O2 generation (not significant) 
(Shigematsu et al., 2008).   
 
This study did not find any evidence of CYGB cytoprotection against H2O2 induced oxidative 
stress in HEK293 cells, and as yet there is nothing in the literature to specifically contradict 
this observation. In rat HSC cells, using a different method of inducing of oxidative stress, 
over expression of CYGB appears to offer some cytoprotection (Bondarenko et al., 2006). 
There is mounting evidence that in neuronal cells CYGB overexpression, or inhibition offers 
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cytoprotection, or increased stress respectively against oxidative stress. It remains elusive 
whether this role is replicated in non neuronal human cells (Burmester et al., 2007; Hodges et 
al., 2008; Kida et al., 2007; Ostojic et al., 2008; Shigematsu et al., 2008).   
  
5.5.2 Induction of Cytoglobin Expression in Response to Hydrogen Peroxide 
Presented here is evidence of a trend in induction of CYGB mRNA in response to, 400, 600, 
800 and 1000 M hydrogen peroxide after 2 and 8 hours, in HEK293 cells. Although this 
isn’t significant the trend shows a peak (3-4fold) at 600 M at both time points. This is in a 
similar range to that which Li et al observed in N2a neuroblastoma cells, following treatment 
with 250 M H2O2 for 3, 6, 12, 24 hours (Hodges et al., 2008). A significant increase in 
mRNA of 2-4 fold was observed. In addition an increase in CYGB mRNA expression was 
observed in vitro, in the regions of rat brain which have previously been reported to respond 
to oxidative stress, following hypoxic treatment (Trandafir et al., 2007). 
 
The evidence in the literature with respect to induction of CYGB mRNA in response to 
oxidative stress is somewhat limited, and further studies are required to make sound 
conclusions. This study hints towards a model in which oxidative stress induces expression of 
CYGB. Further studies in the mechanism of induction are required, especially as there is no 
evidence of an Antioxidant Response Element (ARE) within the CYGB promoter region.  In 
absence of an ARE, it could be speculated that an increase in CYGB mRNA could be a 
downstream consequence, or side effect of oxidative stress rather than a direct response. 
Another potential source of CYGB up-regulation in response to oxidative stress is via HIF-1α.  
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Several papers in the literature suggest that HIF-1α can regulate oxidative stress response 
genes (Kietzmann and Gorlach, 2005), and that ROS may have a level of control over HIF-1α 
activity (Siddiq et al., 2007).  A review by Kietzmann and Gorlach (Kietzmann and Gorlach, 
2005)concluded that under non hypoxic conditions an increase in the levels of ROS lead to an 
increase in HIF-1α expression. Taking this onto account, and the observations made in this 
study, it could be speculated that CYGB upregulation in response to ROS is mediated via 
HIF-1α. 
 
5.5.3 The Subcellular Localisation of Cytoglobin 
The CYGB literature provides contradictory evidence regarding the subcellular localisation of 
CYGB. Geuens et al were the first group to present evidence of CYGB within the nucleus 
(Geuens et al., 2003). In 2003 they showed using IHC that CYGB was found exclusively in 
the nucleus of cells of mouse tissue. In addition CYGB was isolated from nuclear extracts of 
mouse liver, using affinity chromatography and western blotting. 
 
In vitro studies have presented evidence of CYGB expression solely within the cytoplasm of 
A549 cells (Hodges et al., 2008; Huang et al., 2006),  F9 cells (Nakatani et al., 2004), 
HEpG2, MCP13, HeLa and mouse embryonic fibroblasts (Hodges et al., 2008). In contrary, 
HeLa and Vero cells were shown to express CYGB within the nucleus (Schmidt et al., 2004) 
however this was investigated using a Cygb-GFP construct, which was potentially small 
enough to diffuse into the nucleus, as such this study argues against active nuclear transport of 
CYGB in HeLa and Vero cells, rather than for a nuclear subcellular localisation of CYGB.  
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In vitro analysis of neuronal cells, SKHSH, TE671 shows a nuclear and cytoplasmic 
localisation of CYGB (Hodges et al., 2008), which has been supported by in vivo studies in 
dogs, (Ostojic et al., 2006), mice (Geuens et al., 2003), (Man et al., 2008) (Schmidt et al., 
2005)) and rats (Li et al., 2007). In addition, CYGB was found absent from mitochondrial and 
membrane fractions of rat brain (Li et al., 2007).  
 
Nuclear and cytoplasmic expression of CYGB has been presented in mouse liver 
haematopoietic stem cells, and on occasion in fibroblasts (Man et al., 2008). All other cell 
types investigated have shown cytoplasmic localisation of CYGB, including fibroblasts of the 
mouse heart, lung, kidney and thigh muscle (Man et al., 2008),  rat kidney fibroblasts 
(Nakatani et al., 2004). In contradiction of the study by Man et al,  Schmidt et al presented 
evidence of CYGB expression being exclusive to the cytoplasm in HSCs, fibroblasts, 
chondrocytes, oesteoblasts and osteocytes (Schmidt et al., 2004) using IHC on mice tissue.  
 
The relationship between hypoxia and CYGB subcellular localisation was investigated by Li 
et al who observed no change in localisation after 1, 3, 7 or 14 days at 10% O2 in rat brain. 
 
Presented here is evidence of a cytoplasmic localisation of CYGB in HEK293 cells in vitro 
and in numerous cell types in vivo (see Chapter 3). It is evident from the literature and this 
study, that the predominant subcellular localisation of CYGB is cytoplasmic in all non 
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neuronal cells, but in neuronal cells nuclear localisation is also evident. This leads to the 
speculation that the role of CYGB in neuronal and non neuronal cells differs.  
 
5.5.4 Physiological Considerations  
This study has hinted towards induction of CYGB in response to H2O2 induced oxidative 
stress, but showed no evidence that over expression of CYGB offers cytoprotection against 
this insult. Notably, a trend of CYGB mRNA induction was observed which peaked at 600 
M. Lipid peroxidation, endogenous ROS, and DNA damage, in general presented a clear 
increase at 800 M compared to 600 M doses.  It could be speculated that there was no 
difference between the cell lines in terms of these endpoints at doses of 600 M and lower, 
because induction of endogenous CYGB offered comparable cytoprotection to that afforded 
through over expression. After this dose the induction of CYGB is reduced, and it could be 
speculated that as a consequence an increase in cellular damage is observed. The cell viability 
data shows there is reduction in cell viability with 800 M H2O2, it would add weight to this 
argument to determine whether this was due to an increase in cell death or a reduction in cell 
proliferation, and whether there is a significant switch from reduced proliferation to cell death 
at 800 M.  
 
The manner in which CYGB could offer cytoprotection to ROS is unclear, there has been 
evidence presented in the literature that CYGB can act to catabolise H2O2 (Kawada et al., 
2001). Another study showed however that the catalase activity of CYGB was negligible 
compared to true enzymes (Trandafir et al., 2007). It remains elusive whether CYGB could 
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act to directly detoxify ROS, however these studies have demonstrated that CYGB can bind 
ROS. Several studies have shown that an increase in CYGB expression results in lower levels 
of ROS ((Bondarenko et al., 2006; Ostojic et al., 2008; Shigematsu et al., 2008). It could be 
speculated from this that the mechanism of cytoprotection relates directly to managing levels 
of ROS, possibly through savaging ROS, through enzymatic activity to stabilise ROS, or 
potentially the binding of ROS to CYGB could initiate a pathway of ROS degradation, or in 
complexing ROS, CYGB could be signalled for degradation resulting in a simultaneous 
reduction of CYGB and ROS levels.  All of these hypothesises are highly speculative as the 
literature on the subject is somewhat limited. 
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CHAPTER 6: GENERAL DISCUSSION 
 
The cygb gene has been shown to be evolutionarily ancient, arising prior to the development 
of the circulatory system (Sugimoto et al., 2004). It is also well conserved (Pesce et al., 2004; 
Trent and Hargrove, 2002), indicating the role of cytoglobin to be fundamental to an ancient 
biological function.  
 
6.1 Cytoglobin in the Transport of Oxygen to the Mitochondria. 
A role for CYGB in the transport of oxygen to the mitochondria has been both proposed and 
refuted in the literature. The main objection against this role for CYGB concerned the absence 
of CYGB expression in several cell types. Reported here however is evidence that CYGB 
expression was observed in the majority of cell types. The exception to the rule being the 
observation of negative expression in cells which express other members of the globin family, 
potentially however due to other globins compensating for the absence of CYGB. The levels 
of CYGB in the cell have been reported to be low (Fago et al., 2004). One cannot therefore 
assume that cells which appear to offer negative CYGB expression are in fact negative for 
CYGB, as the basal level of expression may just be undetectable via IHC and western 
blotting, the techniques used. Therefore what may have been observed in this study, and 
others, is that cells which are positive for CYGB are presenting with increased expression 
whilst those which appear negative are offering a basal level of expression. Therefore the 
conclusion in the literature that CYGB is not involved in the transport of oxygen to the 
mitochondria, because it is not expressed by all cell types, may not be valid. However, should 
CYGB have a role in transport of the oxygen to the mitochondria, it would be unlikely that in 
a hypoxic scenario upregulation would be observed. In response to hypoxia there is a 
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reduction in transcription and translation of unessential proteins (Wenger, 2002). It would 
appear unlikely that if the primarily role of CYGB was transport of oxygen to the 
mitochondria, where there was little oxygen, and therefore a reduction in the requirement for 
CYGB, that the cell would respond to increase CYGB expression. Additionally the low 
cellular levels of CYGB, would argue against a role in transport of oxygen to the 
mitochondria (Fago et al., 2004). A role of CYGB in transport of oxygen to the mitochondria 
is plausible, should a basal level of expression be observed in all cell types, however overall 
the available evidence suggests that this in unlikely to be the primary role of CYGB.    
 
6.2 Cytoglobin in Oxygen Transport, Storage and Sensing 
There is substantial evidence in the literature to support CYGB binding to oxygen in a manner 
which enables oxygen transport (Sawai et al., 2003; Trent and Hargrove, 2002). CYGB 
expression has previously been shown to increase in response to low oxygen levels (Fordel et 
al., 2004a; Fordel et al., 2004b; Fordel et al., 2007a; Fordel et al., 2007b; Guo et al., 2007; 
Huang et al., 2006; Mammen et al., 2006; Schmidt et al., 2004; Singh et al., 2009), and 
preliminary work done alongside this study showed an increase in CYGB expression, 
although not statistically significant, in BEAS-2B and HEK293 cells after incubation with 1% 
oxygen for 1,3,6 and 9 hours.  This study has further substantiated this by showing an 
increase in the CYGB positive phenotype of cells within hypoxic fibrotic lesions. These 
observations support speculated roles of CYGB in O2 storage, transport and sensing. It has 
been suggested that CYGB could be involved in the supply of oxygen to particular cellular 
processes, such as contraction of myofibroblasts (Kawada et al., 2001) or collagen synthesis 
(Fago et al., 2004; Man et al., 2008; Nakatani et al., 2004; Schmidt et al., 2004). Although 
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this is plausible, it seems more likely that the primary function of CYGB is more 
fundamental, and essential to a wider array of cell types.  
 
CYGB may have a role in extracting O2 from the local environment, in a similar manner to 
myoglobin, facilitating diffusion of oxygen into the cell and then to the mitochondria. The 
immediate upregulation of CYGB in response to hypoxic stimuli, reported in the literature 
and supported by observations in this study, would support this role. CYGB bound oxygen 
would not contribute to the partial pressure of oxygen (PO2) in the region, thus by increasing 
expression of CYGB, and ‘mopping up’ free oxygen within the cell, the partial pressure of 
oxygen within the cell may fall lower than that externally, thus driving diffusion of oxygen 
into the cell. The level of cellular CYGB would therefore correlate to the PO2 within the cell, 
in that higher levels of CYGB would drive down the internal PO2, enabling diffusion of 
oxygen into the cell at lower oxygen tensions.  In this model CYGB could also act as an O2 
reservoir, as the release of oxygen from CYGB would relate to the subcellular PO2, and would 
only be released where and when needed. This would enable the release of O2 by CYGB to 
cellular reactions as previously proposed, such as contraction of myofibroblasts and collagen 
synthesis.  
 
In the current study, CYGB expression was consistently positive throughout the fibroblast 
population, but no other cell type. The relative levels of expression within fibroblasts 
compared to other cell types however, has not yet been investigated. Fibroblasts migrate to 
regions of damage, which are frequently related to vascular damage and subsequent hypoxia. 
As observed in this study, as the predominant cell type within the lesion, and in regions of 
avascularity were fibroblasts. Potentially fibroblasts may present with a higher level of CYGB 
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expression than other cell types, offering an oxygen storage role under normal conditions, and 
in response to damage, a role in transporting oxygen to regions of damage induced hypoxia.  
 
A putative model was proposed at the start of this study which considered that expansion of 
the fibrotic lesion was limited by expression of CYGB at the fibrotic border, which may 
create a hyperoxic environment, protecting the normoxic parenchyma from the hypoxic 
lesion. The data presented here argues against this, as expression of CYGB was variable at the 
edge, but consistent within the lesion.  
 
 A role of CYGB in oxygen sensing is plausible. As previously discussed, up-regulation of 
CYGB in response to hypoxia could facilitate diffusion of O2 into anoxic cells, restoring 
normoxia. The expression level of CYGB may subsequently return to basal levels, as 
observed in in vitro studies looking at reoxygenation (Fordel et al., 2007a), proving a 
feedback loop. The level of CYGB within the cell would therefore be related to the PO2, 
supporting an oxygen sensing role.       
 
6.3 Cytoglobin as a Redox Sensor and in ROS Scavenging 
As previously discussed, one potential role of CYGB could be to increase the capacity of the 
cell to extract oxygen from the local environment. Molecular oxygen is a pre-requisite of 
ROS, and there is a long-standing debate regarding the relationship between ROS and oxygen 
homeostasis. It has previously been proposed that ROS produced from the mitochondrial 
respiratory chain could contribute to oxygen sensing (Kietzmann and Gorlach, 2005). This 
model however assumes under hypoxic condition the levels of ROS decrease. This has been 
shown in several studies, however numerous studies have also presented contradictory 
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evidence (Kietzmann and Gorlach, 2005). The majority of the studies which reported an 
increase in ROS in response to hypoxia, used DFCH to measure the levels of ROS. Although 
DCFH is oxidised by ROS, principally H2O2, to form a fluorescent product, DCF, there is also 
evidence however that heme can also oxidise DFCH to DCF directly (Ohashi et al., 2002). 
These studies could thus have been detecting an increase in heme, potentially due to CYGB 
induction, rather than an increase in ROS. It seems more likely that a decrease in ROS is 
observed with hypoxia. 
 
A model associating oxygen tension and ROS may also involve CYGB. Under hypoxic 
conditions, CYGB expression increases, which may result in normalisation of oxygen levels, 
and subsequently a reduction in CYGB expression back to basal levels, as discussed earlier. 
Under hyperoxic conditions however, leading to the generation of ROS, or in response to 
other causes of oxidative stress, induction of CYGB could also occur, as observed in the 
current study. This may be followed by binding to ROS. CYGB binding could potentially 
stabilise ROS, or target it for degradation, or the degradation of a ROS-CYGB complex. 
There is some evidence that CYGB may have peroxidase activity (Asahina et al., 2002; 
Kawada et al., 2001), and can detoxify reactive nitrogen species (Halligan et al., 2009; 
Smagghe et al., 2008), although as yet a cytoglobin reductase has not been identified to 
enable catalytic cycles of detoxification. Although no evidence has been provided to support 
this, the reduction in ROS levels due to CYGB activity may feedback to reduce the CYGB 
expression back to basal levels. There may also be competitive binding between O2 and ROS, 
with CYGB offering a higher affinity for ROS, thus enabling stabilisation of ROS, and or 
degradation at high oxygen tensions, and under low oxygen tensions where ROS are not 
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generated CYGB could readily bind O2. Cytoglobin may thus be involved at maintaining 
oxygen homeostasis by responding to both hyperoxic and hypoxic insults.  
There was evidence provided in this study of similar patterns of expression of CAIX and 
CYGB, it could therefore be speculated that like CAIX, CYGB is regulated by HIF-1α in 
response to hypoxic and non hypoxic stimuli. Non hypoxic regulation of HIF-1α includes 
stimulation by ROS (Kietzmann and Gorlach, 2005), and thus regulation of CYGB in 
response to hyperoxia and hypoxia may be via HIF-1α. 
 
6.4 Other Potential Roles of Cytoglobin 
CYGB is a putative tumour suppressor, which has been proposed due to the loss of CYGB 
expression within several tumours as a result of promoter methylation (McRonald et al., 
2006; Shaw et al., 2006; Shaw et al., 2009; Shivapurkar et al., 2008; Xinarianos et al., 2006). 
The loss of any of the functions previously discussed could lead to a loss of redox balance, or 
hypoxia which could act as a causative agent, or more likely contribute to tumour progression. 
It appears unlikely that CYGB has a direct role in the cell cycle, especially as CYGB 
expression does not appear to be associated with proliferation. Additionally a yeast 2 hybrid 
study showed no associated between CYGB and cell cycle proteins (Hodges, NJ. personal 
communication). Loss of CYGB expression however could result in aberrant expression of 
cell cycle mediating proteins via a loss of redox homeostasis. 
 
It is evident from observations presented here that the role of CYGB is not directly, or 
specifically related to inflammation, angiogenesis or stem cell mediated repair. The results of 
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this study would also argue against the use of CYGB as a marker of activated fibroblasts and 
stellate cells 
 
6.5 Summary of Findings 
CYGB expression was observed in a range of cell types indicating a fundamental role, of no 
cell type specificity. This study also provides evidence of CYGB upregulation in response to 
oxidative stress in vitro. CYGB expression was most prevalent within a fibrotic lesion and 
more variable at the edge, and was shown to be associated with fibroblast infiltration, 
avascularity and potentially hypoxia. The expression of CYGB within the lesion paralleled 
that of CAIX indicating related regulation of expression. These findings support a role for 
CYGB in cellular redox and oxygen homeostasis, regulated via HIF-1α in response to both 
hypoxic and non hypoxic stimuli.  
 
6.6 Future Work 
Despite extensive work, 10 years after its identification, the subcellular role of CYGB remains 
elusive. However, extensive in vivo and in vitro studies are required to determine the 
subcellular role of CYGB. It would of interest to ascertain the following: 
 Direct evidence of a role in detoxification of ROS, using purified proteins or over 
expressing systems in vitro. 
 The affinity with which CYGB binds ROS and whether this is competitive O2. 
 Whether CYGB expression increases the capacity of the cell to take up oxygen. 
 Determine whether all cell types have a basal level of CYGB expression. 
 Whether fibroblasts have a higher level of CYGB expression than other cell  types 
 Whether CYGB is induced in response to non hypoxic induction of HIF-1α activity. 
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APPENDIX 
A1. Table of Materials 
Generic Chemicals Source Catalogue number 
Acrylamide GeneFlow Ltd  
Ethanol Fischer Scientific  
Formalin VWR International Poole (BDH)  
Hydrogen Peroxide BDH, UK  
Methanol Fischer Scientific  
Generic Lab Equipment   
Cell Scraper Corning Inc  
Centrifuge tubes Falcon, Becton Dickinson Labware  
Eppendorfs Greiner bio-one  
Cell Culture-Cells   
HEK298 Cells AstraZeneca  
Cygb+ HEK298 Cells AstraZeneca  
Cell Culture-Media and supplements   
LHC-9 Medium GIBCO, Invitrogen  
Fetal Bovine Serum Gibco, Invitrogen  
Fibronectin Invitrogen  
Cell Culture- Plates   
Collagen/Poly-D-Lysine coated plates Becton Dickinson  
Flasks 25cm
2
 Falcon, Becton Dickinson Labware  
Flasks 75cm
2
 Falcon, Becton Dickinson Labware  
Lab-Tek II Chamber slides Nalge Nunc. International  
Cell Culture Plates Cellstar  
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Cell Culture- Equipment   
Cryovials Naglene, New york  
Disposable haemocytometer Immune Systems  
Haemocytometer Weber scientific international ltd  
Protein Analysis- Quantification   
BCA Protein Assay Kit Pierce 23225 
Bradford Dye BioRad, Germany 500-0006 
Filter (0.45µm) Pall Corporation 4654 
Protein Analysis- Concentration   
Centrifugal filter units Millipore 42407 
Western Blotting-Generic Materials   
Chemiluminescence detection agents GeneFlow Ltd  
Gels, 12%, 15 wells BioRad, Germany 161-1120EDU 
Glass plates and supports BioRad, Germany  
Hyperfilm Amersham Biosciences, UK  
Kaleisdoscope protein marker BioRad, Germany  
Laemmili buffer BioRad, Germany  
Low fat powdered milk Marvel, UK  
Nitrocellulose membrane Amersham, Biosciences, UK  
Pre-stained protein marker BioLabs, England  
Pre-stained protein marker Pierce  
Tris/Glycine buffer BioRad, Germany  
Tris/Glycine/SDS buffer BioRad, Germany  
Western blotting equipment BioRad, Germany 3342 
Fluorescence Microscopy and IHC   
Vectashield Mounting Medium  Vector Laboratories H00114757-A01 
Immunohistochemistry-Generic Materials   
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Wash Buffer (PBS) Sigma P3813-10PAK 
Diluent (0.1%BSA in PBS) Sigma P3688-10PAK 
10% Buffered Formalin Pioneer Research Chemicals Ltd, Colchester 
Parafin Pfizer Scientific  
Xylene Fisher Scientific X/0100/PB17 
Ethanol Fisher Scientific E/0650DF/P17 
Industrial methylated spirits Fisher Scientific M/4450/PB17 
Immunohistochemistry-H&E   
Gill II haemotoxylin Pioneer Research Chemicals Ltd, Colchester 
Eoisin Y Acros Organics, Fisher Scientific  
Immunohistochemistry-Antigen Retrieval   
Antigen Unmasking Fluid Vector Laboratories H-3300 
High pH Antigen retrieval Solution Dako DM812 
Low pH Antigen retrieval Solution Dako DM809 
Boric Acid Fisher Scientific B/3800/53 
Immunohistochemistry-Serum   
Normal Goat Serum Dako X0907 
Normal Swine Serum Dako X0901 
Normal Horse Serum Vector Laboratories S-2000 
Immunohistochemistry-Amplification Kits   
Tryamide Signal Amplification Kit PerkinElmer NEL700 
Streptavidin AB/HRP Kit Dako K0377 
Envision Flex (anti-Mouse) Dako K4000 
Envision Flex (anti-Rabbit) Dako K4003 
Immunohistochemistry-Chromogens   
DAB Dako  
NovaRED Vector Laboratories SK-4800 
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Peroxidase Subatrate Kit (Nickle DAB) Vector Laboratories SK-4700 
Immunohistochemistry-Pico-Sirius Red    
Sirius Red 
Sigma 
365548 
Primary Antibodies   
CYGB Monoclonal primary antibody  Abnova H00114757-M02 
CYGB polyclonal primary antibody Abnova H00114757-A01 
Lamin Antibody  Santa Cruz  
Monoclonal Anti-β-Actin Antibody  Sigma A1978 
α Smooth Muscle Actin Dako M0851 
CD3 Dako A 0452 
CD31 (PECAM-1) Abcam Ab9498 
CD34 Class II Dako M7165 
CD68 Dako M0814 
Carbonic Anhydrase IX BD Biosciences 15086 
C-Kit Dako A4502 
Collagen I Abcam COL_1 
Cytokeratin Dako M0821 
Desmin Dako M0760 
MAC 387 Serotec MCA 874G 
Proliferative Cell Nuclear Antigen Novocastra NCL-PCNA 
S100A4 Dako A5114 
Surfactant A DakoCytomation M4501 
Tubulin Antibody Calbiochem  
Vimentin Dako M0725 
Von Hippel Lindou  BD Biosciences 556347 
Wheat Germ Agglutinin Vector Laboratories B-0125 
Primary Antibodies-Isotype Controls   
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Mouse IgG1 Dako X0931 
Mouse IgG2a Kappa BD Pharmingen 550339 
Rabbit Ig Serotec PRAB101 
Rabbit Ig Dako X0936 
Mouse IgG2a  Dako X0943 
Mouse IgG2b Serotec PMP50 
Acetylglucoasamine Sugar Vector Laboratories S-9002 
Secondary Antibodies   
Goat anti mouse HRP secondary Dako P0447 
Biotinylated Goat anti Mouse  Dako E0433 
Biotinylated Goat anti Rabbit  Dako E0432 
Biotinylated Swine anti Rabbit  Dako E0353 
Biotinylated Horse anti Mouse  Vector Laboratories BA-2001 
Alexa 488-labelled Rabbit anti Mouse Molecular Probes, Invitrogen A11059 
RNA Extraction   
RNAqueous-4 PCR Kit Ambion, Applied Biosytems AM1914 
RNeasy 96 Qiagen Ltd 74181 
RNeasy mini kit Qiagen Ltd 74106 
RNA Quantification   
RiboGreen Kit Invitrogen R11490 
Agilent RNA 6000 Nano Kit Agilent Technologies 5067-1511 
DNase I Treatment of RNA Samples   
DNase I Ambion, Applied Biosytems AM2222 
Intracellular Fluorescent Dyes   
2,7-dichlorodihydrofluorescein diacetate Molecular Probes, Invitrogen  
cis-parinaric acid Molecular Probes, Invitrogen  
The Comet Assay   
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FPG Enzyme Trevigen 4040-100-01 
Sybr Gold Invitrogen  
Microscope slides BDH, UK  
Coverslips glass 22mmX64mm BDH, UK  
DNase I Treatment of RNA Samples   
DNase I Ambion, Applied Biosytems AM2222 
RT PCR   
18s rRNA primers and probes   
Agilent RNA 6000 Nano Kit Agilent Technologies  
Cytoglobin primers and probes   
DNase I Ambion, Applied Biosytems  
OliGreen Kit   
RiboGreen Kit   
RNAqueous-4 PCR Kit Ambion, Applied Biosytems AM1914 
RNeasy 96 Qiagen Ltd  
RNeasy mini kit Qiagen Ltd  
Superscript II kit   
TAK-1 Primers and probes   
TaqMan Machine   
TaqMan mastermix (one step)   
TaqMan mastermix (two step)   
siRNA transfection   
CYGB siRNA Dharmacon LQ-016960-01 
Transfection Lipid Silence therapeutics Autofect01 #0336 
Luciferase 1 siRNA Dharmacon CLIAA-0047 
Luciferase 2 siRNA Dharmacon CLIAA-0049 
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Negative siRNA #1  Dharmacon D-001810-01-05 
Negative siRNA #2 Dharmacon D-001810-02-05 
OptiMem + Glutamax-1 Gibco 51985-026 #0435 
TAK-1 siRNA (pool 2)  Dharmacon BODKA-00009 
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A2. Example Ethical Consent Form 
 
13.6.2007: Version 1 
 
Subject Information Leaflet and Consent Form 
 
Study Title:    Use of Tissue from Lung Resections to Investigate the Molecular and  
Functional Mechanisms of Human Lung Disease 
 
Principle Investigator: Professor Andrew Wardlaw 
 
Study Funded by: Astra-Zeneca 
 
You are being invited to take part in a research study.  Before you decide it is important for 
you to understand why the research is being done and what it will involve.  Please take time 
to read the following information carefully and discuss it with others if you wish.  Ask us if 
there is anything that is not clear or if you would like more information.  Take time to decide 
whether or not you wish to take part. 
 
Introduction 
Lung disease causes pain, discomfort and can prevent sufferers from carrying out everyday 
activities. Whilst available treatments including steroids and other drugs may relieve 
symptoms, none provide a cure. Operations may help some people. More research is needed 
to find new treatments that can cure lung disease. 
 
What is the purpose of the study? 
In order to find the causes of lung disease such as COPD and lung cancer and to find new 
ways of treating these diseases we have to do more research. It is ideal to do the research on 
tissue from human lungs because we are investigating a human disease.  The lung research 
teams at Glenfield Hospital, Leicester Birmingham Heartlands Hospital, Walsgrave Hospital, 
Coventry and AstraZeneca (a pharmaceutical company) have joined together in order to 
collaborate on studies into lung disease using human lung tissue.  A numbers of diseases will 
be studied and the lung tissue will be used in a number of different laboratory studies. 
AstraZeneca will use the lung tissue in the understanding of lung disease and development of 
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new treatments for lung disease.   These experiments will be done on lung tissue that has been 
removed from patients as part of their medical treatment, which would otherwise be 
destroyed.  In some cases we may also wish to take a blood sample to compare the findings in 
the lung tissue and blood. 
 
Why have I been chosen? 
You have been chosen because your doctor has said that you may need to have some of your lung 
removed to treat your disease.   
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to take 
part you are still free to withdraw at any time and without giving a reason.  A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of care you 
receive. 
 
What will happen to me if I take part? 
You are about to undergo an operation for your current condition.  We would like to retain 
some of the spare lung tissue that will be removed as part of your operation, which would 
otherwise be destroyed.  If you are willing to take part in this research, we will pass the 
surplus lung tissue to the collaborating hospitals and AstraZeneca.. The surgeon will not 
remove any extra lung tissue for this research. We will also record some information about 
your recent medical history, medicines taken and reason for the operation from your medical 
records. In terms of your operation, stay in hospital and subsequent follow up there will be no 
difference to what will happen to you whether you take part in the study or not except that in a 
few cases we may wish to take an extra blood sample of approximately 15mL (about three 
tablespoons full) before your operation.  
 
What happens if I don't want to take part?  
Nothing, you simply don't sign this form.  This will not affect your medical care or your legal rights in 
any way. 
 
What rights do I have to the results of the research? 
You are being asked to donate your tissue as a gift to the researchers in the hospitals involved and 
AstraZeneca.  Any information derived directly or indirectly from this research by the collaborating 
hospitals or by AstraZeneca, as well as any patents, diagnostic tests, drugs, or biological products 
developed directly or indirectly as a result, are the sole property of the company (or their successors, 
licensees, and assigns) and may be used for commercial purposes. You have no right to this property 
or to any share of the profits that may be earned directly or indirectly as a result of this research. 
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However, in signing this form and donating a blood sample, you do not give up any rights that you 
would otherwise have as a participant in research. 
 
What do I have to do? 
There is nothing extra to do as a result of being part of this study 
 
What are the possible disadvantages and risks of taking part? 
There are no disadvantages or risks to taking part in the study over and above the normal risks 
associated with this surgery, which you require as part of your care.  If you are asked to 
donate an additional blood sample there may be some discomfort of the needle being inserted 
into a vein in your arm and the possibility of bruising developing afterwards around the area 
that the needle was inserted. This should disappear in a few days 
 
What are the possible benefits of taking part in the study? 
There are no direct benefits.  Taking part in this study means that you may possibly help 
suffers of lung disease in the future, as information about the changes that occur in the lung 
may be used to develop new treatments. 
 
What if something goes wrong? 
We do not think there is any significant risk of any harm occurring as a result of participating 
in this study. However if you are harmed by taking part in this research project, there are no 
special compensation arrangements.  If you are harmed due to someone’s negligence, then 
you may have grounds for a legal action but you may have to pay for it.  Regardless of this, if 
you wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms would be available to you.’ 
 
Will my taking part in this study be kept confidential? 
All information resulting from you taking part in the study will be stored and analysed in a computer 
and will be treated confidentially. You will be identified in the computer by a number and only your 
doctor will be able to identify the number as belonging to you. The study records will not be made 
available in any form to anyone other than authorised representatives of the health authorities and 
AstraZeneca. In all instances, your confidentiality will be maintained, in accordance with the Data 
Protection Act or as local laws permit. 
 
AstraZeneca and Regulatory authorities may wish to check that this research has been done properly, 
they may have access to your files and know your identity, but they are under a duty of confidentiality 
not to disclose details to others. 
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What will happen to the samples that I have donated?  
The samples will be processed by the research team and used in a range of experiments into 
the causes of lung disease. Samples may be transported to AstraZeneca or other hospitals in 
the collaborating group to do further experiments including tests to develop new drugs.  
Those samples that are not fully used up in experiments may be stored by the research team or 
by AstraZeneca, for use in future experiments, for up to 20 years.  
 
Who is organising and funding the research? 
The research is a collaboration between the lung research teams at the hospitals in Leicester, 
Coventry, Birmingham and AstraZeneca. The study is organised and operated by the 
individual hospitals involved and the overall collaboration has been funded by AstraZeneca. 
The income obtained from AstraZeneca will only be used to support the work carried out as 
pat of this project.  
 
Can I Withdraw my consent? 
You may withdraw your consent to the use of your data and samples at any time. If you 
withdraw your permission consent before your donated tissue and data are used, we will not 
use the data and the samples will be destroyed. If you withdraw your consent after your tissue 
sample has been sent for analysis we will ensure that your sample(s) are destroyed. However, 
if analysis has already been performed neither AstraZeneca nor ourselves are obliged to 
destroy results of this research. 
 
Who has reviewed the study? 
The study has been reviewed by the research teams within the consortium and by the 
members of the Department of Respiratory Medicine, Allergy and Thoracic Surgery.  
Individual research projects where we use the lung tissue have been reviewed by a variety of 
charities and funding organisations 
 
If you have any further questions about this study please do discuss them with: 
 
Professor Wardlaw or Mr Waller (0116 2563841)  
This document must be kept in the investigator’s study file and retained for a minimum period 
of 20 years after completion of the study. 
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Study Title:  Use of Tissue from Lung Resections to Investigate the Molecular  
and Functional Mechanisms of Human Lung Disease 
                                                                                                                                  
1. I confirm that I have read and understood the patient information form on 
the above project and have been given a copy to keep. I have had the 
opportunity to ask questions about the project and understand why the 
research is being done and any foreseeable risks involved. 
 
     Initials  
2. I agree to donate as a gift a sample of tissue for research in the above project. 
I understand how the sample will be collected and that giving the sample is 
voluntary. I am free to withdraw my approval for use of the sample at  any time  
without giving any reason and without my medical treatment or legal rights 
being affected. 
 
 
3. I give permission for my medical records to be looked at and  
Information taken from them to be treated in strict confidence by responsible 
people from Glenfield Hospital and AstraZeneca.  
 
 
4. I understand that my doctor will be informed if any of the results of 
the tests done as part of the research are important for my health. 
 
 
 
5. I understand that I will not benefit financially if this research leads to                                                                 
a new treatment or medical test. 
 
 
6. I do know where to contact Professor Wardlaw, if I need further information. 
 
 
 
 
7. Do you agree to take part in this study? 
 
      
     
YES  NO 
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Signed: ……………………………………….  Date: ………………………………….. 
 
 
Name (Block capitals) ………………………………………………………………….. 
 
I, (Name of investigator, block letters) ……………………………………………… 
have explained the nature and purpose of the study to ………………………. 
and believe that he/she understands what the study involves. 
 
Signed: ……………………………………..    Date: ………………………………….. 
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A.3 Density Grading 
 
All pictures were taken at x20 
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A.4 Isotype Controls 
Pictures are all 20% of original taken at x20.  
αSMA     CAIX    CD3  
 
CD31     CD34    CK 
 
 C-kit      Collagen    CYGB 
 
 Desmin     WGA    MAC387 
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PCNA    pVHL   S100A4 
 
 Surfactant    Vimentin 
 
